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Prescribing of medicines is a major healthcare cost, subject to multiple influences. This study uses the 
lens of a Donabedian Structure-Process-Outcome model, to model those influences. The thesis 
examines the existing literature on the influences on Primary Care Organisation prescribing and 
assesses the utility of the Donabedian model when applied to prescribing.  
Using profiles developed for all Primary Care Organisations in England, differences in prescribing 
were examined over 3 years to test the utility of this model as a framework to understand prescribing 
influences. The prescribing of long acting insulin analogues and Glucagon-like-peptide 1 receptor 
(GLP-1) agonists, were profiled within Primary Care Organisations using the Donabedian model for 
data for three years from 2011/12 to 2013/14. 
This study is the first to apply the Donabedian model to influences on prescribing. This model provided 
a good fit for all known influences on prescribing, providing an overview of how prescribing habits of 
an organisation are balanced against other clinical targets in a disease area.  Using the Donabedian 
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CHAPTER 1: INTRODUCTION AND BACKGROUND 
1.1. Summary 
Prescribing medicines is an area of practice that has major implications for healthcare 
costs, patient outcomes, and patient safety. The area is contested by a number of 
competing interest groups, including professionals, patients, patient advocacy groups, 
the pharmaceutical industry, and government.  
Despite attempts to contain prescribing costs, they have increased significantly 
showing an increase from 29.1% in total spend between 2010/11 to 53.9% in 2015/16 
in primary care (NHS Digital, 2016). Influencing prescribing in primary care has been 
identified as important in order to contain costs, but also to encourage adoption of best 
practice guidelines, to meet disease management and audit targets and to improve 
patient outcomes. In the United Kingdom (UK), variations in prescribing exists across 
all groups of drugs, despite a number of national government-led initiatives (Ewbank 
et al., 2018). 
None of the conceptual models used extensively in health service research have been 
deployed to try and analyse the relative importance of all these influences on 
prescribing behaviour. However, these models can provide a framework for evaluating 
the relative importance of all the competing influences and factors that might affect 
prescribing behaviour. An adapted Donabedian Structure, Process and Outcome 
(SPO) model was chosen as the most appropriate model to use for this research. 
Changes in the availability of National Health Service (NHS) information and data since 
2000 now allow for the construction of Primary Care Organisation (PCO) profiles 
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(structured using the Donabedian SPO model) containing the possible influencing 
factors on prescribing for diabetes. All PCOs in England were included in this analysis. 
The time period from 2011/12 to 2013/14 was chosen to allow for a three year period 
in which to compare PCO profiles. This also coincided with a major organisational 
change in PCO structures and management and thus would allow for investigation of 
the importance of organisational influences on prescribing behaviour. 
Diabetes prescribing has been identified as an area of high cost and significant 
variation for PCOs despite a significant national focus. It has therefore been chosen 
as an area to pilot this novel Donabedian SPO model. 
The aims of the research were fourfold. Firstly, to examine the existing literature on the 
influences on PCO prescribing. Secondly, to assess the utility of the Donabedian SPO 
model when applied to prescribing. Thirdly, to create PCO profiles based on the 
Donabedian SPO model for all PCOs in England by searching for data to measure 
PCO prescribing influences. Finally, to analyse differences in PCO Profiles over a three 
year period in order to test the usefulness of the Donabedian SPO model as a 
framework to understand prescribing influences in PCOs. 
1.2. Summary of research 
The first part of this study was a systematic review carried out to identify influences 
that change prescribing behaviour. From the results of the review it was possible to 
create a list of all known influences that might affect general practitioner (GP) 
prescribing behaviour.  
Following this, conceptual models used in health service research were assessed for 
their suitability as a model for analysing the influences on general practitioner (GP) 
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prescribing. An adapted Donabedian SPO model was developed to be used in this 
research. 
Published information and data from national and local NHS organisations were 
evaluated to ascertain if they could be used to reflect the different influences identified 
from the systematic review. Quantitative data were compiled and qualitative 
information collected, coded and scored.  
A quantitative analysis was then carried out comparing the prescribing of two newly 
introduced drug classes (long acting (LA)  insulin analogues and Glucagon-like-peptide 
1 receptor (GLP-1) agonists) for all English PCOs for each of the three years to assess 
the utility of the developed model. The profiles for each PCO were also examined to 
measure changes in influencing factors in individual organisations over the three years. 
A multiple regression analysis was performed to identify statistically significant 
influences on the prescribing of the two drug classes.  
1.3. Background 
This chapter provides an overview of the background of primary care organisations in 
the UK NHS (with a focus on NHS England), prescribing variation in the UK primary 
care organisations, and attempts to control prescribing, including at a national level. It 
will also introduce the conceptual model that will used in this research. Finally it sets 
out the central research aims. 
1.3.1. Primary care in the NHS 
The NHS has seen significant changes in the organisation of primary care in response 
to changing government policies. The following elaborates on their structure and 
purpose, with a focus on the past thirty years.   
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Development of a ‘primary care led NHS’ has been a central policy within the NHS 
since the early 1990s (NHS Executive, 1994). Successive governments have imposed 
various structures, targets and philosophies on the delivering of primary care but at 
their core they have all encouraged GPs to take a greater role in managing and 
controlling the costs of their activities. Initially this involved creation of GP fundholding 
practices and locality commissioning groups for non fundholding GPs in the 1990s 
(Lewis and Gillam, 2007). With a change of government in 1997, fundholding was 
abolished but in its place, primary care groups (PCGs) were created in England. PCGs 
covered all of England with the aim of controlling and improving clinical quality, cost 
effectiveness and the health of the population they were responsible for (Health 
Committee, December 2005). In 2000, Primary Care Trusts (PCTs) were established, 
followed by practice based commissioning groups and in 2013, 151 PCTs were 
abolished and replaced with 211 Clinical Commissioning Groups (CCGs) (Lansley, 
2010). The management structure of each primary care organisation has varied 
considerably over time and in line with the type of primary care organisation scheme 
being used. Primary Care Trusts were criticized for being bureaucratic with needless 
layers of management (Smith et al., 2010, Miller et al., 2012) and  CCGs were 
introduced with the express purpose of reducing bureaucracy, reducing the influence 
of professional managers and increasing clinical engagement (Lansley, 2010).  
1.3.2. Importance of prescribing costs 
In 2007 it was reported that the NHS had seen expenditure on prescription drugs in 
primary care increase by 60% over the last decade (National Audit Office, 2007b).  
With new drugs being developed; identification of additional uses and applications of 
5 
 
current drugs, and an ageing population rising drug expenditure was expected to 
continue. 
This has indeed been the case, with prescribing costs rising from a total prescribing 
spend in 2010/11 of £13.0 billion to £17.4 billion in 2016/17 (NHS Digital, 2017). Drugs 
treating diabetes have seen the greatest increase in Net Ingredient Cost (NIC) from 
£562 million to £984 million in 2016 (NHS Digital, 2016). 
The costs of prescribing for diabetes represents a significant proportion of the total 
prescribing costs within the NHS and accounted for approximately 9.5% of total 
prescribing in 2013/14, up from 8.4% in 2010/11 (Health and Social Care Information 
Centre, 2011, Health and Social Care Information Centre, 2014d). The costs of 
prescribing in diabetes have been identified as the most significant element in the total 
cost of diabetes care in a review from the  Audit Commission and ACCA (Association 
of Chartered Certified Accountants) (2012). They showed that, for diabetes, inpatient 
admissions are not the dominant driver of costs but that prescription costs account for 
three quarters of the average cost per patient. A 5 per cent reduction in spending on 
inpatients would secure a saving of less than £6 million. A 5 per cent reduction in 
spending on primary care prescriptions would save the NHS £32 million. Not only is 
there a difference in scale of savings, but greater efficiency in prescription costs would 
produce real savings to the NHS.  
1.3.3. Prescribing variation 
The 2007 National Audit Office (NAO) Review, also showed a significant variation in 
prescribing between PCOs. They estimated £200 million could be saved if all the PCOs 
in England prescribed certain drugs in the same way as the 25 per cent most efficient 
organisations (National Audit Office, 2007b). This variation in prescribing still exists 
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today and prescribing data is collated nationally by NHS Digital to identify variations in 
prescribing at practice and PCO level, and to identify trends in behaviour over time. 
Variation is the subject of ongoing scrutiny from NHS England under the responsibility 
of NHSRightCare and the Medicines Optimisation Programme.  
Because of the cost of prescribing for diabetes and the increasing number of patients 
with type 2 diabetes there have been a number of national audits and reports looking 
at the treatment of diabetes (Kerr, 2011). They have reported large variations in both 
the total expenditure on prescribing as well as the uptake of newer drugs. In 2010/11 
PCO prescribing spend for diabetes ranged from £240 to £374 per patient on the 
Quality Outcome Framework (QOF) diabetes register. There was also variation on the 
way in which PCOs spent this money, with insulin prescribing accounting for between 
38% and 58% of total costs and the proportion of the more expensive human analogue 
insulins (rapid and long acting) prescribed varying between PCOs, from 35% to 95% 
of all other insulin prescribed in 2009/1010 (Health and Social Care Information Centre, 
2011). In 2013/14 human insulin analogues made up 88% of all insulins costs and the 
net ingredient cost for human insulins had increased by 91.1% between 2005/6 and 
2013/14. Variation between PCOs in 2013/14 was still evident with a low of 37.6% to 
a high of 97% for percentage human insulin analogues as total spend on insulins 
(Health and Social Care Information Centre, 2014d).  
These differences in prescribing behaviour between PCOs cannot be explained by 
differences in the patient population (Right Care Atlas Series, 2012). In a report by 
NHS England (NHS England, 2014a) looking at 2012 clinical data and information 
from a variety of sources it was concluded that there were large differences in the 
way in which diabetes care was managed and provided across PCOs in England. 
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There was no obvious link between spending on diabetes, clinical outcomes, diabetes 
prevalence, complications or prescribing behaviour. 
Improving disease management does not automatically lead to uniform changes in 
prescribing. One study in 2011 correlated prescribing costs with quality indicators in 
the QOF and found no significant correlation between attainment of quality standards 
and prescribing costs (Fleetcroft et al., 2011). This is backed up by several other 
studies in different disease areas: hypertensive therapies (Aguado et al., 2000); 
clopidogrel prescribing (Petty and Silcock, 2008) and type 2 diabetes (Krass et al., 
2011).  
Other explanations for the variability in prescribing behaviour exist. A review of the 
literature on GP adoption of new drugs showed that there has been no comprehensive 
study exploring reasons for variations in GP behaviour across the UK (Mason, 2008). 
This review focused on the determinants of uptake, the causes of geographical 
variations, and the influence of price, cost and financial incentives on prescribing 
behaviour. It concluded that influences on prescribing behaviour are complex and that 
the UK studies typically surveyed, or undertook data analyses for relatively small 
numbers of GPs within a particular geographical region. 
The UK is not unique in this variation in prescribing behaviour with this situation being 
reported in many other countries. In a large nine country study of primary care 
clinicians across Europe looking at the variation in prescribing behaviour for antibiotic 
prescribing for lower respiratory tract infections, Brookes-Howell (2012) found that 
prescribing decisions were influenced by factors imposed by the healthcare system as 
well as characteristics of the clinicians and patients but that for an intervention to be 
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successful flexibility was needed to take into account potential constraints and 
influences that exist locally. 
1.4. Overview of factors influencing prescribing 
1.4.1. Deprivation 
Prescribing levels may be expected to change according to the deprivation of the 
patient population. A greater number of patients are seen in deprived populations and 
so it would be logical for a more deprived population to be linked to greater levels of 
prescribing for all diseases. However, there are indications that in some cases more 
affluent patients are able to articulate their needs and influence physicians to obtain 
the treatment they want. This was the case in a study looking at disease modifying 
treatments in multiple sclerosis in two centres (Nottingham and Glasgow) in the UK 
(Owens et al., 2013). In another study examining the socioeconomic status on quality 
of prescribing in the elderly (Odubanjo et al., 2004), they found that sub optimal 
prescribing was more likely in patients who were relatively deprived. The link with 
deprivation may depend on the particular disease, and a study in 2003 looking at the 
records of 181,647 patients in Ireland showed that prescribing for symptomatic 
medications increased with increasing deprivation while prescribing for disease 
specific drugs decreased with increasing deprivation (Williams et al., 2003). 
1.4.2. GP characteristics 
Another possible cause of variation in prescribing behaviour that has been studied are 
GP characteristics. In a study of 852 general practitioners in Canada (Cadieux et al., 
2007) an analysis of antibiotic prescribing showed that international medical 
graduates, length of time qualified and high volume practice were all linked to 
increased inappropriate antibiotic prescribing. A questionnaire sent to 258 general 
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practitioners practising in rural locations in Queensland, Australia found that most 
respondents prescribe differently in rural practices compared with cities (Cutts and 
Tett, 2003). Another study found that there was no significant association between 
area of clinical interest and prescribing habits (Hansen et al., 2007). A study in East 
London in 139 practices found that South East Asian trained GPs prescribed less 
antidepressants and 57% of prescribing variation between practices was explained GP 
qualification; proportion of registered female patients; older patients >65 and list size 
per full time GPs (Hull et al., 2005). 
1.4.3. Organisational level factors 
Oragnisational factors may also influence prescribing behaviour. The majority of the 
research on the effects of the PCO on prescribing behaviour of GPs has focused on 
the nature of GP collaboration and the sharing of joint values and culture. Studies have 
demonstrated that those GPs that have chosen to work together in a local group and 
have a degree of autonomy over how they choose to prioritise work have been found 
to work more enthusiastically and more effectively towards jointly agreed target targets 
(Prosser and Walley, 2005). This has been demonstrated in a variety of primary care 
organisations in North London (Ashworth et al., 2000), Italy (Fattore et al., 2009), New 
Zealand (Malcolm et al., 2001) and Sweden (Strandberg et. al., 2013) and (van Eijk et 
al., 2004). 
Organisational change has been found to produce a drop in performance and it is 
thought that it takes the new organisation between 1 and 3 years to become 
established (Lamont et al., 1994). Constant changes and disruptions to the PCOs 
make it difficult for staff within them to focus on improving local services. In a review of 
practice based commissioning by Smith et al. (2005) they concluded that 
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organisational stability particularly the structures of commissioning bodies is very 
important, since it takes time to embed PCOs into the system (approximately 8 years 
for fundholding to cover half of the practices in England; 1-2 years for practice based 
commissioning (PBC), and three years for CCGs to become established).  
A survey by The Kings Fund and Nuffield Trust (Naylor C et al., 2013) over a three-
year period assessing the implementation and impact of CCGs, showed 80% of GPs 
who responded believed that CCGs have a legitimate role in influencing members to 
change referrals and prescribing. The concept of peer reviews amongst GPs has 
become accepted and there was a degree of willingness by GPs take part in the 
process (Mannion et al., 2008) and (Coleman et al., 2009). 
In a qualitative study by Prosser and Walley (2007), focus groups and in depth 
interviews in primary care found that a number of managerial approaches were used 
to try to influence prescribing behaviour. In an qualitative study by Spyridonidis and 
Calnan (2010), the implementation of National Institute of Clinical Excellence (NICE) 
guidelines was studied in four different NHS organisations. The process of changing 
behaviour was influenced by the interactions between managers and clinical staff and 
it was important that all levels of personnel across different disciplines had the ability 
to affect adoption of new guidance and prescribing practice. 
There have been many papers looking at the relationship between the size of a primary 
care organisation and its performance. There is little evidence to support the 
hypothesis that there is an ideal size for these organisations. In an observational study 
of all 152 primary care trusts in England by Greaves et al. (2012) the size of the PCT 
was compared against 36 indicators of commissioning performance. The results were 
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not straightforward, but larger PCTs tended to provide higher quality care services (in 
10 out of 14 indicators) but reported less efficient prescribing. Other research has 
confirmed that size is not a reliable predictor for performance and that performance is 
affected by a combination of their aims, tasks, functions, organisational features and 
environmental factors (Wilkin et al., 2003).  
The number of GPs per head of population within a PCO was investigated in England 
in 1999 when a range of data comparing different health outcomes measures was 
analysed for 99 health authorities (Gulliford, 2002). They matched this against the 
number of GPs per 10,000 population and found that that higher numbers of GPs 
resulted in a decrease in hospital admissions for acute and chronic conditions. GP 
numbers were found to influence antidepressant prescribing rates In a study of 131 
GP practices in a South Wales Health Authority in 2003, although population 
deprivation in practices proved the greatest influence on prescribing volumes and cost 
(Senior et al., 2003).  
1.4.4. Influence of local neighbouring NHS organisa tions 
Local organisations, often acute trusts, exert an influence on the prescribing behaviour 
of GPs within a PCO within the local health economy (LHE) (National Audit Office, 
2007a). An open prospective study of 92 general practitioners in Ireland (Feely et al., 
1999) they found that hospital specialists were responsible for up to 38% of 
prescriptions from some conditions. In a retrospective study in Italy (Florentinus et al., 
2009) in 103 general practitioners in 59 practices the influence of medical specialists 
was dependent on the type of drug (respiratory inhalers were prescribed first by 
medical specialist in 60.2% of patients compared to non steroidal anti inflammatories 
in 23%). Researchers in France, also identified influence of secondary care and in 
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addition saw that small local hospitals where GPs and consultants worked most closely 
exerted the greatest influence (Gallini et al., 2013). This regional variation was also 
studied in the UK (Roberts et al., 1998) in a comparison of the use of anti epileptic 
drugs in general practice across 16 health authority areas in England for four years. 
Individual health authorities showed considerable differences in prescribing rates 
possibly due to different preferences in the catchment secondary care hospitals and 
the presence of different local treatment guidelines. 
1.5. Measures to reduce prescribing cost and variability in England 
There have been a number of government and local PCO initatives to reduce the 
variability in prescribing behaviour. 
1.5.1. Government initiatives 
The reduction of variability between service provision, spend and quality of care has 
long been a national aim, addressed through a range of government initiatives. A new 
pay for performance contract for GPs was launched in 2004 with a range of of clinical 
audit requirements for a range of chronic diseases, as well as medicines management 
and service standards under the QOF (Health and Social Care Information Centre, 
2005). Prior to this, a series of National Service Frameworks from 1999 onwards has 
addressed major disease areas such as coronary heart disease, diabetes, stroke, long-
term conditions. Included in these standards were requirements to change prescribing 
behaviour to ensure that medicines were used appropriately (Department of Health, 
2001b).  
The National Institute for Health and Clinical Excellence (NICE) was created in 1998 
with a remit to reduce geographical variation in availability and quality of NHS 
treatment and care (the so-called ‘postcode lottery’). It also produces national guidance 
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on the best practice in treatment and care, based on principles of evidence based 
medicine (Rawlins et al., 2010).  
The 2010 Quality, Innovation, Productivity and Prevention (QIPP) initiative (Health and 
Social Care Information Centre, 2013b) had one workstream focused on medicine use 
and procurement, including specific targets for medicines management. PCOs were 
tasked with saving money by changing prescribing habits, with prescribing spend on 
the specific drugs reported at quarterly intervals.  
The Better Care Better Value Initiative (Better Care, 2007) was set up to identify 
potential areas where NHS organisations could make savings through changing 
practice changing referral patterns; reducing costs in prescribing; and improving 
efficiency. Opportunities were identified by estimating the savings an organisation 
could if they changed their behaviour to match the best performing organisations.  
The Right Care Initiative (Right Care Atlas Series, November 2010) was developed in 
2010 was aimed at maximising the local use of resources whilst delivering high quality 
care. It was driven by comparing data on spend and outcomes across a range of 
disease areas for PCOs with the focus on reducing variations.  
Despite all of these government initiatives variation  in all aspects of healthcare 
continues. The current drive to reduce prescribing variation is called Medicines 
Optimisation (NICE Guideline NG5, 2015) and a Medicines Optimisation Dashboard 
has been developed to display the continued variation in prescribing behaviour of 
PCOs. This continues to be used in 2018 with no sign that variation in prescribing 
behaviour has been eliminated.  
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1.5.2. Local PCO initiatives 
1.5.2.1. Medicines management 
One of the methods to control prescribing cost and variability in the new PCOs in 1997 
was to utilise the skills of pharmacists (National Audit Office, 2007a). They were 
recruited to work as prescribing advisers within medicines management teams and 
were given responsibility for ensuring adherence to locally prescribing incentive 
schemes (Ashworth et al., 2002). In addition, PCOs were encouraged to utilise 
established area prescribing committees (or set them up if they did not already exist) 
to link up primary and secondary care medicines management teams and obtain a 
unified approach to the adoption and use of drugs in local organisations (National 
Prescribing Centre, 2009). This was found to result in significant changes in prescribing 
patterns in some PCOs. However, there was no consistent change in prescribing in all 
organisations and still some PCOs consistently fell short of national targets (Mossialos 
E, 2005). The use of practice support pharmacists to audit prescribing behaviour and 
deliver prescribing messages and targeted help to practices to change behaviour was 
another way to changes prescribing habits within PCOs. In one study (Cunningham et 
al., 2002) practice visits by pharmacists to reduce prescribing of proton pump inhibitors 
resulted in savings of £46,000. This effect seems to be valid across a number of 
therapeutic areas such as chronic pain (Li et al., 2011); hyperlipidaemia (Diwan et al., 
1995) and diabetes (LaMarr et al., 2010). 
Local prescribing incentive schemes have also been used by many PCOs in order to 
reduce prescribing spend and comply with specific national prescribing targets 
(Ashworth et al., 2003). However, results are not uniform across PCOs and don’t 
represent a wider acceptance of prescribing targets and guidelines (Fernandez 
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Urrusuno et al., 2014). 
1.5.2.2. Responsibility for prescribing costs 
When general practitioners are given their own budget they have been shown in many 
studies to change their prescribing behaviour (Ohlsson and Merlo, 2007). However, it 
should be noted that although the change may be marked both in terms of cost and 
volume, it is not always the case for all prescribers and in a retrospective analysis 
looking at the introduction of a financial incentive scheme in Ireland, it was seen that 
incentives work for some prescribers but often seemed to have little effective on high 
spending practices (Walley et al., 2000). 
In a review of economic factors influencing prescribing of antibiotics (Reed et al., 2002) 
physician knowledge of costs and financial incentives were found to be influential. 
However, a more recent review by the Cochrane Effective Practice and Organisation 
of Care Group (Scott et al., 2011) looking at the effect of financial incentives, found 
limited evidence to support their use and that at best only small effects in generally 
poorly designed studies.  
1.5.2.3. Formularies 
The development of drug formularies has also been a popular way to limit drug choices 
and improve prescribing in line with clinical guidelines (HillSmith, 1996). However, the 
adherence to formulary recommendations differs greatly across prescribers within an 
organisation (Buusman et al., 2006) and GPs do not always view restrictions positively 




Another approach to reducing the prescribing variability in primary care and ensure 
that drugs are prescribed according to national standards has been to encourage 
regular clinical audit of the care provided in practices. This is an accepted way to 
change behaviour supported by a number of reviews such as the Cochrane review of 
the usefulness of audit and feedback on prescribing behaviour in 2012 (Ivers et al., 
2012). Their conclusion was that audit and feedback generally leads to small but 
potentially important improvements in professional practice.  
Educational programmes to influence the choice of a drug have been shown to be 
more effective for a single short term treatments (urinary tract infection) than for a 
chronic diseases such as asthma in a study in Sweden (Lundborg et al., 1999). This 
was confirmed in Australia in 2010 (Gnjidic et al., 2010). 
1.5.2.5. Clinical guidelines 
Clinical guidelines are seen as a key tool in reducing variation in health care and cost 
(Borowitz and Sheldon, 1993) and improving quality of patient care and prescribing 
(Feder et al., 1999). In a cross sectional study involving analyses of prescribing data 
before and after the publication of NICE prescribing guidance in a PCT in Devon it was 
found that NICE guidance in isolation had little impact, but adoption was more likely 
when supported by other sources of information (Wathen and Dean, 2004). Another 
qualitative study reported by Rashidian et al. (2008) explored key themes for the 
implementation of clinical GP attitudes and beliefs about guidelines, and barriers to 
and facilitators of implementation. They identified a number of themes such as local 
ownership; credibility of source; organizational factors; disease characteristics; 
influential people and dissemination strategies that were important if guidelines were 
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to be adopted and used by general practitioners. 
1.5.2.6. Pharmaceutical industry influence 
Pharmaceutical companies were identified as a significant influence on prescribing 
behaviour in 66% of studies included in a systematic review in 2010 (Spurling et al., 
2010) and were identified as the primary source of drug information in another study 
in Turkey (Vancelik et al., 2007). 
1.6. Donabedian SPO model 
Published research on influences on prescribing behaviour provides no single 
conceptual model to study prescribing variation in either single practices, PCOs or 
between individual GPs. However, looking at other forms of health services research 
has allowed an exploration of possible conceptual models that could be applied to this 
research. The most similar area of research has been that of identifying indicators for 
performance assessment and improvement of quality in health services and systems 
(Bowling A, 2009).  
Conceptual models all share a number of common themes focusing on the 
measurement and improvement of quality in healthcare. One of the first theoretical 
evaluation models to measure quality in healthcare was postulated by Avedis 
Donabedian in the 1960s (Donabedian A, 1966). He created a Structure, Process and 
Outcome (SPO) Model that is still widely used today and forms the basis of a number 
of Countrywide Conceptual Models (Kelley E, 2006). Donabedian’s approach focuses 
on (a) the measurement of structure (inputs and resources – including staffing, finance 
and other resources). (b) the measurement of process (service delivery, prescribing 
18 
 
practices, referral rates, access, and other productivity measures) and (c) the 
measurement of outcomes (death, morbidity, patient satisfaction) (Donabedian (1980).  
Prescribing has been identified as one of the quality indicators in many of the quality 
frameworks that have been developed and used by many countries (Kelley E, 2006). 
For example, in the Donabedian SPO model, prescribing is regarded as one of the 
process indicators (together with referral rates, service delivery and other productivity 
measures) (Donabedian A, 1980). The Donabedian SPO model was originally 
developed to assess clinical practice. However, it has subsequently been adapted and 
used extensively as a basis for evaluating healthcare systems (Donabedian A, 2003). 
In a review of how to promote quality in the health care organisation by Glickman et al. 
(2007) argued that the following organisational attributes should be included in any 
Donabedian SPO model: Physical characteristics of the organisation; Management; 
Organisational Culture; Organisational Design; Information Management and 
Incentives.  
Therefore a Donabedian SPO model that includes organisational measurements 
would provide a useful framework in which to investigate the relative importance of 
influencing factors on prescribing behaviour in PCOs. 
Such a conceptual model would have the benefit of ensuring that all aspects of disease 
care and quality would be assessed not simply prescribing behaviour. This would 
endorse the initial observations made in this chapter that there are many influences 
that possibly interact to alter behaviour within local healthcare organisations and that 
the particular disease and how care is provided locally is potentially important in the 
analysis. The health service research on conceptual models and use in performance 
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measuring in health systems across many countries will be examined in more detail in 
Chapter 3.  The use of such models as a means of grouping and understanding the 
influences on prescribing that were identified in the systematic review will also be 
evaluated. 
1.7. Availability of PCO data and information 
The availability of comparative NHS data at PCO and practice level have been 
increasing steadily since the first PCO organisations were created in 1997. This is 
firstly because of the response by the NHS to The Freedom of Information Act (NHS 
England, 2015) but also from a release of  comparative data in response to the UK 
Government Transparency Agenda policy in 2012 (House of Commons Committee of 
Public Accounts, 2012). Following these changes, Local PCO prescribing data, 
attainment of audit targets and outcomes, formularies, population and organisation 
profiles are now accessible. 
1.8. Conclusion 
This chapter has described the changing environment of PCOs, the continuing need 
for systems to control prescribing, some of the possible reasons behind PCO 
prescribing variation and the methods adopted by organisations to control prescribing 
behaviour. Diabetes prescribing has been identified as an area of high cost and 
significant variation for PCOs despite a significant national focus. None of the 
conceptual models used extensively in health service research have been deployed to 
try and analyse the relative importance of all these influences on prescribing behaviour 




PCOs are responsible for delivering prescribing change on accordance to national 
standards and targets. Research has shown that differences in organisations in terms 
of the degree of cohesiveness within the organisation as well as the organisational 
attributes can influence the ability of the PCO to change prescribing behaviour.  
The structure and management of PCOs themselves has altered over the period 
2011/12 to 2013/14 from 151 management led primary care trusts to 211 GP led 
clinical commissioning groups and so this was an ideal period of time to explore the 
importance of the organisation as a factor influencing prescribing.  
Prescribing cost variation is apparent in all disease areas, but type 2 diabetes is an 
area of particular interest both nationally and locally because of the increasing costs 
owing to a rising patient population and an introduction of a number of new drugs for 
its treatment.  
None of the published literature has systematically analysed all the possible factors 
influencing the prescribing behaviour of general practitioners in  PCOs in the UK. 
Prescribing has been identified as one of the important indicators in many of the 
performance and quality frameworks used in health service research. For example, in 
the Donabedian SPO model prescribing is one of the process indicators together with 
referral rates, service delivery and other productivity measures (Donabedian A, 1980).  
In order to build up a set of data to populate the proposed conceptual model, a single 
disease area was chosen with a further focus on two recently introduced drug classes. 
Type 2 diabetes was chosen because prescribing costs are significant, accounting for 
approximately 10% of total NHS prescribing spend, and there is also significant 
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variation in prescribing habits for diabetes in PCOs. Moreover, it is an area where costs 
have risen more than any other disease category in the last ten years and where there 
have been a number of new drugs introduced in the last twenty years.  
The increased production of publicly available data and information now makes this a 
viable way in which to examine differences between PCOs over a period of time.  Also, 
because diabetes is an area of national focus there are many comparative datasets 
available measuring the attainment of a range of disease management targets and 
outcomes.  
1.10. Aims and objectives of this research project 
This thesis examines the influences on prescribing in the published literature, looking 
to develop and apply a widely used health services research conceptual model called 
the Donabedian SPO model.  
There were four specific aims of the research project. 
1.    To perform a systematic review to critically appraise and synthesize the present 
published research on the possible influences on prescribing behaviour in PCOs.  
In order to meet this aim the following objectives were met: 
• Identification of the significant non-clinical prescribing influences that have 
been measured at an organisational level 
• An understanding of the relative importance of these influences on prescribing 
decisions within organisations 
• An insight into how the identified influences have been found to account for all 
the variation in prescribing behaviour 
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• Identification of any theoretical models that have been used to frame the 
analysis in the published quantitative research 
• An understanding of whether the prescribing influences are disease specific. 
• Collection of any influences that are specific for diabetes prescribing.  
2.    The second aim of this research was to ascertain if there were any conceptual 
quality models used in health service research that could be used to provide a useful 
insight into the influences on prescribing behaviour, and develop a model to apply to 
prescribing.  
In order to meet this aim there were four main objectives: 
• Investigation of the theory behind the use of quality models and identify what 
were the key elements in the most commonly used conceptual models.  
• Identification of the most suitable conceptual model that is most appropriate to 
be used in this research. 
• In order to test the utility of the Donabedian SPO model when understanding 
the interaction of influences on prescribing in English PCOs two new specific 
classes of drugs to treat diabetes (LA insulin analogues and GLP-1 agonists) 
were chosen as outcome indicators. 
• Alignment of the influences identified in the prior systematic review (Chapter 2) 
to the Donabedian SPO conceptual model, according to their similarity, and 
based on their relationship to the two outcome indicators.  
3.    The third aim of this research project was to construct PCO profiles for all PCOs 
in England based on the Donabedian SPO Model. In order to do this the following 
objectives were met: 
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• Examination of the data and information from national and local sources to 
ascertain if they could be used to measure the individual influences that had 
made up the indicators in the  structure and process domains in the Donabedian 
SPO model. 
• Creation and development of standards to be applied when considering 
acceptable data coverage levels; standards for inclusion of data; scoring criteria 
for data and information and rationale behind the division of all data into 
quintiles. 
• Collection of data and collection, coding and scoring of information and storage 
in Excel spreasheets to reflect individual indicators  for all PCOs for each of 
three years from 2011/12 to 2013/14. 
• To allow for comparison of each influence within the PCO Profile all collected 
data and information was also scored into one of 5 groupings (quintiles). The 
rationale for scoring following the general principle that the greater the value (be 
it prevalence, level of spend, numbers of referrals, cohesiveness and 
achievement of management goals of the organisation) then the higher score. 
4.    The final aim of this research was to compare PCO profiles for all 211 PCOs in 
England over a 3year period. Changes in the importance of individual influences 
within individual organisations over time as well as differences in profiles between 
organisations were measured. 
There were two specific objectives: 
• Examination of the structure, process and outcome indicators (scored into 
quintiles) across all PCOs for three years. Understanding of (a) Pattern of 
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scoring for the three years, for the individual indicators and individual PCOs (b) 
Difference between PCO profiles with the same outcomes and (c) examination 
of PCO profiles in a subset of PCOs with similar outcomes. 
• Analysis using multiple regression to ascertain if there were any statistically 
significant relationship between the indicators in the structure and process 




CHAPTER 2: SYSTEMATIC REVIEW - INFLUENCES ON GP 
PRESCRIBING WITHIN PCOs IN ENGLAND 
2.1.Introduction 
The aim of this research project was to test the usefulness of the Donabedian SPO 
model containing all the possible influences on GPs when they are making prescribing 
decisions in primary care. This approach has not previously been used in published 
research examining the influences on prescribing behaviour. Instead, the majority of 
published literature on this subject has either tended to focus on examining a single 
influence in order to try and change the behaviour of individual GPs. When 
organisations have been studied, variation in prescribing has been recorded but only 
a few of the possible influences have been measured.  
In addition, the subject of influencing prescribing behaviour of GPs in primary care has 
most often focused on the prescribing of antibiotics because this is an important area 
where it is acknowledged that prescribing is often inappropriate (Pinder et al., 2015). 
The area of interest in this research project was type 2 diabetes, a chronic condition 
where patients are often managed in primary care but with a varying degree of help 
from specialist colleagues in secondary care. Far less has been published about the 
influences on prescribing in chronic diseases such as diabetes and no papers have 
specifically looked at the relative importance of different influences on prescribing 
decisions for diabetes in individual PCOs.  
Therefore, this research project investigated a subject using a novel approach where 
there was no directly comparable published literature. The systematic review was 
required to identify influences on prescribing in PCOs. These influences would then be 
incorporated into the adapted Donabedian SPO model and the data measuring the 
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individual influences could be collected to allow for a profile of each organisation to be 
built.  
2.2. Aims and objectives 
The overall aim of this systematic review was to critically appraise and synthesize the 
present published research on the possible influences on prescribing behaviour in 
PCOs.  
There were a few specific objectives that needed to be addressed in order for the 
systematic review to deliver this aim: 
• Identification of the significant non-clinical prescribing influences that have been 
measured at an organisational level. 
• An understanding of the relative importance of these influences on prescribing 
decisions within organisations. 
• An insight into how the identified influences have been found to account for all 
the variation in prescribing behaviour. 
• Identification of any theoretical models that have been used to frame the 
analysis in the published quantitative research. 
• An understanding of whether the prescribing influences are disease specific. 
• Collection of any influences that are specific for diabetes prescribing.  
2.3. Method 
The methodology described in the University of York’s Centre for Reviews and 
Dissemination Systematic reviews was used as a guide in this systematic review 
(Centre for Reviews and Dissemination, 2009). The methodology employed in this 
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systematic review was also appraised using the Checklist developed by The Critical 
Appraisal Skills Programme (2018). 
The methods involved in identifying suitable papers to be included in this systematic 
review included a number of steps:  
1. Initial screening of title and abstracts against the inclusion criteria 
2. Data extraction  
3. Quality assessment of the papers included in the systematic review 
2.3.1. Inclusion criteria 
The overriding inclusion criteria for papers to be included in the systematic review was 
that the primary focus of the research should have been on the influences that affect 
the prescribing behaviour of primary care physicians.  All primary and secondary study 
designs were considered. The papers were focused in a primary care setting (defined 
as community based generalist staffed care including ambulatory care). Included 
papers focused on the range of influences on general practitioner (or equivalent) 
prescribing behaviour and habits; looked at the hierarchy of importance of influences 
or studied the reasons behind variations seen in prescribing across geographical 
regions or PCOs. Papers from all countries were also included despite this research 
being limited to PCOs in England.  Because of the lack of published literature, the 
review was also widened to include papers that have looked at the influences on 
prescribing at individual GPs level rather than at an organisational level. Research in 
this field and specifically focused on type 2 diabetes was too restricted so the search 
included all disease areas. 
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2.3.2. Exclusion criteria 
Papers focusing on treatment outcomes for specific diseases following changes in 
prescribing or those that charted the variability in prescribing habits but did not 
investigate the reasons why this had occurred were excluded for inclusion. 
Additionally, papers that examined the importance of a single influence or the effect of 
an intervention to change a single influence were excluded. Conference proceedings, 
editorials, letters and reviews were also excluded. 
2.3.3. Search strategy 
The following medical databases were searched as part of this systematic review: 
Cochrane, Medline and Embase on OVID; Web of Science and The Health 
Management Information Consortium (HMIC) (1979 to 2014). Construction of the 
search terms was done using the Population, Intervention, Comparator and Outcomes 
(PICOS) elements and following the directions outlined in the University of York 
Guidance (Centre for Reviews and Dissemination, 2009). 
The themes that were searched on were: 
1. General practitioners (or family physicians, or primary care (depending on the 
database searched).  
2. Prescribing  
3. Influence on clinical practice or physician practice patterns 
In addition, hand searching of specific journals (Social Science and Medicine; Health 
Policy and British Journal of General Practice) and following up on references was 
carried out.  
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2.3.4. Data extraction 
Abstracts from all the papers retrieved in the searches from the four medical databases 
were obtained. All the papers were imported into a referencing software package called 
EndNote and also imported into an Excel spreadsheet. 116 duplicate papers were 
removed using the EndNote software. 
The guidelines for data extraction published in the University of York Guidance (Centre 
for Reviews and Dissemination, 2009) were followed as a template.  
The key aim of data extraction and evidence synthesis was to: assess the relative 
importance of each influence; record any interaction with other influences; identify any 
previously unrecorded other influences on prescribing; understand how much variation 
in prescribing could be explained by differences in the influences in various local health 
economies; understand if the situation is the same for different disease area / drug 
classes; understand if the situation is the same for different countries; identify any 
conceptual  models that have been used to understand the interaction of influences; 
assess the way in which influences were identified (qualitative or quantitative research) 
and compare the methods for statistical analysis. With this in mind the following pieces 
of information were recorded about each study.  
Information recorded: 
• Country of origin 
• Disease area / drug studied 
• Prescriber role (general practitioner or specialist) 
• Type of paper: (Qualitative study, quantitative study or review) 
• Statistical Analysis 
30 
 
• Influences studied 
• Conceptual models used 
• Outcome / conclusion 
Following the exercise to exclude unwanted papers, a grid was created in the Excel 
spreadsheet to identify the influences(s) that were being examined in each paper. A 
copy of the full papers was obtained and all the papers were then assigned to a 
separate folder in the EndNote system 
2.3.5. Outcomes section 
The primary outcome was the identification of all influences that have been found to 
affect prescribing decisions.  Ideally, the population would have been primary care 
organisations, the disease would have been type 2 diabetes and quantitative research 
analysis using theoretical models would have been used. However, there were too few 
papers and so all papers investigating the possible influences on GPs were included 
in order to meet the primary objective. 
2.3.6. Evaluation of quality  
The 48 papers included in the systematic review were assessed for the following 
quality standards that have been described in the chapter titled “The Principles of 
Research” (Bowling A, 2009) and Guidance from The University of York (Centre for 
Reviews and Dissemination, 2009) was also followed.  
2.3.6.1. Qualitative research papers 
• Was there a quantitative analysis or recording of the number of times influences 
were mentioned following interviews, questionnaires or focus groups? 
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• Were no figures given in the results, only quotes and examples from selected 
responses? 
• How were subjects chosen? How representative a sample were they? 
• Were GP demographic details collected and used in the results / discussion?  
• Were practice level details collected and used in the results / discussion? 
• Did the discussion / conclusion reflect the study design and results obtained? 
2.3.6.2. Quantitative papers 
• Did the variables chosen for examination in the study reflect those reviewed in 
the introduction, discussion or conclusion? 
• Was there a rationale for the influences that were included?  
• How were subjects chosen? How representative a sample were they? 
• Did the discussion / conclusion reflect the results and study design? 
2.3.6.3. Mixed methods papers 
• How were subjects chosen? How representative a sample were they? 
• Was there a clear link between the qualitative and quantitative parts of the 
study? 
• Were GP demographic details collected and used in the results / discussion for 
the qualitative part of the study?  
• Were practice level details collected and used in the results / discussion for the 
qualitative part of the study? 
• Did the variables chosen for quantitative analysis in the study reflect those 
reviewed in the introduction, discussion or conclusion? 
• Was there a rationale for the influences that were included?  
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• Did the discussion / conclusion reflect the results and study design? 
2.3.6.4. Assessment of quality for the methods adopted by this systematic review 
At the outset of this systematic review it was agreed that the included papers would be 
checked by a second person. This was to ensure that results were consistent with the 
eligibility criteria, that the subsequent categorisation was an accurate reflection of the 
research reported in the included papers and that the quality assessments of the 
included papers were appropriate and correct. Due to the lack of a second researcher, 
a compromise system was used to for assessment of abstracts and full papers against 
the exclusion and inclusion criteria. Assessment of the included papers was carried 
out a second time, without recourse to the initial results, and decisions then made on 
discrepancies that were found as to the possible inclusion and categorisation of the 
paper.  
2.4. Results 
2.4.1. Systematic literature review 
The systematic review search was undertaken 27 January 2015 and the following 
references were obtained: 
Medline:         468 references 
Embase:        662 references 
HMIC:         76 references 
Web of Science:  469 references 
Total number of references from Medline, Embase, HM IC and Web of 
Science:  1,675 
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Reducing duplicates: 116 references 
This search was repeated on 31st August, 19th May 2016 and 8th November 2016 and 
05 May 2018 and a further 29 references were produced. 
In addition, when the full papers from the references above were read for inclusion in 
this review, a number potentially interesting references were identified. Copies of these 
papers were obtained and a further 21 papers were included in this systematic review.  
The breakdown of search terms and results for each database is given below: 
Medline 1947 – 27 January 2015 
MESH terms: 
1. Primary Health Care (expanded) 55046 
2. Prescribing as a keyword 25731 
3. Physician’s Practice Patterns (expanded) 42310 
4.Combine (1) (2) and (3) 
Result: 468 papers 
The updated searches produced an additional 6 references  
Embase: Excerpta Medica (Ovid) 1974 to 27 January 2015 
1. General practitioner (MESH term): - all subheadings included: 65749 results 
2. Clinical Practice (MESH term): 177605 results 
3. prescription [MESH] 117510 results 
4. Combine (1) (2) and (3)  
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Result: 662 papers. 
The updated searches produced an additional 29 references  
Health Management Information Consortium (HMIC) 1979 to 2015 
Prescribing as an expanded search term: results 3331 results 
Primary care (expanded terms for all subheadings): 21146 results 
General practitioner as an expanded search term for all subheadings: 9719 
results 
Combine (1) (2) and (3) 
Result: 76 papers 
The updated searches produced an additional 4 references  
Web of Science 
Topic search: prescribing* primary care* influence 
1. Prescribing* 26,342 results.  
2. Primary care* 144,637.  
3. Influence* 2,020,209 results 
4. Combine three search terms with “and”” 
Results: 469 results 
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2.4.2. Reasons for exclusion 
Focus on specific disease outcomes: 
ANTIBIOTIC USE: Antibiotic prescribing linked to drug resistance, choice of antibiotics 
according to clinical and diagnostic indicators; very specific actions connected to 
antibiotic prescribing (delaying the issue of prescriptions etc. that are not applicable to 
diabetes); description of antibiotic prescribing habits (no focus on influences) - 159 
records (4 records in the update) 
DISEASE MANAGEMENT: Papers focusing on the improvement of disease 
management, comparisons between or reviews of possible treatments in a specific 
disease or patient groups (elderly or children for example) where prescribing is 
discussed but not the influences on prescribing decisions - 399 records (16 records in 
the update) 
GENERAL PRACTITIONERS: GP variability (where prescribing was not the main 
focus of the paper); GP workload; general practice management and initiatives; 
information systems and training - 46 records (2 records in the update) 
LETTERS OR OPINIONS: Letters or leader comments, opinion articles discussing 
general issues in general practice - 54 records (2 records in the update) 
NO FULL PAPERS / ABSTRACTS: No translation available / no abstract or full paper 
or paper described a study that is not yet complete - 20 records 
NURSING or ALLIED PROFESSIONALS: Papers focusing on nurse prescribing, allied 
health prescribing or nursing initiatives - 32 records (1 record in the update) 
37 
 
PAPER WITHDRAWN FROM SEARCH ENGINE – (paper retrieved as part of search 
strategy but had been subsequently withdrawn) - 1 record 
PATIENTS: Patient attitudes to prescribed drugs, adherence or compliance to drug 
regimens; choices for non-prescription drug, relationships with medical practitioners - 
15 records. 
PHARMACY: Papers focusing on pharmacy issues (electronic prescribing, pharmacist 
prescribing; repeat prescribing; medication reviews, adverse events or prescribing 
errors, off label prescribing; drug utilisation reviews; prescription costs; drug 
interactions; drug formulations; prescribing information systems and development of 
prescribing indicators) - 161 records (2 records in the update) 
PLACES OF CARE: Treatment focused in acute care or other sectors (specialist units, 
nursing homes for example) - 52 records. 
VARIATION: General variability in prescribing across different countries or in specific 
patient groups. Prescribing for certain groups of patients; specific indications for a drug; 
inappropriate prescribing. Whilst variation in prescribing has been studied the 
influences that might explain the differences have not been explicitly studied - 213 
records (2 records in the update) 
Total number of papers excluded: 1181 
2.4.3. Papers included in analysis 
There were 48 papers that discussed multiple influences on the prescribing behaviour 
of GPs. All of the papers have been included in the systematic review. The papers are 
not of equal standard in terms of design, quality, analysis or their degree of relevance 
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to this research but all have been included in this analysis because the main aim of 
this review was to identify all possible influences on prescribing. 
Of the 48 papers included in analysis; there were 25 that described qualitative 
research; 18 quantitative research; 5 Mixed methods (Qualitative and Quantitative). 
A summary of the findings from these papers is displayed in Table 3 below with a 
brief description of the Type of Study; Setting and sample size; theoretical models 
used; influences on prescribing studied; Conclusion made from the research and 
finally, an assessment of the quality of the study based on the criteria described in 
section 2.3. 
2.4.3.1. Qualitative research papers 
All the papers describing qualitative studies have been included in this review because 
it was felt important to identify all possible influences.  However, there are several 
issues with the studies. Out of the 25 studies only eight papers included any analysis 
of the number of times an influence was mentioned as important, and of these eight 
papers incomplete presentation of data was common (some influences were deemed 
more important than others) and so analysis was only presented for them. For 
example, the paper by Hunt et al. (2012) presents statistics available on the 
percentage of clinicians who mentioned certain influences but it was not given for all 
influences and there was extensive discussion about two of the influences mentioned 
with the others largely being ignored despite their apparent importance in the results. 
Although GP demographics (age, sex, training, education) and organisation details 
(size, geography, type - fundholding or non fundholding for example) are 
acknowledged as being influences in altered prescribing behaviour only a few of the 
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studies included this information in the analyses. If it was collected then it was usually 
presented simply as a description of the participants with no subsequent link to any of 
the results, making it impossible to ascertain if any of the influences that had been 
identified were linked to these characteristics. Where it is mentioned the analysis is 
incomplete, for example in the study by Baker and Klein (1991) results from 
fundholding and non-fundholding practices are reported separately but only for specific 
questions about financial constraints and incentives. 
2.4.3.2. Quantitative research papers 
All the Quantitative papers that were identified have also been included in the analysis, 
but are not without several common issues. The main problem with the quantitative 
research, was that they acknowledged that there were a number of influences thought 
to influence prescribing behaviour but they only chose variables in their research that 
were easy to obtain and there was no attempt to reflect the influences identified from 
the qualitative research. Some of the variables appeared to be included simply 
because they were available for the organisations. This is demonstrated in Table 4 
where the influences indentified in qualitative papers are compared with those studied 
in quantitative papers. 
2.4.3.3. Mixed methods research papers 
There were five mixed methods papers and they have all been included in the analysis. 
These were all very useful papers because of the combination of collecting qualitative 
information and analysing quantitative data. 
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2.4.3.4. Description and analysis of the qualitative research papers included in the 
systematic review 
The qualitative research papers included in the systematic review (Table 1) found that 
not only are there a number of possible influences that GPs must take into account, 
but that these varied according to the situation of the GP (what type of organisation 
they are part of, how they feel about incentives and guidelines, how confident they are 
about treating a particular disease).There was no clear hierarchy of the influences 
although one of the papers found that that organisation; education; contact with 
professionals accounted for 47.9% of the total reasons for change in prescribing (Allery 
et al., 1997). Clinical Guidelines were identified as important (67% clinicians) in a study 
in America in patient with diabetes and hypertension (Hunt et al., 2012). This was 
corroborated in another survey of clinicians treating patients with osteoarthritis where 
NICE guidelines were important for 65% of respondents and professional experience 
for 64% (Kingsbury and Conaghan, 2012). 
The complexity of the interaction of influences is highlighted in all the qualitative 
research papers, but not all the papers agreed on the most critical issues. The theme 
that emerges from the papers are that the decision-making process of GPs is itself 
very complex, with GPs taking account of their own personal knowledge of the patient 
as well as other influences. The disease and drug in question are very important in this 
because decisions to treat with a one off short course of therapy (as in the case with 
antibiotics) are very different from starting the patient with a chronic disease on a 
lifelong treatment with likely side effects. Two of the papers compared the difference 
between the attitudes of hospital specialists and GPs in chronic diseases (Greenfield 
et al., 2005, Kedward, 2003) and both identified that knowledge of the patient’s 
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situation and implications (both for the patient and on cost) of starting long term 
treatment was deemed much more important for GPs than for specialists. 
The interaction between primary and secondary care is very important and one of the 
key influences of changing prescribing behaviour of GPs. In Crowe et al. (2009) the 
subject of prescribing of shared care specialist drugs was examined in the North West 
of England. This is an important area of research because increasingly more and more 
drugs previously thought of as specialist only are being moved into primary care. The 
study conducted semi structured interviews with GPs, PCO and strategic health 
authority staff and found that the most successful joint working was achieved if shared 
care protocols were developed with involvement of all staff and took into account of 
the local environment. The authors cite one possible weakness of this research that it 
was undertaken within a single strategic health authority on England and although the 
research had great breadth in the views that were obtained, it was narrow in terms of 
the number of organisations and locations. However, this highlights a potentially 
important fact, suggested elsewhere – namely that there is a local dynamic to the way 
in which patients are treated, and large scale studies that ignore this, may not fully 
elucidate reasons why decisions are made.  
This was also demonstrated in a comparison of prescribing in non-fundholding 
practices in the UK (Eccles, 1996). The aim of this research was to understand GPs’ 
attitudes to three things (a financial incentive scheme, use of guidelines and influence 
of secondary care). The results indicated that practices that achieved the savings 
under the incentive scheme were happier with timescales and targets and the 
philosophy behind the schemes. The willingness of health professionals within 
practices to work together with other local organisations and personnel is important to 
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the success of interventions. However, they also found that no one single influence 
was significant when changing prescribing behaviour and it would seem that it is a 




Table 1: Qualitative papers included in the systema tic review 




Interviews. Type 2 
Diabetes in older 




interviews focused on 
information related when 
prescribing insulin. 
Interview guide modified 
as interviews proceeded 
to reflect emerging 
themes. GROUNDED 
THEORY APPROACH.  
NO conceptual model 
utilised. 
Seven main influences 
identified  
GPs beliefs about older 
people. GPs beliefs 
about diabetes and 
management. Gauging 
intensiveness of 
therapy required. Need 
for preparation of 
insulin therapy. Support 
available for individual. 
GP experience with 
insulin. Frustration with 
management 
complexity. 
Patient and GP influences 
have an impact on insulin 
prescribing. GPs’ 
prescribing varied 
depending on their 
assessment of the 
patients’ situation. Under-
prescribing of insulin could 
be improved by more GP 
education, better 
specialist-GP 
communication, and the 
use of other professionals 
to provide support 
networks for patients and 
GPs. 
 
Not random selection of 
GPs (personal 
contacts) and 16 out of 
21 GPs interviewed are 
male. Not many GPs 
had actually initiated 
insulin in their older 
patients. No analysis of 
data only quotes and 
discussion. GP 
demographic data 
collected and presented 
but not used to 
enhance results. No 
organisation details. 
Diabetes area of study. 
(Allery et al., 
1997) 
Qualitative Study - 
(interviews) – general. 
Random sample of 50 
GPs and 50 
consultants in South 
Glamorgan. 
Interviews using the 
critical incident technique 
resulted in classification 
framework of 12 
categories and 50 
subcategories. 
NO conceptual model 
utilised. 






workload, uptake of 
new post); Education 
(literature, meetings, 
research, audit, 





centred (patient led, 
patient need) 
Technology / tests 
The main reasons for 
change in prescribing 
behaviour found (in order 
of the number of times 
they were mentioned) to 
be economic, education, 




companies and clinical 
experience. 
The study was not 
solely focused on 
prescribing change and 
also focused on 
management, referrals 
and investigations. 
However, all areas 
were discussed 
separately. Random 
sampling in 1 Family 
Health Authority. GP 
demographics collected 
but not included in 
discussion of results. 
All consultants (50) 
were men and GPs (50) 





use) Economic (wish to 
save money, pressure 
to save money, lack of 
funding, prescription 
charges, PACT data, 
indicative drug budget, 
income generation). 
collected. Analysis of all 
the important influences 
was presented. 
(Armstrong 
et al., 1996) 
Qualitative Study – 
semi structured 
interviews. General.     
18 GPs in South East 
London, UK. The 
sample was selected 
to include GPs who 
differed in age, sex, 
and ethnic group and 





and deprived areas.  
 
GPs were asked to 
identify any changes in 
their prescribing practice 
over last 6 months.  
NO conceptual model 
utilised. 
 
For most changes 
several determining 
influences could be 
identified: these tended 
not to reveal a single 
trigger to behaviour 
change but rather an 
accumulation of cues 
that change was 
possible, desirable, and 
worthwhile. Mainly 
reading, influence by 
consultants, other GPs 
and the GPs own 
personal experience 









Three models of change 
were identified: an 
accumulation model, in 
which the volume and 
authority of evidence were 
important; a challenge 
model, in which behaviour 
change followed a 
dramatic or conflictual 
clinical event; and a 
continuity model, in which 
change took place against 
a background of 
willingness to change, 
modulated by other things 
such as cost pressures 
and the comprehensible 
therapeutic action of a 
drug. Behaviour change 
was reinforced and 
sustained by experiences 
with individual patients.  
GP demographics 
collected from GPs in 
South East London. 
GPs chosen to reflect 
variation in age, gender 
and type of practice. No 
analysis of data. Only 
quotes and discussion. 
(Buusman 
et al., 2007) 
Qualitative Study – 
interviews. General. 
15 GPs from the 
counties of both 
Funen and West 
Zealand in Denmark 
were selected with 
Transcriptions were 
analysed in accordance 
with the sociological 
phenomenological 
approach of Schutz and 
systematic ethnographic 
domain analyses were 
Influences identified 
include: drug price; 
external influences 
outside the GP's control 
such as governmental 
regulation on 
prescribing and the 
GPs balance both internal 
and external influences 
when choosing between 
analogues. Drug costs 
were very important. 
External influences: 
Formularies acknowledged 
GPs chosen to reflect 
variation in age, gender 
and type of practice. No 
analysis of data only 
quotes and discussion. 
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reference to variation 
in organizational 
structure, age, and 
gender 
performed. YES a 
conceptual model was 
used. The complexity 





influences related to the 
actual consultation 
included characteristics 




as useful as were 
recommendations from 
secondary care and sales 
reps. Internal included 
patient demands, GP’s 
previous experience. 
Prescribing decision 
requires GP to balance 
competing influences as 





Qualitative Study – 
semi structured 
interviews. Antibiotics. 
Eighty primary care 
clinicians randomly 
selected from primary 
care research 
networks based in 
nine European cities 
Data subjected to a five-
stage analytic framework 
approach (familiarisation, 
developing a thematic 
framework from interview 
questions and emerging 
themes. 
NO conceptual model 
utilised. 
Non-clinical influences 
imposed by healthcare 
system: patient access 
to antibiotics; systems 
to reduce patient 
expectations; 
guidelines; and clinician 
characteristics. 
Healthcare system 
influences (e.g., limiting 
patients' self-management 
with antibiotics before 
consulting in primary care, 
increased public 
awareness and provision 
of more consistent 
guidelines). Promoting 
clinicians' receptivity to 
change, confidence in 
decision-making and 
readiness to invest in 
explaining prescribing 
decisions may also be 
beneficial. Influences were 
emphasised differently 
between networks so local 
flexibility in interventions is 
likely to maximise 
effectiveness. 
80 clinicians previously 
involved in research. 
No GP demographics 
or organisation details 
collected. NO analysis 




Qualitative Study – 
semi structured 
interviews. Several 
disease areas. 17 
GPs in Avon, South 
West UK. 
Qualitative research 
principles were used to 
identify, log and list 
emerging themes, 










require complex personal 
and professional 
judgements about 
physical, psychosocial and 
cost dimensions. 
GPs randomly selected 
but 15 out of 16 were 
male. Also assessed by 
prescribing behaviour 
(high, medium or low 
spend). Organisation 
details collected. No 
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prescribing policies and 
prescribing costs also 
seen as important 
influences. GPs had 
their own personal 
formulary shaped by 
medical training, 
colleagues, patients 
policy and own 
experience.  
analysis of data only 
quotes and discussion. 
No linking of GP or 








primary care trust and 
strategic health 
authority level staff in 
North West of 
England. 
Analysis was carried out 
using the five-stage 
‘framework’ approach. 
This involved developing 
a workable list of main 
and subthemes and 
applying it systematically 
to the whole data set . 
NO conceptual model 
utilised.  
Six Influences were 
identified: The 
specialist medicine; 




the patient, the practice 
decision and GPs 
specific area of interest. 
Main themes were the 
GP’s lack of knowledge 
and expertise using 
specialist drugs; 
relationship between GPs 
and local specialists and 
hospital staff. Shared care 
protocols are of variable 
quality and do not always 
involve GPs. 
No analysis of data only 
quotes and discussion. 
Not just GP opinions – 




randomly chosen – 
practices chosen in GP 
was willing to be 





Qualitative Study – 
postal questionnaire. 
General. 348 GP 
practices in former 
Northern Region, UK. 
The questionnaire 
covered a number of 
areas: the influences on 
a practice's decision on 
whether or not to try and 
achieve its target saving 
under the incentive 
prescribing scheme  
NO conceptual model 
utilised 
GPs attitudes to 
financial prescribing 
incentive scheme; 
presence of guidelines 
and influence of 
prescribing initiated in 
secondary care (this 
included the influence 
of medical and 
pharmaceutical 
advisers. 
Practices had no one 
overriding influence that 
affected them and it was a 
combination and their 
interplay that was 
important. 45% practices 




compared with formal 
meetings 35%; local 
consultant opinion 17%, 
financial incentive not 
No GP demographics 
collected and all 
fundholding practices. 
Analysis (chi squared 
test) on the results. 
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enough 16%, national 
professional opinion 12% 
and informal discussions 
with colleagues outside 
practice 11%. 
(Greenfield 
et al., 2005) 
Qualitative Study – 
postal questionnaire. 
Coronary Heart 
Disease (CHD). 296 
respondents from 
West Midlands, UK. 
43 cardiologists; 192 
GPs and 61 practice 
nurses. 
A questionnaire with 
general questions about 
CHD; six scenarios 
representing patients 
with CHD and 2 CHD risk 
questions. Open and 
closed questions.  
NO conceptual model 
utilised. 
5 main themes: the 
risks and benefits of 
treatment; the patient's 
role, patient 
characteristics, costs to 
patients and costs to 
health services. 
Prescribing lifelong 
preventative medication for 
CHD is difficult and 
decisions about treatment 
thresholds are most 
difficult. The same broad 
issues of cost to patient 
and health service, the 
characteristics of the 
patient themselves and 
their role in treatment 
decisions and the nature of 
risk assessment tools were 
raised not only by GPs and 
practice nurses but also by 
cardiologists. Cardiologists 
emphasized role of patient 
– but GPs did not talk 
about shared decision 
making. Their focus was 
on treatment thresholds 
and practice nurses were 
concerned about costs to 
health service. 
No GP or organisation 
details collected. 
Analysis was presented 
on the results as well 
as quotes and 
discussion/ 
(Hedenrud 
et al., 2013) 
Qualitative Study – 
four focus group 
discussions. 
Psychiatry.   21 
participants (GPs, GP 
interns and heads of 
primary care units) 
from Gothenburg, 
Sweden 
The focus group 
discussions were 
transcribed verbatim and 
analysed using manifest 
content analysis. 
NO conceptual modeul 
utilised. 
Three different themes 
emerged. 1. Seeking 
care for symptoms, 
reflects the participants' 
understanding of why 
patients approach 
primary care. 2. 
Lacking a framework, 
resources, and 
treatment alternatives, 
A variety of influences may 
affect the prescribing of 
psychotropic medications 
in primary care. Many 
influences were related to 
characteristics of the 
patient, the physician or 
their interaction, rather 
than the patients' medical 
needs per se. The results 
No GP or organisation 
details collected. 21 
GPs chosen through 
personal contacts. No 
analysis of data only 








aspects. 3. Restricting 
or maintaining 
prescriptions, with the 
subthemes Individual 
influences reflect the 
physicians' internal 
decision making and 
comprised categories 




may be useful for 
interventions to improve 
psychotropic prescribing in 
primary care. 
(Hunt et al., 
2012) 
Qualitative Study – 
Interviews. Type 2 
diabetes and 
hypertension. 44 
primary care clinics in 
Michigan - 58 
clinicians and 70 of 
their patients, and 







developed, piloted, and 
revised 2 sets of 
standardized open-ended 
unstructured questions 
followed by focused 
probes, with advice from 
a cross-disciplinary 
expert panel. Clinician 
interviews explored 
concepts and strategies 
for managing type 2 
diabetes and hyper- 
tension. Patient 
interviews focused on 
understanding causes, 
course, and 
consequences of these 
diseases, and patients’ 
treatment experiences.  
NO conceptual models 
utilised 
Clinical guidelines; 




Guidelines were identified 
as important (7% 
clinicians) – no 
reservations about 
appropriateness of targets 
or strategic use of 
medication to reach 
targets. Pay for 
performance (17% said 
this motivated them). 
Patient wellbeing does not 
seem to be high on 
agenda. Influence of 
Pharmaceutical company 
pushing more medication 
seen as deleterious. 
Clinicians not randomly 
chosen. Deliberately 
chosen from clinics with 
a high number of low 
income and ethnic 
minority patients. Some 
statistics available on 
the % of clinicians who 
mentioned certain 
influences but not all of 
them. Big focus on cost 
of drugs and influence 
of pharmaceutical 
companies in 
discussion but not 
necessarily in the 





ne et al., 
2013) 
Qualitative Study – 
Focus Groups. 
Antibiotics.  Five focus 
groups with 22 GPs 
from Lithuania and 29 
GPs from Kaliningrad 
Region of the Russian 
Federation. 
Themes were grouped 
into categories; reviewed 
and summarised in terms 
of what they revealed 
about external enabling 
influences. 
NO conceptual models 
utilised 
Six thematic categories 
were identified the 
necessity for political 
leadership to 
encourage clinically 
grounded antibiotic use; 
over-the-counter sale of 
antibiotics; designation 
of antibiotics as 
reimbursable 
medications; 
supervision by external 
oversight institutions; 
lack of guidelines for 





The enabling environment 
around the physician 
should be addressed as 
well as the GP /patient 
influences. 
 
GPs already taking part 
in a multicentre audit of 
antibiotic prescribing 
(HAPPY AUDIT). More 
females than males. 
Organisation details 
collected but not linked 
to the discussion of 
results. No analysis of 




Qualitative Study – 
semi structured 
interviews. Coronary 
heart disease and 
statins. 26 GPs from 
General practices in 
mid and south 
Bedfordshire, UK. 
Interviews until saturation 
point was reached with 
no new themes 
emerging. 
NO conceptual model 
utilised 
Concerns about cost 
and cost effectiveness; 
workload; adherence to 
treatment; 
medicalisation; effects 
on health behaviour - 
lifestyle issues  
There are complex barriers 
to statin prescribing and 
coronary prevention in 
general practice, which 
may explain some of the 
variation that exists. Statin 
prescribing guidelines – 
interpreted differently by 
GPs for number of 
reasons.  
Purposively samples to 
select GPs with 
diversity of sex, year 
qualification, practice 
size and location. 
Quarter GPs already 
known to researchers. 
No analysis of data only 





Qualitative Study – 
online survey. 
Osteoarthritis. 232 
GPs across UK. 




sources of information; 
disease management; 
barriers to better care; 
strategies to improve 
care. 
NICE guidelines (65%) and 
professional experience 
(64%) were biggest 
influences on OA 
management. 52% did not 
use educational materials 
and only a third rated their 
current educational 
material as good. 
Prescription review carried 
GP demographics and 
organisation details 
collected. GPs across 
UK contacted and 
those who selected a 
special interest in 
musculoskeletal 
disorders were 
included. Analysis of 
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out by 74%. Most common 
needs identified to improve 
care: more time with 
patients, collaboration with 





(Khan et al., 
2015) 
Qualitative Study – 
semi structured 
interviews.19 patients 
with migraine; 6 
physicians who have 
prescribed triptans for 
migraine; 8 
pharmacists who have 
dispensed them. 
Canada. 
Coding and analysis of 
transcripts using a 
Framework Approach by 
two independent analysts 
to identify common 
themes.  
NO conceptual model 
utilised 
Four themes that 
emerged at the patient, 
provider, and health-
care systems levels: (1) 
awareness; (2) apathy; 
(3) advocacy; and (4) 
affordability. 
Patients were sometimes 
apathetic about seeking 
treatment and physicians 
lack of concern about 
migraine. Pharmacists 
seen as advocates to help 
patients receive triptans. 
GP demographics 
collected but not used 
in discussion. Not just 
GPs in the focus 
groups. No analysis of 
data only quotes and 
discussion. Extensive 
focus on specific 
problems associated 
with triptan use and 
insurance / payment 
issue. 
(Klein et al., 
2006) 
Qualitative Study – 
individual semi 




 prescribing.  A 





Interviews about  real-life 
clinical management 
decisions. The dataset 
was coded into key 
thematic areas following 
the analytic inductive 
method suggested by 
Ritchie and Spenser. 






affordability to patients, 
availability of samples, 
drug company 
marketing practices, 
habit formation, time 
constraints, previous 
clinical experience of 
doctors and/or patient 
with certain drugs and 
doctors’ perception of 
absolute versus relative 
risk. 
In terms of influences 
important in deciding 
whether to use COXIBs to 
combat Musculoskeletal 
(MSK) pain and mobility 





Although drug marketing 
plays a key role in a 
doctor’s choice of drugs for 
MSK disorders, this study 
shows that doctors rely on 








collected. No analysis 
of data only quotes and 
discussion. GPs 
chosen their own index 
cases so may have 
chosen exemplary 
examples of treatment 





Focus groups with 36 
Theoretical sampling 
procedure was adopted. 
Three broad themes 
emerged: Doctor 
Lack of rules around the 
supply of antibiotics (and 





physicians in public 




focused on the 
motivations and 
behaviours leading to 
antibiotic misuse. 
Information coded 
according to Grounded 
Theory. 







patients; type of 
practice (public or 
private). Influence from 
medical 
representatives. Patient 
related Influences (not 
completing the course, 
self-medication, lack of 
education/understandin
g). Lack of guidelines 
several ways for a patient 
to get the drugs apart from 
a GP prescription) 
seriously compromise a 
reduction in antibiotic 
misuse. Other influences 
such as lack of time, 
financial considerations 
and patient expectation, 
patient education, lack of 
guidelines and the type of 
organisation (public or 
private) are also important 
types of organisations 
(public or private) 
deliberately chosen 
across a geographical 
area. No analysis of 
data only quotes and 
discussion. Ability to 
buy antibiotics over the 
counter in important for 
private GP practices. 
(Magzoub et 
al., 2011) 
Qualitative Study – 
Questionnaire. 
General. 87 Primary 
Health Care 
physicians. working in 
the private and public 
PHC centres in 
Rhiyadh City, Saudi 
Arabia who were 
previously selected for 
a study of prescribing 
Principal component 
analysis was used the 
pattern of correlations. 
The questions were 
combined to identify a 
smaller number of 
influences that accounted 
for most of the variance 
observed in the 
physicians’ questionnaire 






scores were saved as 
variables to undertake a 
logistic regression model 
to predict prescription 
quality.  











Of the 7 influences found 
to explain 46% of variance, 
4 components positively 
related to perceived good 
prescribing behaviour: 1. 
clinical experience of 
physicians; 2. use of 
educational materials for 
continuous updating of 
medical knowledge; 3. 
enhanced levels of 
continuing medical 
education and 4. 
willingness to involve 
patients in decision-
making; and working as a 
team using pharmacists for 
consultation and 
emphasizing the role of 
medical education. The 
other 3 influences are less 
easy to interpret – 5. Value 
of educational meetings 
(but not those organised 
GP demographics and 
organisation details 
collected and 47 public 
GPs and 40 private 
GPs. GPs previously 
involved in other 
research. Sample 
stratified to ensure full 
range of primary care 
practices covered in 
both sectors. influence 
analysis carried out on 
the influences identified  
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by pharma) 6. Effect of 
size and organisation of 
the health centre and 7. 
Physician nationality and 









(PPI)s. 9 general 
practices in the North 
Staffordshire Health 
Authority (UK) were 
approached and 
seven agreed to take 
part in the study (26 
GPs) 
Semi structured home 
interviews conducted. 
NO conceptual model 
utilised. 
Prescribing pattern for 
PPIs; effect of cost 
cutting on GP / patient 
relationship; response 
to guidelines; clinical 
need; situational 
pressures; stereotypes 
of patients; cost 
effectiveness; 
organisation type 
(fundholding or non 
fundholding practices); 
incentive schemes 
There was an adverse 
impact on medical practice 
because of the competing 
pressures of meeting 
patient needs while 
complying with prescribing 
incentives and guidelines. 
GPs felt that policies 
relating to cost 
containment and patient-
centred medicine are 
incompatible and may help 
to explain the systematic 
inertia which appears to 
have hindered the 
development of genuinely 
patient-centred medicine 
over the last few decades. 
GP demographics and 
organisation details 
collected. Of the 18 
GPs interviewed, 17 
were male. Analysis of 
some of the influences 
(those focused on cost 
containment and linked 
to fundholding or not). 
But for other influences 




Qualitative Study – 
semi structured 
interviews. New 
drugs. 107 GPs 
selected purposively 
from high, medium 
and low new drug 
prescribing practices 
in two health 
authorities in the north 
west of England 
Interviews used the 
critical incident technique 
to encourage GPs to give 
factual accounts of 
prescribing events and 
explain why they had 
prescribed a new drug. 
NO conceptual model 
utilised. 
Influences influencing 
new drug uptake were: 
failure of current 




consultants opinion and 
prescribing; patients; 
local guidelines. 
Prescribing of new drugs is 
not simply related to 
biomedical evaluation and 
critical appraisal but, more 
importantly, to the mode of 
exposure to 
pharmacological 
information and social 
influences on decision 
making 
GPs purposively 
sampled to reflect high, 
medium and low 
prescribing of new 
drugs in North West 
England. Some 
analysis of influences 
provided (% mentioned) 
as well as quotes and 
discussion. 
(Scott et al., 
2011) 
Qualitative Study – 
semi structured 
interviews with 11 
GPs in UK 
Interviews revolved 
around 3 set questions.  
NO conceptual model 
utilised. 
3 questions – 1. main 
influences on 
prescribing; 2. specific 
influences of local 
GPs cited the following 
influences cost and PCO 
(cited by all GPs) then 
NICE guidelines, 
GP gender collected. 
No organisational 
details. No analysis of 
53 
 
influences – local 
organisational; national; 
pharma industry and 
financial incentives. 3. 
Future influences. 
consultants, British 
National Formulary (BNF), 
Pharma industry, patients, 
information sources, 
previous experience / 
training, colleagues, 
educational meetings, 
familiarity and drug safety. 
data only quotes and 
discussion. 
(Strandberg 
et al., 2013) 
Qualitative Study – 
focus groups and 
semi structured 
interviews. Antibiotics.  
Two focus groups 
representing rural and 
urban areas in primary 
health care (13 GPs) 
in 2 counties in 
Southern Sweden 
An editing analysis style 
according to Miller and 
Crabtree. Once units 
were identified they were 
sorted and organized into 
categories in an iterative 
process throughout the 
analysis.  
NO conceptual model 
utilised. 
Influences connected to 
the GP, the 
relationship, and the 
setting; organization as 
well as professional 
culture. 
Synergies between the 
influences exist, and one 
can sometimes 
compensate for lack of 
another. Continuity and 
mutual trust can make a 
brief consultation 
successful, but lack of 
continuity can eliminate the 
effects of knowledge and 
professional skills. 
Importance of an 
appropriate organization of 
primary care, which 





participants chosen for 
heterogenicity in sex, 
age and professional 
experience. GPs 
previously involved in 
multicenter audit of 
antibiotic prescribing 
(HAPPY AUDIT). 2 
focus groups – 1 urban 
and 1 rural. No analysis 
of data only quotes and 
discussion 
(Tan et al., 
2009) 
Qualitative Study – 
focus groups. Asthma. 
29 Singapore Family 
Physicians working as 
private GPs, polyclinic 
doctors and locums -
recruited into five 
focus groups 
A qualitative method 
using focus group 
discussions (FGD) was 
used to gather qualitative 
data based on a semi-
structured topic. 
NO conceptual model 
utilised. 
Prescribing Decisions 
related to medical 
training; acquisition of 
asthma related 
information and 
updates. Uncertainty of 
disease diagnosis, 
patients' beliefs and 
their perceptions of the 
disease; concerns 
about drug side effects, 
costs related to 
differential subsidies. 
Family Physicians' asthma 
drug prescribing behaviour 
is influenced by their 
medical training, disease 
definition, patient 
influences and drug costs 
in the context of the local 
primary healthcare system 
and policy. 
Age of GPs collected 
but not chosen for 
anything else. 5 focus 
groups with GPs 
specifically from 
organisation types 
(private, polyclinic and 
locums). No analysis of 








Qualitative Study – 
focus groups. Genera 
GPs from private and 
public sector in 
primary care in three 
geographically defined 
areas in Greece. 
 
 
Study part of a European 
project entitled 
‘Assessing the Over-the-
counter Medications in 
primary care and 
translating the Theory of 
Planned Behaviour TPB) 
into interventions’ 
(OTCSOCIOMED) . 
YES Conceptual model 
used – Theory of 
Planned Behaviour 




GPs and specialists; 
public health 
authorities; patient 
income and limited time 
availability 
Influences that are not 
common in the usual 
European setting were 
revealed, such as the 
influence of the patients' 




collected but not used 
in results. GPs 
previously part of 
OTCSOCIOMED study. 
3 geographically 
defined areas in public 
and private sectors. No 
analysis of data only 
quotes and discussion 
(Vazquez-
Lago et al., 
2012) 
Qualitative study – 5 
focus groups with 33 
physicians in Spain. 
Antibiotics. 
Focus group method 
using themes and 
categories found on a 
previous systematic 
review to provide an 
agenda for discussion. 
NO conceptual model 
utilised. 
 
The influences / 
attitudes that were 
identified by the groups 
as influencing GP 
prescribing of 




industry, patients and 
antibiotics. Antibiotic 
resistance was not 
thought to be a problem 
n the community.  
GPs proposed more 
manageable clinical 
guidelines, and rapid 
diagnosis. Important that 
GPs did not think 
resistance was a problem. 
They also blamed other 
professionals (dentists, 
vets, pharmacists). The 
industry was only 
mentioned as important by 
2 of the groups. 
GP gender only 
collected. GPs within 
one area but 75 
contacted (no rationale 
given). Focus group 
from 5 health centres. 
No statistics but some 
explanation of 
differences in results 
between groups and 
total number times an 
influence was 
mentioned. Older 
patient population so 
fear of complications a 




2.4.3.5. Mixed methods research papers included in the systematic review 
In the 5 mixed methods papers (table 2) that have combined qualitative and 
quantitative research, the quantitative analyses only investigated a small number of 
critical influences (Weiss et al., 1996) or simply used the results from the quantitative 
work as a means of stratifying the GPs prior to taking part in the qualitative study 
(Jones et al., 2001; Jacoby et al., 2003). Only one study (Houten et al., 2014) used a 
wider range and type of possible influenes. It analysed the supply influences that 
affected prescribing across six therapeutic areas in primary care trusts in the UK.  A 
number of variables were measured (QOF scores – including clinical, patient 
experience and organisational influences); CG Annual Health Check score, GP list size 
(number of patient per GP); Services offered (screening, mental health services, 
medication reviews); Strategic health Authority linked to the PCT (indicating regional 
variation in policy at SHA level); drug spend; disease prevalence and population 
demographics. The results of the detailed regression analysis showed that drug use 
varied significantly in the PCTs in England and that a wide number of general 
influencers impacted in most of the therapeutic areas as well as individual influences 
for specific therapeutic areas. They found that PCT organisational standards (part of 
the QOF score and the Care Quality Commission (CQC) annual health check score) 
also seemed to influence levels of prescribing. Unfortunately, the paper did not present 
the differences in prescribing levels between PCTs for the therapeutic areas nor did it 
look for any patterns of scores in the different variables for the PCTs. The authors have 
acknowledged that they have only looked at some of the known influences on 
prescribing so the analysis was incomplete. 
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Table 2: Mixed methods papers included in the syste matic review  
Referen
ce 





Mixed – Qualitative data 
from a survey and 
prescribing and 
demographic data from 
national database. 138 
GPs in 93 practices in 
The Netherlands. 
Range of drugs 
measured.  Data from 
Second Dutch National 




variables and overall 
range. Multiple 




explanatory variables.  




practice information (type 
of practice, dispensing 
status, number of 
prescriptions per head, 
urbanisation; GP age, 





No clear relationship 
between prescribing 
behaviour and any one 
influence. 
Examining a range of drugs 
can be useful to understand 
prescribing behaviour but 
the study did not link 
prescribing against 





Mixed - Qualitative 
Study linked with 
quantitative data –
Questionnaire in 25 
primary care units in 
Sweden. General.  
Result from the 
questionnaire were 
analysed against 
Sales information for 











calculated to evaluate 
bivariate correlations. 
NO conceptual model 
utilised. 
Characteristics of practice 
settings – size unit; 





information; education for 
physicians.  
A physician as head of 
organisation; independent 
drug information were 
positively correlated with 
adherence to prescribing 
objectives. Presence of 
Pharma company 
information; education for 
physicians were negatively 
associated. 
No GP demographics 
collected. Analysis focused 
on primary health care units. 
Lots of influences identified 
as being important but not 
collected or measured. 
Despite aims of study being 
broad investigation into 
characteristics of units and 
prescribing behaviour there 








Mixed Study – semi 
structured interviews. 
new drugs. Quantitative 
prescribing data. 38 
consultants and 56 GPs 
who regularly referred to 
the teaching hospital in 
Birmingham, UK. 
Issues from the 
interviews were 
categorized into main 
themes. Prescribing  
data from hospital and 
general practice 
analysed. 
NO conceptual model 
utilised 
Issues from the interviews 
could be organised into 
three main themes: use of 
new drugs, attitudes to 
innovation and sources of 
information. 
Decisions to prescribe new 
drugs based on a 
combination of influences 
and these varied between 
consultants and GPs. GPs 
relied more on drug 
representatives, and hospital 
specialists. 
No GP (or consultant) 
demographic data or 
organisation details. 
Prescribing data for each 
GP, but no analysis of 
influences and themes only 








enzyme (ACE) inhibitor 
prescribing of 735 
patients from 95 GPs in 
The Netherlands. 
Study part of a 
baseline study from a 
larger research 
project. Evaluating 
audit programmes for 
diabetes, hypertension 
and Coronary heart 








each of the outcome 
variables. 
NO conceptual model 
utilised. 
Influences recorded: GP 
gender, work experience, 
dispensing status, size 
and type of practice and 
location. Patient visits of 
outpatient clinics, referrals 
to cardiologist and 
hospitalisations in 
previous year. Patient 
demographics were age 
and gender as well as 
comorbidities. Patients 
with a diagnosis of heart 
failure were included for 
study. 
Underuse and under-dosing 
of ACE  inhibitors were 
mainly associated with 
patient characteristics, such 
as gender, age, concomitant 
hypertension and the use of 
a diuretic. Organisational 
influences as specialist care 
and 
outpatient heart failure clinics 
were also associated with 
higher prescribing of ACE 
inhibitors. General GP 
characteristics, such as work 
experience or gender, did 
not determine whether heart 
failure patients received 
ACE inhibitor treatment. 
GP demographics, specific 
patient population with Heart 
failure with GPs who had at 
least 10 patents being 
chosen. Organisation details 
collected and information 
about referrals to hospital 
and cardiologists. Multilevel 
analysis of the most 






Quantitative analysis of 
prescribing data. 
Qualitative 
questionnaire (228 GPs) 
and interviews 23 
GPs.Antibiotics.  
In depth qualitative 
interviews were 
conducted with 23 




analysis revealed 4 
themes. A fixed choice 
questionnaire was 
then created. Twenty 
4 broad areas of 
prescribing 1. sense of 
burden providing 
healthcare; 2. views on 
financial constraints and 
incentives; 3. clinical 
workload and 4. patient 
pressure. Secondary aim 
to relate concerns to PCT 
prescribing data. 
Sense of burden not 
reflected in prescribing data. 
Fundholders and non 
fundholders saw the financial 
constraints very differently 
and tending to behave 
differently in their prescribing 
habits.  
GP demographics collected. 
386 GPs in Southern 
England sent questionnaire. 
Organisation details 
collected and used in 
analysis of some of the 
questions. PACT data used 
to create prescribing 
dependent variables. 





statements with a five-
point Likert raring 
scale were developed 
to address the 
themes. 
NO conceptual model 
utilised. 




2.4.3.6. Quantitative research papers included in the systematic review 
In contrast to the qualitative research, the papers describing quantitative research 
(Table 3) had pre-defined influences that had been studied often because of their 
availability. There was no consensus on the critical influences that might be 
responsible for variation in prescribing behaviour. In the study by Baker and Klein 
(1991) four influences accounted for 69% of variation (Lower rates of prescribing per 
10000, fewer GPs per 10000 patients on lists, a smaller proportion of GPs over 65, 
and a larger number of ancillary workers per general practitioner). Pharoah and Melzer 
(1995) found that the proportion of temporary residents and proportion of women over 
65 explained 25% of variation in prescribing and in Morton-Jones and Pringle (1993) 
four explanatory variables showed a correlation with Net ingredient cost – list inflation, 
standardised mortality ratio, % pensioners and % prepayment certificates. 81% of 
variation explained by these influences. There was no consistent pattern in the 
influences found to be significant in accounting for prescribing variation. 
The relationship between spend on prescribing and good management of the disease 
was not proved in any of the papers looking at chronic disease. An observational study 
looking at the variability in potentially preventable hospitalisations and outcomes in 
clinical practice patterns of GPs in Spain (Orueta et al., 2015) analysed data for the 
entire healthcare system for a population in one location in Spain. They were able to 
examine variables at several levels (patient, doctor, primary and secondary healthcare 
institutions and found that GPs with a greater than expected number of visits with 
patients, higher prescribing costs or lower referral rates were associated with higher 




Table 3: Quantitative papers included in the system atic review  
Referen
ce 





Quantitative Study – 
General 90 family health 
services authorities in 
England.. 
The family health 
services authorities 
were treated as 
discrete primary 
health care systems. 
MAIN OUTCOME 
MEASURES: Rates of 
cervical smear testing, 
immunisation, 
prescribing, and night 
visiting. No conceptual 
model 
Nineteen performance 
indicators reflecting the 
size, distribution, and 
characteristics of the 
population served; the 
organisation of general 
practice (inputs); and the 
activities generated by 
GPs and their staff 
(output) were analysed. 
Lower rates of prescribing 
per 100,000 population were 
associated with lower 
standardised mortality ratios, 
fewer GPs per 100,000 
patients on lists, a smaller 
proportion of GPs over 65, 
and a larger number of 
ancillary workers per general 
practitioner. These four 
influences accounted for 
69% of variation). 
Healthier areas might be 
expected to have lower 
prescribing rates, and these 
are also strongly associated 
with better staffed practices. 
But this does not mean that 
lower prescribing can always 
be interpreted as a positive 
indicator as such rates are 
also associated with fewer 
practitioners per patient. 
No rationale as to why 
variables have been chosen 
so not obvious why some 
data has been included. 
Outcome measures not just 
prescribing but also focusing 
on smear testing, 
immunisation and night 
visits. SIMILAR to this 
RESEARCH. Data not 
linked to specific patients. 
(Bjerrum
, 1999) 
Quantitative study - 
comparing 
polypharmacy (more 
than 5 drugs) in 173 
GPs in Denmark.  
Prescribing data from 
National database. 
Other data from 
Regional Health 
Insurance database. 




No conceptual model 
Practice characteristics 
(type of practice (solo or 
group, number of GPs and 
number of patients per 
GP); workload in practice; 
referral patterns; clinical 
work in practice and 
prescribing profile 
Predictors related to practice, 
structure, workload, clinical 
work profile, and prescribing 
profile could explain 56% of 
the variation in major 
polypharmacy between 
practices. 
All GPs in one district in 
Denmark. SIMILAR to this 
RESEARCH. Data not 







Quantitative study – 
investigating the 
number of different 
drugs prescribed in 173 
practices in Denmark 
 
Prescribing data from 
National database. 
Other data from 
Regional Health 
Insurance database. 




No conceptual model 
 
Practice characteristics 
(type of practice, workload 
in practice, number of 
GPs, number of patients 
per GP, age and gender 
of patients, workload in 
practice and referral 
pattern / procedures 
performed in practice. 
 
Four practice characteristics 
were significant predictors of 
the number of different drugs 
prescribed. explaining 74% 
of the variation. 
 
Prescribing data across 
several drug groups as the 
dependent variables. 
Explanatory variables 
include GP demographics, 
patient characteristics and 
practice attributes. Also 
some reflection of workload, 
referrals and procedures 
performed in practice. 
SIMILAR to this 
RESEARCH. Data not 




Quantitative study to 
examine –The Supply 
hypothesis to explain 
medical practice 
variation on sample of 
GPs in New Zealand.  
Data from a regional 
survey of GPs. Multi-
level statistical 
analysis. Predictions 
were made about inter 
practitioner variations. 
3 areas of clinical 
decision making used 
as outcomes – 
prescribing, follow up 
visits and test ordering 
are examined. Supply 
Hypothesis as a 
conceptual model. 
Paper studied at effect on 
the 3 clinical decision 
making areas of,1. income 
incentives (doctor density) 
2. Physician agency (who 





characteristics and GP 
demographics. Were also 
collected. 
The Supply hypothesis – that 
practice and practitioner 
differences explain medical 
variation did not fit with the 
results of the analysis. Other 
influences are also important. 
Not so relevant to this 
research – several areas of 
research and focusing on 
the Supply Hypothesis. Data 






looking at inter 
practitioner variation in 
prescribing in general 
practice. Range of 
drugs in GP practices in 
Waikato region of New 
Zealand. 
A multivariate analysis 
is carried out on seven 
measures of 
prescribing activity in 
the areas of 
prescribing volume, 
script detail (generic 
or combination), and 
therapeutic choice 
(antibiotic, analgesic 
or psychotropic). No 
conceptual model 
Study uses The Sources 
of Variation (morbidity, 
population, health system, 
professional and 





practice attributes were 
recorded. 
Inter practice variation 
remains (although reduced) 
once GP, patient and 
practice variation are taken 
into account.  
Focus on variables 
associated with GP 
demographics, patient 
characteristics and some 
practice attributes. Patient 
morbidity (diagnosis and 
severity) also recorded. 
SIMILAR to this 
RESEARCH Useful 
because focus is on relative 
impact of groups of 
influences on prescribing. 
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looking at prescribing of 
antidepressants and 
anxiolytics in 164 
practices in E London, 
UK 
A practice based 
cross sectional survey 
using prescribing rates 
of antidepressants 
and anxiolytics as 
dependent variables. 
Multivariate repression 
model to examine 
influence of 
explanatory variables. 
No conceptual model. 
Explanatory variables: 
partnership size; practice 
locality; training status; 
practice manager; no 
GPs; patient age, 
deprivation, % practice 




cervical screening %. 
10 explanatory variables 
accounted for 47.7% 
variance in antidepressants 
and 34% of anxiolytics. 
Focus on variables 
associated with GP 
demographics, patient 
characteristics and practice 
attributes but also with 
measure of use of asthma 
prophylaxis and cervical 
screening (no explanation). 
SIMILAR to this 
RESEARCH. Data not 







use for acute respiratory 








provider and setting 
characteristics extracted.  
Patients commonly received 
antibiotics regardless of 
patient, provider or setting 
characteristics. Use 
increased over time and 
substantial variation 
identified at provider level. 
Focus on variables 
associated with GP 
demographics, patient 
characteristics including 
specific disease features 
and organisation type. No 
inclusion or discussion of 
other relevant influences. 
SIMILAR to this 
RESEARCH. Data not 
linked to specific patients. 
(Mazzag
lia et al., 
2003) 
Quantitative study - 
prescribing of antibiotics 
for acute respiratory 
infections in patients 
from 469 GPs in Italy. 
Patient demographic 
data, drug history and 
physician information 
available. A frequency 
analysis for antibiotic 
prescribing by acute 
respiratory infection 
(ARI ) 
Group and patient and 
GP characteristics. No 
conceptual model 
Antibiotic appropriateness 
(according to guidelines) 
was assessed; patient 
demographics and 
diagnosis and physician 
features (gender, 
geographical region, type 
of practice, experience, 
number of patients and 
use of diagnostic tests. 
Results did not show link 
between antibiotic use and 
patients characteristics. 
Antibiotic use was associated 
with physicians’ 
characteristics, such as area 
of practice, and the number 
of patients under care. 
Practices in southern Italy 
and living in an urban area 
were also important in 
determining the choice of 
parenteral antibiotic use. 
Finally, the use of diagnostic 
tests showed a significantly 
Focus on variables 




Frequency analysis for each 
outcomes and multiple 
regression analysis. Data 




associated lower risk of 
antibiotic use 
(Morriso
n et al., 
2009) 
Quantitative cross 
sectional Study – 
antidepressants 983 
general practices in 
Scotland 
Age-sex standardised 
prescribing rates were 




were undertaken to 
examine how the 
variation in prescribing 
was related to 




level. No conceptual 
model 
Population, GP, and 
practice characteristics at 
practice level. 
Significantly higher 
prescribing than expected 
was associated with more 
limiting long-term illness 
(highly correlated with 
deprivation and the single 
most influential influence), 
urban location, and a greater 
proportion of female GPs in 
the practices. Significantly 
lower prescribing than 
expected was associated 
with single-handed practices, 
a higher than average list 
size, a greater proportion of 
GP partners born outside the 
UK, remote rural areas, a 
higher proportion of patients 
from minority ethnic groups, 
a higher mean GP age, and 
availability of psychology 
services. None of the quality-
of-care indicators 
investigated was associated 
with prescribing levels. The 
model explained 49.4% of 
prescribing variation.  
Focus on more variables 
than usual: GP 
demographics, patient 
characteristics and 
organisation attributes also  
QOF points, involvement 
with clinical audit and some 
service provision relevant to 
the area of research. 
SIMILAR to this 
RESEARCH. Data not 





Quantitative study – 
total prescribing costs in 
90 health authorities in 
England  
24 influences covering 
patient demographics, 
GP and practice 
details as explanatory 
variables against total 
net ingredient cost 
(NIC). Multiple 
regression analysis. 
No conceptual model 
Patient demographics 
deprivation, mortality 
ratios, % pensioners and 
prepayment certificates. 
GP and practice variables 
including number GPs per 
population, age, 
movement, other staff, 
dispensing and single 
handed practices 
Four explanatory variables 
showed a correlation with 
NIC – list inflation, 
standardised mortality ratio, 
% pensioners and % 
prepayment certificates. 81% 
of variation explained by 
these influences. 
Focus on variables 
associated with GP 
demographics, patient 
characteristic and 
organisation attributes as 
well as number of 
pharmacies, ancillary 
practice staff, health 
authority staff per population 
and movement of GPs (no 
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rationale as to why these 
things are included). 
SIMILAR to this 
RESEARCH. Data not 








prescriptions by 144 
GPs in Spain. No 
conceptual model 
Insulin and oral diabetic 
medication compared 
against GP characteristic, 
work place or patient 
population demographics 
 
The GP characteristics had 
little effect on prescribing but 
the type of practice / 
workplace (teaching facility) 
and the patient population 
(age) had a much greater 
influence. 
 
Focus on variables 




SIMILAR to this 
RESEARCH. Data not 
linked to specific patients. 





patients with ACSC 
(Ambulatory care 
sensitive conditions) 
admitted over 12 month 
period in 1 primary care 
network in Spain over 
12 month period. 
Cross sectional study 
analysing outcomes of 
the primary care 
network for a 1 year 
period. Multilevel 
mixed effect logistic 
regression. Analysed 
at patient, GP and 
organisation level. No 
conceptual model 
Demographics and 
morbidity of patients; GP 
characteristics; health 
centre attributes were 
explanatory variables 
comparing visits, referrals 
and prescribing costs. 
Patient admission more likely 
when seen by GPs with 
greater number of patients 
visits (less likely to refer?) 
and higher prescribing costs.  
Focus on variables 
associated with GP 
demographics, patient 
characteristic and 
organisation attributes. Also 
included data for referrals 
and level of patient 
satisfaction. Complementary 
to this research and data 
linked to specific patients so 
can link prescribing and 
disease outcomes in same 






Quantitative study – 
hypnotics and 
anxiolytics in 61 
practices in 
Cambridgeshire, UK. 
 Multiple regression 
analysis of prescribing 
rates for hypnotics, 
anxiolytics and 
antidepressants 




patient age, deprivation, 
nursing home and 
learning disability; 
standardised mortality 
ratios; practice size, 
number temporary 
residents, no GPs per 
population, ancillary staff, 
presence of counsellor, 
rural/urban location, GP 
Proportion of temporary 
residents and proportion of 
women over 65 explained 
25% of variation in 
prescribing. 
Focus on variables 
associated with GP 
demographics, patient 
characteristic and 
organisation attributes but 
also some disease specific 
variables. SIMILAR to this 
RESEARCH. Data not 
linked to specific patients. 
65 
 
age and GP with interest 




Quantitative study in 
diabetic patients in US 
(retrospective analysis 
of prescribing data) 
Multivariate logistic 
regression model to 
assess prescribing of 
sulphonylureas (SUs) 
with number of 
variables. No 
conceptual model. 
SU use after  Dipeptidyl 
peptidase 4 (DPP4) 
inhibitors or GLP-1 
agonists were introduced 
was measured against 
age, sex, ethnicity, 
primary care physician 
type 
Data showed differences in 
prescribing rates for different 
patient age and sex and 
ethnicity subgroups and type 
of physicians seen.  
Focus on variables 
associated with patient 
characteristics and type of 
physician and limited 
organisation attributes type 
and region but also some 
disease specific variables. 
SIMILAR to this 
RESEARCH. Data not 







patients from two 
geographically diverse 
regions (Florida/Puerto 
Rico and New England) 
who were regular users 





provides a relevant 
theoretical model for 
understanding 
specialist - generalist 
differences 
Time, provider type, and 
geographic location are 
supported 
by DI theory and are 
important, the ability to 
analyse these patterns 
simultaneously provides 
insight into the process by 
which generalist-specialist 
differences may occur. 
The data suggest that DI 
theory is useful in examining 
both adoption of new clinical 
recommendations and 
differences in care provided 
by specialists and 
generalists. Our data suggest 
that DI theory is useful in 
examining both adoption of 
new clinical 
recommendations and 
differences in care provided 
by specialists and 
generalists. 
In depth study of 2 distinct 
areas in Diabetes patients 
with prescribing linked to 
other measurements – 
complementary to this 
research area. Highlights 
importance of the local 
heath economy and relative 





Quantitative Study – 
Asthma, diabetes and 
depression. 131 
doctors’ practices in a 
South Wales health 
authority 
Novel use is made of 
a negative binomial 
model for prescribed 
items. These models 
are then evaluated, 
particularly by offering 
explanations for 
residual variations, 
which often identify 
more specific and 
localised influences on 
prescribing. 
The determinants of 
practice prescribing 
behaviour can be broadly 
categorised into need and 
supply influences. Need is 
represented by patients 
with various medical 
conditions, with those 
illnesses in turn influenced 
by demographic, socio-
economic, cultural and 
environmental conditions. 
The health authority's 
population is characterised 
by substantial inequalities in 
wealth and health. Statistical 
analyses reveal the 
consistent influence of 
deprivation on prescribing 
costs and volumes, with the 
exception of items of insulin. 
Supply influences exert more 
selective influences. Thus, 
the number of doctors per 
Focus on variables 
associated with patient 
characteristics and type of 
physician and limited 
organisation attributes. 
SIMILAR to this 
RESEARCH. Data not 
linked to specific patients. 
Diabetes Prescribing one 
area of interest in this study. 
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NO conceptual model  practice and per patient has 
a positive influence on 
antidepressant prescribing; 
fundholding status is 
associated with lower costs 
for bronchodilator 
prescribing; and older 
doctors tend to prescribe 
more bronchodilators and 
oral antidiabetics. Residuals 
from the statistical analyses 
suggest further systematic 
influences, notably advice 
from hospital consultants, as 
well as more localised and 





Quantitative Study - The 
1998 National 
Ambulatory Medical 
Care Survey (NAMCS) 
was used to examine 
the treatment patterns 
of depressed patients in 
ambulatory settings 
 








associated with the 
visits, and includes 





Heckman’s 2 step 





Theoretical model was 
Eisenberg’s typology of 
sociological influences on 
physician decision 
making. Physician 
demographics were not 
available but specialty 
was included. 
 
The four influences that were 
investigated were all found to 
affect decision making 
physician prescribing of 
antidepressants was 




physician's interaction with 
the health care system, and 
the physician's relationship 
with the patient. 
 
Focus on variables 
associated with patient 
characteristics and type of 
physician and organisation 
attributes as well as 
diagnosis of patient and 
patient insurance status. 







Quantitative study - 
anxiolytic and hypnotic 
prescribing – all GPs in 
England. 
QOF data, prescribing 
data and practice 
characteristics, 
Multivariate analysis 









training history.  
Ten variables explained 
20.5% of the variation in 
anxiolytic and hypnotic 
prescribing volume. 
After adjustment, the 
predictive power of four 
variables increased: the IMD 
score, the proportion of black 
or black British, and Asian or 
Asian British, and the Clinical 
Care domain score; these 
variables accounted for 
17.7% of the variation. 
Focus on variables 
associated with patient 
characteristics and type of 
physician and organisation 
attributes as well as general 
QOF domain scoring. 
SIMILAR to this 
RESEARCH. Data not 




2.4.3.7. Influences identified by the papers included in the systematic review. 
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(Tan et al., 
2009) 
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2.5. Summary of influences on prescribing 
The main groups of influences on prescribing  together with a description of the specific 
aspects of that influence that have been identified in the papers included in this 
systematic review is  summarised in the Table 7 below: 















Adherence to clinical guidelines 
Financial 
influences 
Financial situation at organisation; financial incentives 
GP influences GP demographics; GP training specialist qualified; GP patient 












Organisational level priority and interest in specific project 
Patient 
influences 
Patient characteristics; patient education; patient opinion 
Patient 
population 





Sales and marketing approaches to GPs; involvement in research 
 
2.6. Discussion 
The aim of the systematic review was to critically appraise and synthesise the 
published research in the possible influences on prescribing behaviour in PCOs. Doing 
this revealed a number of important facts.  
The qualitative studies included in this review brought up a number of common themes 
and consistently identified the same influences on prescribing despite using a range of 
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qualitative study methods such as semi structured interviews using: thematic research, 
critical incident technique, manifest content analysis, purposive sampling frame; focus 
groups, questionnaires and surveys. This has been demonstrated by table 4. There 
was general agreement from the qualitative studies that influencing prescribing is multi 
influential and that specific individual influences were more important for some GPs 
than others. The research consistently showed that sometimes an interaction will affect 
the prescribing but not for all GPs and not necessarily for a long time.  
There was a noticeable difference between the influences identified in the qualitative 
papers compared to the papers describing quantitative research. This is likely to be 
due to difficulty in collecting some of this information in the quantitative research. 
However, it does mean that influences identified in qualitative research papers as 
being potentially important were ignored in the quantitative research and so the 
usefulness of this research in elucidating key influences was greatly diminished. The 
influences identified as most important in these quantitative papers were not 
reproducible from one study to the next and appeared to differ according to the local 
health economy studied; the country of origin; the type of drug and disease area being 
investigated (antibiotics or chronic disease); the organisation under investigation and 
finally the focus of the study (for example cost or clinical outcomes). The focus of all 
the quantitative research was to discover the most important influences on prescribing 
in the study population so that this result could be extrapolated to other organisations. 
However, one of the main conclusions from most of the papers included in this 
systematic review was that the organisation, the local environment and the influence 
of the local hospital - defined as the local health economy (LHE) need to be included 
in these quantitative analyses to more fully explain the reasons behind variations 
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(Senior et al., 2003). Therefore, it is unlikely that results from one small population 
sample are going to be applicable to other organisations. It is perhaps more important 
to investigate all the possible influences found from qualitative research as well and 
build up a picture of what is happening in each LHE so as to understand the relative 
importance of each influence in that particular locality (Pugh et al., 2003, Houten et al., 
2014).  
A good summary of the interaction of the influences on prescribing decisions was 
presented in a systematic review in 2008 on the uptake of new drugs (Mason, 2008). 
This review investigated the possible influences that might influence the uptake of new 
drugs in the UK. The determinants were classified using Bonair and Persson’s 
framework for diffusion of innovation which categorises influences influencing adoption 
as (1) people influencing prescribing (2) structural / environmental characteristics (3) 
product characteristics (Szczepura and Kankaanpaa, 1996). The review found that in 
terms of people influencing prescribing there was evidence that: hospitals specialists 
were important in initiating new drugs that then filter down to influence GPs; other 
healthcare personnel and the way in which services are integrated are also important; 
prescribing advisers and drug company representatives. Structural / environmental 
characteristics included: education, guidelines, and incentive schemes. Product 
characteristics included: cost awareness and attitudes. It was also useful because it 
confirmed that there has been no single study exploring the reasons for variations in 
GP prescribing behaviour across the UK and that research typically focuses on a small 
number of GPs within a small geographical area. However, despite this usefulness, 
this review did not cover all the issues that are pertinent to this research, namely: it 
fails to differentiate between classes or therapeutic areas of new drugs; included no 
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discussion of patient influences; there was no analysis of the type of primary care 
organisation; and the only product characteristic discussed was the cost.  Another 
review of new drug uptakes by Lubloy (2014) concluded that each influencing variable 
has only a small impact, and predicting doctors’ prescribing behaviour is a complex 
and multi influenceable exercise. They conclude that models with high numbers of 
variables and high explanatory power would be needed to help design policy 
approaches. 
This systematic review was designed to examine the influences affecting prescribing 
decisions in primary care across all disease areas so as to get the widest level of 
understanding. However, from the papers identified it was clear that whilst the 
influences on the prescribing decision can be generalized, the relative importance of 
them varies according to the disease studied. The majority of research of influences 
influencing prescribing in primary care has studied the prescribing of antibiotics 
because they represent an important area of inappropriate prescribing, However the 
relative importance of the influences when prescribing antibiotics are quite different 
when compared with, a complex chronic condition such as type 2 diabetes. The 
patients’ ability to cope with treatment changes and  side effects as well as the 
availability of specialist advice and training to help support the GP are significant for 
this disease (Agarwal et al., 2008). The influence of secondary care and the local 
interactions between organisations are also much more significant in chronic diseases. 
In a study of patients with osteoarthritis, GPs cited the relationship with specialists as 
crucial, as was their own expertise and experience in treating the condition and 
national guidelines (Kingsbury and Conaghan, 2012). In managing a chronic disease 
there is also a tension between attaining clinical targets and balancing side effects of 
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increased medication. In a study in the United States by Hunt et al. (2012) looking at 
diabetes and hypertension, guidelines were cited as being very important in 67% of 
clinicians but attaining clinical markers of better management of a disease often led to 
increased side effects and poorer quality of life for patients. 
The significance of the organisation and networks of people working across interacting 
organisations was investigated in a study in The Netherlands (van Eijk et al., 2004) 
where they used the natural networks of practice study groups consisting of GPs and 
pharmacists and measured the relative success of a group approach educational 
intervention against an individual intervention to reduce anticholinergic prescribing in 
the elderly. The groups had been in existence for varying times, differed in their set up 
and aims, use of formularies and in use of feedback data. They found that all three of 
these characteristics modified the effect of the group educational intervention. This 
would fit in with accepted general theory on the diffusion of innovations that concludes 
that diffusion is a social process and networks are important (Rogers, 1995). An in 
depth study of the use of antibiotics in the USA found the way in which the organisation 
of primary care is managed was important in helping to develop a professional culture 
with a locally owned common prescribing policy. They found that if this was achieved 
it helped to improve prescribing habits (Strandberg et al., 2013). 
One weakness of this systematic review was that it included research from countries 
outside the UK, and in some instances, some of the conclusions drawn from 
international research may not be relevant in the UK. In the qualitative study in Greece 
(Tsiantou et al., 2013) they found that some of the influences that were important were 
not necessarily applicable to other European countries such as the influence of the 
patients’ family on decisions. In the study of antibiotic prescribing in Lithuania and 
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Russia (Jaruseviciene et al., 2013) legal and political constraints and interference 
impacted of prescribing decisions and created an environment where it might be 
advantageous to prescribe antibiotics more frequently than necessary to avoid 
potential medico legal problems. The way in which healthcare is funded (insurance 
systems, or population tax) also affects prescribing decisions - a fact demonstrated by 
a study of asthma prescribing in Singapore (Tan et al., 2009) and antibiotics in India 
(Kotwani et al., 2010). 
Out of the 48 papers included in the systematic review, only five utilised any conceptual 
models. In the qualitative studies Buusman et al. (2007) used the Complexity Model 
and Tsiantou et al. (2013) used the Theory of Planned Behaviour. In the quantitative 
studies, Davis et al. (2000) studied the Supply Hypothesis and Pugh et al. (2003) used 
Diffusions of Innovations and a third used Eisenbergs typology of sociological 
influences (Sleath and Shih, 2003). A review by Mason (2008) investigated the 
adoption of new drugs  also used the Diffusion of Innovations Model by Bonair and 
Persson as a method of analysis. Another review of the models and theories of 
prescribing decisions in 2017 confirmed this lack of research into the use of conceptual  
models when analysing prescribing decisions. In their research they put forward a new 
conceptual model but only looked to explain links between marketing efforts, patients 
and pharmacists on physician prescribing decisions (other influences have not been 
considered). Their model was also derived from social and behavioural theories 
(Murshid and Mohaidin, 2017).  
2.7. Conclusion 
This systematic review identified a number of influences that have been found to affect 
prescribing behaviour. The review also found that there has been no published 
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research using the adapted Donabedian SPO model to look at prescribing influences.  
None of the quantitative research papers were able to identify influences to explain all 
the variation in prescribing and they restricted their study to the measurement of 
influences that are easy to obtain and readily available. This is despite the results from 
the qualitative research identifying important influencing influences. 
Meaningful quantitative research should therefore take the influences and themes that 
have evolved from qualitative research should be used to frame the areas of analysis 
in the quantitative analysis. Moreover, since the local dynamics both within the 
organisation and between the acute sector and local networks within the local health 
economy are crucial, it is unlikely that studying one organisation will provide 




CHAPTER 3: THE DEVELOPMENT OF A CONCEPTUAL 
MODEL FOR THE MEASUREMENT OF INFLUENCES ON 
PRESCRIBING 
3.1. Introduction 
This chapter investigates conceptual models used in the area of health services 
research, and then seeks to develop a conceptual model for exploring influences on 
prescribing behaviour.  
Prescribing research has not previously engaged with conceptual models used in 
health services research. None of the studies in the systematic review (chapter 2) or 
in a recent review of models and theories to explain the prescribing decisions by 
Murshid and Mohaidin (2017) considered any of the conceptual models used in this 
branch of research. However, In health services research it is acknowledged that there 
is a need to create and develop conceptual models in which to place indicators and 
understand the relevance, meaning and importance of these indicators in improving 
healthcare (Zelman et al., 2003). This chapter considered whether application of such 
conceptual models could be useful in understanding the importance of influences on 
prescribing behaviour. 
Health service research is a discipline involved in examining the relationship between 
the provision, effectiveness and efficient use of health services and the health needs 
and demands of the population (Bowling A, 2009). A distinction between heath service 
research and quality and audit assessment is that audit and quality tend to monitor 
whether predefined and agreed standards have been met, whereas health service 
research concentrates on evaluating the different aspects  by recording what changes 
have happened (Bowling A, 2009). Health service research would therefore 
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encapsulate all the aspects of influences on prescribing that are the subject of this 
research project.  
A number of conceptual models have been developed to evaluate health services. One 
of the first conceptual evaluation models to measure quality in healthcare was first 
postulated by Avedis Donabedian in the 1960s (Donabedian A, 1966). He created a 
Structure, Process and Outcome (SPO) Model. Donabedian’s approach focused on 
(a) the measurement of structure (inputs and resources – including staffing, finance 
and other resources). (b) the measurement of process (service delivery, prescribing 
practices, referral rates, access, and other productivity measures) and (c) the 
measurement of outcomes (death, morbidity, patient satisfaction) (Donabedian A, 
1980). 
This conceptual model has been used extensively to evaluate a range of clinical 
processes, service developments, disease management tools and clinical staff 
interventions (Ameh et al., 2017, Bainbridge et al., 2010, Gardner et al., 2013, Gardner 
and Mazza, 2012, Neville et al., 1996). In each case it is adapted to fit the specific 
subject being studied and has been found to provide some useful insights into the 
interactions between the various important influences on the quality of the service / 
condition being studied. Prescribing has been identified as one of the indicators in the 
Donabedian SPO models (together with referral rates, service delivery and other 
productivity measures) (Donabedian A, 1980) However, this model has not previously 
been used to study the influences on prescribing. This model could therefore provide 
a useful conceptual basis for understanding the influences on, and the indicators and 
measurements in these models are similar to the influences on prescribing behaviour 
that were identified by the systematic review described in chapter 2. Using this area of 
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health service research opened up the possibility of measuring prescribing behaviour 
within the context of the other measurements made in quality models. 
3.2. Aims and objectives 
The aim of this chapter was to ascertain if there were any conceptual quality models 
used in health service research that could be used to provide a useful insight into the 
influences on prescribing behavior, and develop a model to apply to prescribing. In 
order to meet this aim there were four main objectives: 
• Investigation of the theory behind the use of quality models and identify what 
were the key elements in the most commonly used conceptual models.  
• Identification of the most suitable conceptual model that is most appropriate to 
be used in this research. 
• In order to test the utility of the Donabedian SPO model when understanding 
the interaction of influences on prescribing in English PCOs two new specific 
classes of drugs to treat diabetes (LA insulin analogues and GLP-1 agonists) 
were chosen as outcome indicators. 
• Alignment of the influences identified in the prior systematic review (Chapter 2) 
to the Donabedian SPO conceptual model, according to their similarity, and 
based on their relationship to the two outcome indicators.  
3.3. Literature review 
The literature search for this part of the research project, was divided into two separate 
parts: 
1. General search on a number of terms to understand the background to the 
subject of performance and quality frameworks and conceptual models. 
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Terms searched (in Medline, Embase, Web of Science and HSMC) 
Quality framework; Performance framework; Quality indicator; Quality 
improvement; Quality indicator and Performance indicator 
Useful papers were identified from this search and references in these papers were 
followed up by hand searching. 
There is considerable difficulty in defining search terms with quality frameworks and 
conceptual models. Similar concepts can be described by different terminology. For 
instance, performance frameworks and conceptual models are used interchangeably 
in many papers. Similarly, quality domains, categories and dimensions were all terms 
used to describe a grouping of similar indicators that make up part of a framework or 
model. These findings are corroborated by other researchers that have examined this 
subject (Klassen et al., 2010, Gardner and Mazza, 2012). 
A second more focused search was carried out, once the primary literature search has 
been performed and reviewed. At this stage the Donabedian conceptual model had 
been identified as chosen model to develop a framework to evaluate the influences on 
prescribing. 
The literature searching that was performed for this was based on searching for the 
use of Donabedian structure process outcome model in a clinical setting. 
Search terms were: 




Using the keyword search of Donabedian found many irrelevant papers and no 
consistent MESH term identified the use of the model in papers. Therefore, a keyword 
search was undertaken together with the terms above across all databases available 
at The University of Birmingham, including Medline, EMBase and HMIC. Abstracts 
were read to discard unsuitable papers. Handsearching of relevant papers were 
performed in order to retrieve other original research where the model had been used 
as a relevant evaluation framework. 
The search strategy was set up to identify research where the Donabedian SPO model 
had been used as a conceptual framework in a similar manner to that intended in this 
research. Papers where it had been used to evaluate a clinical service, management 
of a condition, evaluate a primary care service / organisation or a specific part of the 
management of a disease were all of interest. Original research was selected rather 
than review papers for this literature review because it was important to understand 
how the model had been adapted for research into different subjects. In addition, 
original research that only focused on one aspect of the model was not included in this 
review. 
Full copies of the papers were obtained and read to discern how the model was 
adapted, what indicators were used to populate the system, how they were analysed 
and how useful the model was. 
3.4. Theory behind the use of conceptual models 
The improvement of quality within the health service has been consistently identified 
as a key issue in the industrialised and developed countries (Gardner and Mazza, 
2012, Klassen et al., 2010). One of the ways in which healthcare systems have tried 
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to improve and measure the quality, care and cost effectiveness is to deploy a range 
of performance measurements and improvement initiatives reflecting dimensions of 
quality (Mainz, 2003). In the UK measurement of performance of local NHS 
organisations was first introduced in 1999 (The Performance Assessment Framework) 
where a range of indicators were measured. This developed into performance league 
tables, the setting up of the Care Quality Commission, the Quality and Outcomes 
Framework (QOF) in 2004 and the development of 200 Indicators for Quality 
Improvement (IQIs) in 2009 (Raleigh and Foot, 2010). More recently, the NHS 
Outcomes Framework (Department of Health, 2011) has been developed with a 
specific aim to help to improve quality and outcome measurement throughout the NHS. 
There are various dimensions of health care performance that have been developed 
to define of quality. They have variously been used in performance frameworks in a 
number of countries and share many similarities. 
1. The Institute of Medicine (IOM) six dimensions of quality – effectiveness, safety, 
efficiency, timeliness, patient-centredness and access (Institute of Medicine, 
2001).  
2. The Maxwell six dimensions of quality: appropriateness; social acceptability; 
effectiveness; relevance to need; equity and accessibility (Maxwell, 1984).  
3. Donabedian seven attributes of quality - efficacy, effectiveness, efficiency, 
optimality, acceptability, legitimacy and equity (Donabedian A, 1990). 
These attributes of quality are reflected in the individual indicators that are used in the 
Frameworks (Mainz, 2003, Raleigh and Foot, 2010). A systematic review of 
performance and quality models was carried out by Klassen et al. (2010) to identify the 
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common quality domains across them all. This work found that regardless of how they 
were constructed or where they originated from there were 16 quality concepts 
applicable across health, education and social care that could be grouped into five 
common themes.  
1. collaboration – partnerships, networks and links among service delivery 
systems 
2. learning and innovation  – commitment to learning environment that supports 
research, development and dissemination of information and knowledge, 
evidence based guidelines etc.  
3. management perspective  – leadership, organisation, infrastructure capability, 
business and financial management. 
4. service provision  – equity (provision of services distributed according to 
population, geography, ethnicity, need); availability, comprehensiveness, 
appropriateness and client centredness. 
5. outcomes  – measure of effectiveness at patient, population or organisational 
level.  
They also concluded that the different conceptual models had been developed by 
building on existing frameworks and models. The most popular one in the health sector 
was the Balanced Scorecard (consisting of quadrants measuring financial 
performance, customer satisfaction, internal processes and learning and growth). 
However, it should be noted that the majority of frameworks (54 out of 97) were being 
used to analyse health systems for national performance frameworks and so the 
importance of and need to record customer satisfaction and financial performance may 
be different from the use of a framework to measure and gauge quality and 
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performance in an organisation. Organisation level frameworks such as the 
Donabedian SPO model were used in ten frameworks.  
This review is of interest to this research because it identified that the quality concepts 
were applicable across many settings and levels of application despite being labelled 
variously as domains, dimensions, or quadrants. These common elements were 
important in measuring quality and performance regardless of the model used. 
However, national performance frameworks comparing measures across a health 
system were most commonly studied in this paper and their focus was different from 
those focusing at an organisation level. The review also reinforced the view that 
conceptual models whilst important, are flexible and should be adapted to fit the 
context and setting being studied. 
Indeed, the fact that common quality themes are identified in different models makes 
it important that an appropriate one is chosen to underpin the development of a 
conceptual model to evaluate a specific clinical situation or condition. In 2012, a review 
of the published literature on definitions of quality and the use of quality frameworks in 
primary care in the UK, New Zealand, Australia and Germany was published (Gardner 
and Mazza, 2012). This paper included 47 papers in its review and concluded that in 
all four of the countries the fundamental principles behind the Donabedian SPO model 
of structure-process-outcome have been adopted but with a need in each case to 
translate the theoretical concepts into individual situations. For example, in New 
Zealand, the frameworks are used as part of pay for performance programme for their 
primary care organisations whereby the standards to be attained were categorized as 
part of the structure domain; the national programme to meet the standards as the 
process domain and local implementation and measurement as the outcome domain. 
88 
 
This published review does not give any details about the relative success of the 
different quality frameworks but concludes that the essential quality dimensions are 
similar and that the Donabedian SPO model is the basis for the primary care country 
wide frameworks studied. 
Another comparative analysis of the characteristics of national frameworks and 
performance indicators was published in 2017 (Braithwaite et al., 2017). In this 
analysis, countries that were at the forefront of adopting performance indicators for 
quality improvement and where details of the indicators, domains and frameworks to 
apply them were available were studied. The most common domains measured were: 
Effectiveness (8 frameworks); access and safety (7), efficiency (5), quality (4), 
appropriateness (4), patient experience (4).  Creating a conceptual framework for the 
development of indicators to measure and assess these domains was found to be an 
important issue for the countries because it sets out the rationale and principles behind 
the collection and measurement of indicators and could be modified to suit the local 
health system (Braithwaite et al., 2017) . A paper by Arah et al. (2006) has described 
the development of a framework for the Organisation for Economic Co-operation and 
Development (OECD) Health Care Quality Indicators Project (HCQI). The proposed 
framework was based on models developed in many countries, including the USA 
Institute of Medicine’s National Health Care Quality Indicator Framework; Canadian 
Health Indicator Framework; adaptions in Australia and ECHI (European Health 
Indicators) project and on the World Health Organisation (WHO) and OECD proposals 
for identifying key economic and social goals for health policy.  This HCQI framework 
has four interconnected tiers to represent (a) health – broader measures of heath that 
may be influenced by health care and non-health care factors; (b) non health care 
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determinants of health (c) health care system performance – processes, inputs and 
outcomes of health care system and its efficiency and equity and (d) health system 
design and context – country and health system policy and delivery characteristics 
which affect cost , expenditure and utilisation patterns (Arah et al., 2006). 
The HCQI Project used the structure, process and outcome model to categorise the 
indicators. However, in their project it was decided that the indicators that form the 
structure domain were likely to be less important because their presence would not 
ensure that necessary processes were carried out or that satisfactory outcomes were 
achieved (Kelley E, 2006). This is in contrast to the findings of the Klassen et al. (2010) 
or Arah et al. (2006) reviews where indicators that made up the structural domains 
were found to be critical.  The importance of the structural domain has been highlighted 
by other research (Glickman SW, 2007) that has focused on the role of the 
management organisation as an important factor into the success of quality initiatives. 
in this review looking at the use of the Donabedian SPO model but drawing upon 
organisational behaviour they concluded that the organisational characteristics, culture 
and management capabilities as well identification of relationships between 
individuals, leadership, group dynamics and incentive schemes and information 
technology, all influenced changes in processes and ultimately health outcomes. They 
suggested that these features should be included in the structure domain of the 
Donabedian SPO model.  The review looked at the key elements of organisational 
attributes that have been shown in the medical and business literature to be important 
in delivering improvements in process and outcomes. The importance of organisational 
level attributes have been identified in other healthcare research fields. For instance, 
in the field of primary care research; organisation cohesion, management, structure 
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and financial stability have all been identified as crucial when making improvements in 
the quality of care in PCOs (section 1.4.3.). In addition, the papers identified in the 
systematic review of this thesis (Chapter 2) identified the importance of the 
organisation when trying to change prescribing behaviour. 
Whilst the Donabedian SPO model is a useful conceptual model to consider as a basis 
for understanding the quality and performance indicators important in clinical care 
there are some recognised limitations (Donabedian A, 2003) . Firstly, the three 
domains are linked in a linear relationship with the structural domain influencing the 
process domain and the process domain influencing outcomes. To counteract this 
issue many studies that use the Donabedian SPO model as a basis for evaluating a 
healthcare process look at the effects of the structure domain directly upon outcomes 
as well as the traditional S-P-O relationship (Ameh et al., 2017, Kunkel et al., 2007). 
Secondly, the model was created to look at clinical quality and so when it is used in 
other ways it needs to be adapted to reflect the situation being studied. Thirdly, there 
is no way of measuring how the three domains may interact with one another and there 
is a degree of blurring between the three domains (Donabedian A, 2003). 
3.5. Why use the Donabedian SPO model in this research? 
In order to assess whether the Donabedian SPO conceptual model would be 
appropriate to be used as a framework to evaluate the influences on prescribing in 
primary care, a literature search was carried out to identify where the model had 
previously been used in similar clinical situations. 
A summary of the ways the model has been implemented and adapted in nine different 
healthcare settings is given in the table below (Table 8). In all of these examples the 
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indicators chosen to measure three themes of structure, process and outcomes have 
varied according to the subject being studied. 
Table 8: Summary of adaptations to Donabedian SPO m odel by other 
researchers 

































(Neville et al., 
1996) 






Audit of asthma 
care, consultations 



























































































allowed use of 
currently 
collected data 






were related to 
one another 
Costs in Diabetes 












Cost of disease 
progression, 
complications 






a Quality Cost 
Framework for 
glycaemic 






with the above 
2 diabetes. It 















Contextual factors : 
disease and socio 
demographic 
characteristics 
Hours of care, 

















SPO in 6 
regions in 
Europe. 
SPO analysis of 
hospital 
departments 











provided useful  








et al., 2013) 
 
Three levels of 
primary care 
analysed – primary 





service provision at 





















dimensions of the 
nurse practitioner 



















In all of these examples the model provided a useful method to consider all the possible 
factors that might affect the type of outcomes obtained, be it an entire local primary 
health service (Reeve et al., 2015), a specific diseases specific service (Nocella et al., 
2016) a disease quality outcome (Neville et al., 1996); or the evaluation of costs for a 
disease intervention (Nuckols et al., 2013). However, the studies are not all of equal 
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quality, nor are they all of equal relevance to this research project. A number of them 
only consider a limited range of possible indicators in each of the SPO domains. For 
example,  the Swedish study of hospital quality systems (Kunkel et al., 2007) found a 
strong relationship between the SPO domains. The indicators included in the three 
domains were elucidated by the results of questionnaires but were limited and did not 
take into account many of the possible indicators. This was also the case in the paper 
describing the telemonitoring for diabetes service (Nocella et al., 2016); and the 
evaluation of palliative care (Bainbridge et al., 2010) and evaluation of the nurse 
practitioner role in Australia (Dwyer et al., 2017). The QUALICOPC project (Quality 
and costs of primary care in Europe),  examined the effect of the strength of the primary 
care system on the quality of health care provision. Indicators were created as a result 
of information and data collected from questionnaires from approximately 7500 GPs 
and 7500 patients as well as existing sources of data from 34 countries. The level of 
analysis was very complex but broadly supported the value of a strong primary care 
system to help achieve healthcare that scored highly in quality costs and equity. Whilst 
this supports the inclusion of indicators measuring primary care organisation attributes, 
the scope of this study was too large to be of specific use in adapting a Donabedian 
SPO model in this research project. 
One paper that is useful to this research described the adaption of the Donabedian 
SPO model to understand and evaluate the relationship between quality and cost for 
type 2 diabetes (Nuckols et al., 2013). It describes a similar situation to the one 
identified by this research project (see chapter 2), namely that in the field of research 
looking at quality and health costs there is no one accepted framework that connects 
up the specific dimensions of quality to variations in healthcare costs. They have 
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searched the literature and concluded that the lack of a conceptual model has led to 
published research where measurements differ from study to study (some focusing on 
structural quality indicators and others looking at process and outcome indicators). The 
framework that they have developed has taken the Donabedian SPO model and 
adapted this by taking into account work by the Institute of medicine (IOM), RAND 
Corporation researchers and economic methodology used in cost effectiveness 
analyses and cost benefit analyses.  This is very similar to the methodology adapted 
here, whereby the Donabedian SPO model is the starting point for the development of 
PCO profiles with additional research from literature examining the influences on 
prescribing as well as research into the importance and influence of PCOs on 
prescribing behaviour. 
The approach adopted by Nuckols et al. (2013) has been to take the outcome measure 
of costs that are influenced by health driven quality of care and identify the potential 
structural, process and outcome indicators. They firstly identified that there were three 
external factors that influence quality and cost but are not dimensions of quality, 
namely: the specific clinical indications or disease that define the healthcare process 
and population; the demographic characteristics of the target population and the 
characteristics of the local healthcare provision. They have given no detailed 
explanations as to how they arrived at these three categories, although the categories 
have been identified in some of the research into quality of healthcare described in this 
chapter (Klassen et al., 2010, Kelley E, 2006, Arah et al., 2006). They mirror the 
systematic review into prescribing influences described in chapter 2. This review found 
that the patient characteristics were deemed to be important; the local healthcare 
provision of services and interactions between professionals from other organisations 
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were crucial and varied according to the disease area; the characteristics of the 
organisation being studied were important. Their second change to the model was to 
add sub domains to three SPO domains and their third was follow the reasoning to join 
up specific quality issues to the related economic costs. They were able to draw up a 
model with indicators chosen to fit into the following principles: 
• Structural subdomains: disease or circumstance specific characteristics; quality 
improvement systems and general structural characteristics 
• Process subdomains: Appropriateness and Medical errors 
• Outcome subdomains: Disease or condition specific and Health Status  
Another paper of particular interest was that of Mahdavi et al. (2018) where they 
adapted the Donabedian SPO model a disease specific model where the outcomes 
were glycated haemaglobin (HBA1C), measurements, quality of life and patient 
satisfaction. They had added in context measures of disease and patient 
characteristics of the population studied as a separate domain although these 
subdomains are defined in the structural domain by other researchers. The main 
relevance to this research was the creation of a SPO model where the individual 
indicators formed the variables in the statistical analysis to determine the relationship 
between outcomes and the context, structure and process variables. There were 
issues around the completeness of the data in the different regions, there was no 
explanation as to why some of the indicators were included in the analysis (for example 
smoking, physical activity, age) and some of the data was collected at network level 
with other data at patient level. In addition, structural indicators previously found to be 
significant (organisation management, collaboration) were ignored. However, the 
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research did demonstrate how it is possible to adapt the Donabedian SPO model and 
use this structure to perform a statistical analysis of the relationship between outcome 
variables and the structural and process variables. Similarly to this research project, a 
number of organisations were compared. The statistical analysis in this study was 
complex with several analyses run to investigate the S-O, P-O relationships for each 
of the 3 outcome variables. However, the researchers unable to reach any generalised 
conclusions as to the link between SPO domains in the different regions.  
A third paper that was of importance in helping to shape my own adaptation of the 
Donabedian SPO model was the evaluation of primary health services (Reeve et al., 
2015). Their adaption of the Donabedian SPO model was illuminating because they 
took the SPO model and applied the common quality dimensions (accessibility, 
appropriateness, effectiveness, responsiveness, continuous care and efficiency) to 
each of the domains.  They also used nationally produced health indicators that were 
most relevant to their context and where they answered the questions that they needed 
to ask. However, there are some differences and there are additional tables (called key 
foundations) included in the framework to measure the socio-economic determinants 
of health; essential requirements for the structural domain  and quality of care 
indicators needed to ensure service performance and monitoring. The key foundation 
tables and indicators are similar to those included in other Donabedian SPO models in 
their relevant domains, the content follows the same pattern and methodology as other 
adaptations of the Donabedian SPO model. The ultimate model may be much more 
complete, but this paper only describes the process of creating the model and deciding 
upon the individual indicators. There is no description of it being used with actual data 
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and so no elucidation of how the different tables within the framework would be joined 
together to analyse the primary health services.  
The final paper that was useful in pulling together ideas on how to adapt the model for 
this research project was an evaluation of asthma care in general practice in the UK 
(Neville et al., 1996). This paper focused on 200 practices recruiting 30 patients each 
and collecting data and information from these patients in the manner of a clinical trial.  
The structural domain was only concerned with the age and gender of patients, 
whether they were FHSA accredited, recently audited asthma care or whether there 
was a specialist asthma nurse. Despite this it was instructive in the development of a 
framework using UK data and opening up the possibility of using this sort of analysis 
to examine primary care behaviour of another type, namely prescribing behaviour. 
3.6. Adaptation of the Donabedian SPO model 
In considering whether to use the Donabedian SPO model as a basis for understanding 
influences on prescribing it was important to look at the list of influences identified from 
the systematic review (Chapter 2) and see if they were consistent with the possible 
descriptions of individual indicators that make up the three domains (structure – 
process – outcomes) of the model.  When allocating the influences the definitions of 
the three domains by Donabedian A (2003) will be followed, namely: 
• Structure Domain. The conditions under which care is provided. This includes 
facilities and equipment, human resources and organisation characteristics. 
The way that the healthcare system is set up and managed and influenced. 
• Process Domain. The activity constituting the healthcare and the way in which 
it is provided. 
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• Outcomes Domain. The changes seen as a result of the processes. 
The adapted Donabedian SPO model in this research used the examples of the 
adaptations described in table as well as the results from Klassen et al. (2010) outlining 
the common features of adapted quality and performance frameworks  and Glickman 
SW (2007) on the organisation aspects of the structural domain. That is, in addition to 
the descriptions of each domain developed by Donabedian himself, who during his 
time researching this area adapted his own SPO model to fit the subject area being 
studied (Donabedian A, 1980). Finally, in a paper by Mainz (2003) the definition and 
classification of clinical indicators used to describe health care performance and 
outcomes making up the structure, process and outcomes domain are reviewed and a 
list of type of information in each domain has been described. The principles outlined 
in this paper were also used to assign the influences on prescribing to the appropriate 
domain. When considering how the influences might fit into the model it is important to 
understand the ultimate aim of this research – namely to understand the influences on 
prescribing.  
3.6.1. Structure domain 
The following subdomains and indicators in Table 9 have been identified as being part 
of the Structure Domain (Donabedian A, 1980, Mainz, 2003, Nuckols et al., 2013, 
Klassen et al., 2010, Glickman SW, 2007). 
Table 9: Structure domain in the Donabedian SPO mod el 
Subdomains or groupings Descriptions of the type of information 
structural Organisation culture; organisation management; type of 
organisation 
Collaborative Organisations working together within local environment; 
professionals working together 
Organisation Organisational priorities and plans 
Workforce Numbers of available personnel; type of personnel 
Quality systems Local responses to national quality / guidelines 
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Financial  Resources available 
Health and socioeconomic 
demographics 




Government departments, parent management structures; 
external organisations  
 
All of the papers that have described adaptions to the Donabedian SPO model have 
stressed that the subject being studied defines the outcome indicators that are 
chosen and these in turn influence the way in which the structural and process 
indicators are chosen (Table 8). Some indicators may be generic whilst others are 
specific to the disease or condition being studied (Mainz, 2003). 
3.6.2. Process domain 
The following subdomains and indicators (Table 10) have been identified as being 
part of the Process Domain (Donabedian A, 1980): 
Table 10: Process domain in the Donabedian SPO mode l 
Subdomains or groupings Descriptions of the type of information 
Services or processes 
available 
clinical audit of the quality of services available 
Responsiveness, accessibility of services 
Equity and appropriateness of care 
 
3.6.3. Outcomes domain 
The following subdomains and indicators have been identified as being part of the 
Outcomes Domain (Donabedian A, 1980) (Table 11): 
Table 11: Outcome domain in the Donabedian SPO mode l 
Subdomains or groupings Descriptions of the type of information 
Disease specific morbidity  
General health status  
Measures of effectiveness Specific indicators relevant to the disease or clinical situation 




3.7. Matching the Influences on prescribing to the domains and 
indicators in the Donabedian SPO model 
The influences on prescribing that were identified in the systematic review in Chapter 
2 are listed in the table below, together with more detailed description of the type of 
influence that was described in the individual papers included in the review. 














Adherence to clinical guidelines 
Financial 
influences 
Financial considerations for the organisation 
GP influences GP demographics; GP training specialist qualified; GP patient 












Organisational level priority and interest in specific project 
Patient 
influences 
Patient education; patient GP relationship 
Patient 
population 





Sales and marketing approaches to GPs 
Secondary Care 
and other NHS 
organisations in 
LHE influences 
LHE analysis - Relationship between acute and primary care; 
organisations involved in area prescribing committees; involvement 
between primary and secondary care in joint formularies 
3.7.1. Defining the outcomes indicators 
The process of matching these influences with the descriptions of the three domains 
of the Donabedian SPO models in Tables 9, 10 and 11 was carried out in stages. The 
first stage involved clarifying what the outcomes of the model would be. This research 
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is focused on the influences on prescribing for type 2 diabetes by GPs in primary care. 
Therefore, the logical outcome measures will be the prescribing for drugs to treat 
diabetes by GPs in primary care over the period of study. The specific outcome 
indicators chosen were the prescribing of two relatively new classes of drugs used to 
treat type 2 diabetes during the period of this study, namely the LA) insulin analogues 
and the GLP-1 agonists. Both of these two groups of drugs had recently been 
introduced prior to the period of this study but during this study period had been two 
areas where the reduction of prescribing has been an aim of national initiatives and 
guidelines because of cost issues (National Prescribing Centre, 2012), but their use 
was part of the treatment options available to help control and lower blood glucose 




Figure 2 Indicators used in the outcome domain 
 
3.7.2. Matching influences on prescribing to the su bdomains and indicators in 
the structure domain 
The next stage of the exercise was to take the structure domain categories and see 
how they matched up to the influences in Table 12 above. Crucially, it was important 
to go back to the aims of this research where the level of analysis was chosen as the 
PCO. This meant that the structural dimensions would need to correspond to this 
organisational level. The description of the structural subdomain corresponds closely 
to the organisational influences identified in the table above. 
When considering the collaborative subdomain it became clear that there are two 
dimensions to the level of collaboration that might be evident when considering 
prescribing influences. There are the collaborative efforts associated with GPs working 
with professional colleagues (such as consultants specialising in diabetes) at the local 
acute trusts). This is a disease specific collaboration. However, there are also more 
generic collaborations between GPs in PCOs such as the links between GPs and 







Domain                                           Disease or generic                                            Indicator 
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staff who work together on area prescribing committees. This is also the situation for 
local formulary committees that seek to influence prescribing behaviour of acute trust 
staff as well as the PCOs that refer patients to these trusts.  The prescribing influences 
in Table 12 that correspond to these dimensions are the Secondary Care and other 
NHS organisations in LHE influences. 
The importance of the organisation and how involved and committed to improving the 
outcome is the next subdomain to be considered. This is mirrored in the prescribing 
influences (Table 12) by the identification of diabetes as an organisational priority and 
the planned developments to improve diabetes care. The next subdomain was 
workforce and in the context of the PCO this would correspond to the GPs working in 
practices that are attached to each PCO. The GP influences on prescribing that 
correspond to this subdomain are the characteristics of the GPs, and the specialist 
training in diabetes that they might have.  
The quality systems subdomain refers to the national quality initiatives and guidelines. 
When we are considering this project, it is the PCO response to these quality systems 
that is of importance. However, the quality systems most relevant to the prescribing for 
type 2 diabetes are those that make up the clinical audit targets of the diabetes QOF. 
Details of the diabetes QOF targets and use of the data is available in chapter 4 and 
Appendix 1). These specifically address the control of blood glucose levels in patients 
with diabetes. However, when the outcome indicator is the prescribing rate of drugs 
used to control blood glucose levels, data pertaining to the achievement of blood 
glucose levels in patients reflects the process that the GP is following. It is the same 
situation when we consider the adherence to national clinical guidelines that are also 
measured in the diabetes QOF targets (see chapter 4 for a description of the individual 
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data that make up these targets). Another possible indicator could be the local 
guidance for the use of drugs to treat type 2 diabetes restrict the choice of drugs 
according to the clinical needs of the individual patient. The local PCO response to 
encourage GPs to prescribe in accordance to the national guidelines is to produce 
local formularies with specific advice and restrictions. This is a disease specific 
indicator (and is actually more specific being focused on particular drugs in a class of 
drugs). However, since this model is specifically concerned with prescribing choices 
this indicator has been deemed to be more appropriately placed in the process domain. 
The financial subdomain refers to the amount of resources that are available to the 
organisation. This could be a generic indicator although prescribing spend is only a 
small percentage of total spend of each PCO and so it would be more useful to look at 
the total spend on diabetes for each PCO. This indicator matches the financial 
influences on prescribing described in Table 12. 
The health and socio-economic subdomain is a mixture of a disease specific indicator 
In terms of the patient population with diabetes and a more general description of the 
population reflecting their need in relation to diabetes. This matches to the patient 
characteristics identified in Table 9. 
External organisations in the final subdomain can be matched in the prescribing 
influences table to the influence of pharmaceutical companies who have contact with 
PCOs and the GPs in the organisations in order to promote the prescribing of their 
drugs to treat diabetes. Other influences that might be matched to this subdomain 
could be government and Department of Health (DoH) initiatives to change prescribing 
behaviour, however, as was discussed above for the quality systems subdomain- 
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these are more relevant to the process domain in this particular adaptation to the model 
because they directly affect changes in prescribing behaviour. 
Having gone through this exercise, the structure domain in this adapted Donabedian 
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3.7.3. Matching influences on prescribing to the su bdomains and indicators in 
the process domain 
The process domain, related to prescribing influences, concerns the way in which the 
GPs in a PCO carry out the process of prescribing. There are two aspects to this – 
how they prescribe in general and how they prescribe for diabetes. Furthermore, the 
Donabedian SPO model describes a measurement of the quality of the process. This 
would translate in this adapted model to measures of how well the prescribing of GPs 
in each PCO corresponds to national standards, initiatives and guidelines both in terms 
of general prescribing and for diabetes specific prescribing behaviour. The influences 
on prescribing that match to these descriptions are for disease specific indicators; the 
attainment of audit and education targets and adherence to the clinical guidelines. The 
other measure is how GPs in a PCO are prescribing appropriately would be to look at 
the local formulary guidance for drugs to treat diabetes. This indicator matches up to 
the specific guidance in local formularies and local prescribing incentive schemes 
described under the heading of medicines management influences in Table 12. It 
reflects the local response to national guidelines outlining the recommended use of the 
two classes of drug. The degree to which patients are able to understand the 
importance of taking their medication and managing their disease appropriately also 
influences the take up of both groups of drugs, particularly since both classes are 
usually self -injected and patients need to be competent to do this. Other patient factors 
such as patient - GP relationship may also be included in this group of indicators. 
General prescribing behaviour and variations within an organisation, in accordance 
with national recommendations were identified as part of the medicines management 
influences (this is generally the part of the PCO charged with getting GPs to achieve 
nationally created and locally agreed prescribing targets). Finally, innate GP 
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characteristics in terms of adoption of new drugs (part of the GP influences in Table 
12) was identified in the systematic review of chapter 2 as a possible influence on GP 
prescribing behaviour. Therefore, this is another measure of generic GP prescribing 
behaviour in PCOs that can be captured in the process domain indicators. Using this 









In this chapter I have shown that the Donabedian conceptual model is a useful 
framework for evaluating the factors that influence a clinical process and subsequent 
outcomes (Braithwaite et al., 2017, Gardner and Mazza, 2012). The model has been 
used and validated in a range of projects in a variety of clinical situations from disease 
management (Mahdavi et al., 2018, Neville et al., 1996) to whole healthcare systems 
(Reeve et al., 2015, Ameh et al., 2017), individual interventions such as telemonitoring 
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diabetes interventions (Nuckols et al., 2013).This has suggested that the model might 
be suitable to use when evaluating the influences on prescribing in type 2 diabetes.  
The use of the model is not without issues because it implies that the structure – 
process – outcome relationship is a linear one and therefore that indicators in the 
structural domain have no direct effect on final outcomes. However, there is evidence 
in some of the research using this model that the relationship may not be so strictly 
defined and that structure can have a direct relationship with outcome measures 
(Ameh et al., 2017). This has also been concluded by Donabedian himself 
(Donabedian A, 2003). It has also been found to be essential to adapt the indicators in 
the three domains to the subject being studied.  The outcomes are specific to the 
research aims and the structure and process indicators must relate to them. Indicators 
must be carefully chosen and measured to provide an accurate picture of the 
relationship the three domains (Mainz, 2003). 
A possible limitation of choosing to define the outcome indicators purely in terms of 
prescribing is that other wider outcome measures reflecting the effects of the 
prescribing on the health status of patients may be missed. Outcomes could have 
included overall patient satisfaction, clinical morbidity and mortality. Prescribing is just 
one aspect in the management of a chronic condition such as diabetes. Low levels of 
prescribing for the two classes of drug studied in this research could be associated 
with the poor clinical outcomes that result from inadequate control of HbA1C. However, 
it could also be found in patients with good clinical outcomes being treated with older 
alternative drugs but more intensive clinical support systems within their local 
organisations. It might therefore be argued that the Donabedian SPO model would 
more appropriately be utilised to understand the influences on overall management of 
111 
 
diabetes and that the outcome indicators could also reflect overall disease outcomes 
as well as specific prescribing outcomes.  
There has been no published research on the use of this model when analysing the 
influences on GP prescribing behaviour (or on any prescribing behaviour). However, it 
seems that adopting this conceptual model would be appropriate and could provide a 
useful framework to evaluate the importance of the possible influences on prescribing 
that were identified in the systematic review in Chapter 2. Therefore, a process of 
mapping the influences on prescribing against the three Donabedian domains was 
carried out. Modifications and adaptations to the definitions of the type of indicators 
that  should be considered in each domain were summarised in Tables 10,11 and 12, 
taking into account work from the field of organisational behaviour (Glickman SW, 
2007) and work identifying common themes that have been identified as important 
when measuring factors important in quality improvement and performance 
management (Klassen et al., 2010). 
The exercise to map the influences on prescribing onto the three domains started by 
defining the outcome indicators. These were chosen according to the aim of this 
research project, namely the prescribing behaviour of GPs in PCOs when prescribing 
for patients with type 2 diabetes. Once this was agreed, it was found that the influences 
on prescribing corresponded closely to the descriptions of indicators in the three 
domains.  This model was then applied in the next part of this project, where specific 
indicators to reflect the influences on prescribing were sought to allow the population 




The Donabedian SPO model is a suitable conceptual model to use to group the 
influences on prescribing in primary care. Having decided upon the outcome indicators, 
it was possible to assign the influences on prescribing to the structure and process 
domains that make up the remainder of the Donabedian SPO model, creating a new 
framework for the analysis of prescribing. Population of the PCO profiles with data is 
discussed in the next chapter.The resulting framework and PCO profiles will then be 
used connect the influences on prescribing and prescribing rates for 2 classes of drug 




CHAPTER 4: APPLICATION OF MODEL TO SAMPLE DATA 
4.1. Introduction 
In the previous chapter, an adapted Donabedian SPO model for prescribing was 
developed, and then tailored for prescribing in diabetes. This model formed the 
structure used to create the PCO Profiles. This chapter collates publically available 
data and information and sets out the criteria for assessing the data for validity and 
usefulness in measuring the influences on prescribing in PCOs. The suitable data and 
information is then used  to create PCO profiles for all 211 PCOs in England for three 
successive years from 2011/12 to 2013/14. 
The information sources used in this research are all publically available and can be 
categorized as follows: 
• Diabetes datasets – nationally available; 
• Diabetes specific information – available from local PCOs and other local NHS 
organisations; 
• PCO organisational and non-disease specific information – nationally available 
• Local NHS Organisational and non-disease specific information - available from 
local PCOs and other local NHS organisations. 
The information used to create the indicators is both quantitative and qualitative in 
nature. For the purposes of this analysis it was important that the qualitative 
information (textual) was coded and scored to allow for a quantitative comparison 
across organisations.  
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4.1.1. Selection of outcome indicators 
Before it was possible to identify suitable information and data to create the indicators 
it was important to identify specific outcome indicators. Once this was done it was 
possible to find structure and process indicators that were relevant to the outcome 
indicators. 
Two outcome indicators, both measuring the prescribing of two classes of new drugs 
that had been introduced for management of type 2-diabetes (LA insulin analogues 
and GLP-1 analogues). Both of these two groups of drugs had recently been 
introduced prior to the period of this study but during this study period had been two 
areas where the reduction of prescribing has been an aim of national initiatives and 
guidelines because of cost issues. Prescribing of both groups of drugs was consistently 
targeted in an effort to save money on prescribing costs from 2011/12 to 2013/14 
(National Prescribing Centre, 2012). 
The increasing uptake of the expensive LA insulin analogues over cheaper isophane 
insulin products was targeted by the QIPP programme (Health and Social Care 
Information Centre, 2013b) as a way of reducing prescribing spend in PCOs. It was 
therefore an example of a drug class that may have been actively discouraged by many 
PCOs. This was reflected in the recommendations in many of the formularies during 
this period whereby prescribing was only recommended as a second line option if 
isophane insulin was found to be unsuitable. It was often also one of the indicators 
chosen by PCOs as part of their prescribing incentive schemes to reduce or contain 
costs in prescribing budgets. In a similar way, GLP-1 agonists were chosen because 
they were a relatively new therapeutic class of drug used as third line therapy in type 
2 diabetes often as an alternative to initiating insulin. GLP-1 agonists’ place in the 
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treatment of type 2 diabetes, according to NICE Guidance (NICE Guidance CC87, 
2009) was after the cheaper and more established agents (metformin and 
sulphonylureas). To encourage the use of metformin and sulphonylureas, the rate of 
their use was also measured, and they both were also the subject of QIPP (with the 
aim of increasing use in the majority of patients). Despite these initiatives, however, 
during 2011/12 to 2013/14 analysis of diabetes drug prescribing data in England from 
2005-6 to 2013-14 found that the number of items of newer antidiabetic drugs 
increased by 164.3% from 2005-6 to 2013/14 with an attendant rise in net ingredient 
cost of 129.6% for the same period (£102.9 million) (Health and Social Care 
Information Centre, 2014d). Uptake of GLP-1 agonists was greater than predicted 
(according to costing models created by NICE) when the 2013/14 prescribing patterns 
were analysed, with prescribing rates being 8% higher than expected (Health and 
Social Care Information Centre, 2014c). A study in the UK (y Thong et al., 2014) 
reported two nationwide audits on the use of GLP-1 agonists and found that they were 
being used outside the indications recommendations by national guidelines available 
at the time. 
Analysis of the prescribing behaviour of individual PCOs showed that that the rate of 
adoption of these newer drugs was very different depending on the particular 
organisation studied. It was found that prescribing of the newer insulin analogues (as 
a % of all long and intermediate acting insulins) ranged between 38% and 98.6% 
across organisations (average being 85.3%) (Health and Social Care Information 
Centre, 2011). An updated report in August 2014 showed that this variation between 
PCOs still existed following the organisational changes. The difference between the 
prescribing rates of LA insulin analogues in 2013/14 in PCOs ranged from 37.6% to 
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97% in 2013/14 (average figure of 82.2%). These differences cannot solely be 
explained by a variance in the prevalence of diabetes (Health and Social Care 
Information Centre, 2014d).  
This intended restriction on the prescribing of these two groups of drugs for type 2-
diabetes to save money did not necessarily fit in with the clinically orientated targets to 
gain a tighter control of blood glucose levels. NICE in its national guidance has 
recommended that tower blood glucose levels are critical to reducing complications, 
improving patient outcomes and reducing (or at least, limiting) total money spent on 
type 2 diabetes (NICE Guidance CG66, 2008). In the treatment of type 2 diabetes, it 
is recommended that the prescribing of different medications and alterations of dosing 
of insulins and oral diabetic medication is done in response to a number of clinical 
markers such as levels of blood glucose (measured as HbA1c). It has been found in a 
number of studies that intensive treatment with antidiabetic drugs can reduce micro 
(amputations, chronic renal disease and retinopathy) and macro (myocardial infarction, 
heart failure and stroke) vascular complications that are causes not only of major 
disability but also shortened life expectancy (Control and Complications Trial Research 
Group, 1994). The LA insulin analogues and GLP-1 agonists are both groups of drugs 
that can be added in to the drug regimens of type 2 diabetics when the control of 
HbA1C is suboptimal (NICE Guidance CC87, 2009).  
It was clear from looking at the published data described above that there was an 
opportunity within this research project to obtain a range of comparative data and 
information for all PCOs in England that could reflect influences on the prescribing 
behaviour of GPs as well as recording the differences in prescribing data down to 
individual drug level for the organisations from 2011/12. If this year was used as the 
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first year for this research then the enormous changes to PCOs as organisations taking 
them from largely management controlled Primary care Trusts in 2011/12 towards GP 
led organisations (Clinical Commissioning Groups) in April 2013 could also be studied. 
Finally, if diabetes was the chosen disease area, then the uptake and use of two new 
drug classes (LA insulin analogues and GLP-1 agonists) could be compared in 
different PCOs. A three-year study period from 2011/12 to 2013/14 would provide an 
opportunity to use the newly available data and measure influencing factors for PCOs 
that have undergone significant organisational change. Limiting the research to type 2 
diabetes and specifically to two classes of drugs would further allow for analysis of the 
factors influencing an important and costly chronic disease over this time 
4.2. Aims and objectives 
The third aim of this research project was to construct PCO profiles for all PCOs in 
England based on the Donabedian SPO Model. In order to do this the following 
objectives were met: 
• Examination of the data and information from national and local sources to 
ascertain if they could be used to measure the individual influences that had 
made up the indicators in the structure and process domains in the 
Donabedian SPO model. 
• Creation and development of standards to be applied when considering 
acceptable data coverage levels; standards for inclusion of data; scoring 




• Collection of data and collection, coding and scoring of information and 
storage in Excel spreasheets to reflect individual indicators for all PCOs for 
each of three years from 2011/12 to 2013/14. 
To allow for comparison of each influence within the PCO Profile all collected data and 
information was also scored into one of 5 groupings (quintiles). The rationale for 
scoring following the general principle that the greater the value (be it prevalence, level 
of spend, numbers of referrals, cohesiveness and achievement of management goals 
of the organisation) then the higher score. 
4.3. Method 
National guidance documents that focused on prescribing, diabetes, PCOs, quality 
indicators, and performance measurements were read to gain an understanding of the 
general situation in the NHS at the time of this research. Specifically, the pressures, 
targets, standards and guidelines that influenced and impacted upon PCOs 
(particularly those that affected prescribing, diabetes care and PCO organisations) 
during the three years were recorded. Following this, national datasets and local 
information sources that might be relevant to this research were identified and 
assessed to ascertain if they represented a measurement of the individual indicators 
previously identified as important as influences on GP prescribing behaviour. Finally, 
data and information was collected and saved onto Excel spreadsheets for all PCOs 
for each of three years. All the data and scored qualitative information was divided into 
quintiles to allow for comparison (see chapter 5). 
4.3.1. Criteria for using data and information 
The inclusion criteria for using data from these information sources to populate the 
PCO Profile followed previous published work by Mainz on the definition and 
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classification of clinical indicators in the Donabedian SPO model (Mainz, 2003). Also, 
more broadly by the guidelines for choosing indicators to measure quality 
improvements developed in 2010 (Raleigh and Foot, 2010) . Accordingly, an inclusion 
criteria for the data was developed and is described below. In summary, data was 
included only if it provided a measure of the importance of each individual influence on 
prescribing within the PCO previously identified in the systematic review described in 
chapter 2.  Simply having access to a dataset that covers all the PCOs in England over 
the time period of this study was not a reason for inclusion. When a possible data 
source was identified, it was examined to see why and how it was being collected. It 
was assessed to look for coverage across all PCOs for the three years, and the source 
of the data was identified; nationally collected (for example, QOF yearly data) or locally  
published by PCOs and acute trusts ( local formulary guidance). The inclusion criteria 
described in the next section was developed. 
4.3.1.1. Inclusion criteria for data and information 
• it identified how well an influence has been adopted (in the case of audit and 
education; clinical guidelines; prescribing control; new drugs adopted; financial 
balance) or 
• it described the relative situation in the organisation – relatively stable 
(population description; GP characteristics; involvement of local organisations 
within area prescribing committees) or 
• it outlined patterns of behaviour (referral patterns, spend analysis) 
In addition, the following rules applied: 
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• Wherever possible diabetes specific information was used, unless it was not 
relevant to the influence (for example organisational culture) 
• Data had to be available for over 90% PCOs  
• Nationally available and locally available sources were examined to see if useful 
data was available for each influence. 
• Data was chosen to measure the effectiveness of the intervention wherever 
possible (for example the effectiveness of audit and education and prescribing 
incentive schemes) 
• Wherever possible, raw data was used that had not been adjusted for 
differences in the population (this was been taken into account by other 
indicators). 
• Once the dataset had been identified, the data was examined to ascertain 
whether it had stayed the same over the research period and whether it had 
been collected in the same way over the three years.  
• To create the most robust analysis possible, wherever possible more than one 
set of data was used to score each influence. Where this was possible, each 
influence was scored separately and these scored combined to provide a final 
single score. 
The period of study was from 2011/12 to 2013/14, and followed the NHS financial year 
from April to March. This period encompassed the change in PCOs in England from 
Primary Care Trusts (PCTs) to Clinical Commissioning Groups (CCGs). To allow for 
the analysis to provide a meaningful comparison for organisations over time, wherever 
possible data was built up from practice level information. Organisational data and 
textual information at PCT level that could not be created in this way, was scored at 
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the separate organisation level and matched from parent PCTs to the related CCGs 
across the three years.  
4.3.2. Potential data sources 
There were two sources of information and data for this research, nationally collected 
from all PCOs or locally published by individual PCOs and acute trusts. 
4.3.2.1.Nationally published information 
There were a number of datasets collected nationally from or about all PCOs in 
England for the period of this study.  National guidance and review documents 
discussing prescribing, diabetes management, PCO management and development, 
targets and priorities, and measurement of quality indicators and outcomes produced 
by the DoH, NHS Commissioning Board, NHS England, NICE, Public Health England, 
Audit Commission, National Audit Office, Right Care, Atlas of Variation and The Kings 
Fund were read to identify possible datasets that may be relevant to this research. The 
main source of relevant data was the Health and Social Care Information Centre 
(HSCIC). Other sources are listed in Table 13 below together with those datasets that 
were scrutinised to ascertain their relevance for this research. A more detailed 
description of the datasets is given in Appendix 1. 





Diabetes Clinical Data sets HSCIC 
Hospital Episode Statistics HSCIC 
Innovation Scorecard HSCIC 
Mortality data HSCIC 
National Diabetes Audit HSCIC 
Prescribing Data HSCIC 
Prescribing comparators HSCIC 
Quality Outcomes Framework (QOF) HSCIC 
Workforce Analysis HSCIC 
Years Lost HSCIC 
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Better Care Better Value NHS Improving Quality 
Programme Budgeting Spend Analysis NHS England 
PCO Organisational Changes NHS England 
PCO Annual Risk Assessment Reports NHS England 
PCO Authorisation Waves NHS England 
CCG Diabetes Classification Public Health England 
Diabetes Outcomes versus Expenditure (DOVE) 
Tool 
Public Health England 
Healthier Lives Public Health England 
Atlas for Variation Right Care 
CCG Commissioning for Value Right Care 
Spend and Outcome Tool Right Care 
The nationally collected data had many advantages. The major one was that there was 
excellent coverage of data across all the PCOs in England over the period of this 
research for all of the major data sources such as QOF, Prescribing data, HES, Better 
Care Better Value, NICE Innovation Scores and Programme Budgeting. Another 
advantage was that the data sources were already being used extensively to compare 
PCOs and help them to gain an insight into how they might wish to improve or change 
their services and are publically available for inspection and scrutiny so there is a 
pressure on the reporting PCOs and managers of the national dataset for accuracy. 
However, there are also some potential disadvantages. Firstly, there is a potential 
political motivation to present the most positive picture for any individual indicator. 
Secondly, often only the final situation is presented – for example the information about 
the CCG waves of authorisation is accurate but does not give the full picture of 
organisational change before that situation was arrived at. Specific limitations with 
each dataset have been described in Appendix 1 but there are some general issues in 
terms of measurement and validity. There was a possibility that differences recorded 
from year to year may be due to changes in recording rather than clinically significant 
differences and data quality is impossible to control and there is always the possibility 
that this has caused anomalies in the results. However, the importance of these 
datasets has increased over the last ten years and since PCOs, acute trusts and NHS 
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management have focused on this area, it might be argued that accuracy of the data 
has become more important to the PCOs. 
4.3.2.2. Local NHS organisations as a source of information 
One of the main sources of information about PCOs was the organisations themselves. 
They are publically accountable organisations and under a legal obligation to make 
available certain pieces of information to the public. Under the Freedom of Information 
Act, they must provide organisational information, governance arrangements, financial 
information (income and expenditure breakdown), strategy and performance 
information, plans and reviews, how the organisation makes decisions, policies and 
procedures (NHS England, 2015). All PCOs produce an Annual Report and Annual 
Accounts, as well as yearly commissioning intentions and plans.  
4.3.2.3. Pre April 2013 
Following the 2010 White Paper (Lansley, 2010), PCTs joined together to form clusters 
and SHA grouped together to form SHA clusters. They facilitated the creation of 
pathfinder and emerging CCGs. During 2011/12 and 2012/13 PCTs remained 
statutorily accountable as organisations although PCT Clusters were formed (to allow 
some capacity to help create emerging consortia and as part of a bigger drive to reduce 
running costs in the NHS). PCTs or PCT clusters were responsible for delivery of 
2011/12 and 2012/13 operational plans, although some pathfinder or emerging CCGs 
produced their own commissioning plans during this period and even if they did not 
produce their own plans, they were encouraged to take part in planning and 
development of the operating plans. SHAs (or SHA Cluster) were responsible for 
operational delivery and management of the PCT’s delivery of requirements set out in 
the NHS Operating Frameworks (Department of Health, 2010).  
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4.3.2.4. Post April 2013 
From April 2013, PCT Clusters and SHAs were dissolved and CCGs and Area teams 
became the new organisations with responsibility for The Planning Cycle for PCOs is 
approximately 18 months. CCGs share first draft of plans with the Area Team 
Directors. Final Plans were agreed by 5 April 2013 and approved by the NHS 
Commissioning Board by 10 May 2013 (NHS Commissioning Board, 2012d). 
4.3.2.5. Documents produced by PCTs, PCT Cluster, Practice Based Commissioning 
Groups and CCGs 
Table 14 below sets out the different types of documents produced by PCOs over the 
period 2011 - 2014. It is not exhaustive because some have produced additional 
strategy and commissioning or planning documents, and others have produced less. 
Similarly, the documents (other than the Annual Reports) are not all named in the same 
way. 
Table 14: Documents produced by local PCOs 
Document Year Organisation 
Integrated Strategic and 
Operational Plan (ISOP) 
2011/12 PCT or PCT Cluster (with or 
without input from CCGs) 
Operating Plan 2011/12 PCT or PCT Cluster (with or 
without input from CCGs) 
Annual Report 2011/12 PCT or PCT Cluster 
Integrated Strategic and 
Operational Plan (ISOP) 
2012/13 PCT or PCT Cluster (with or 
without input from CCGs) 
Clear and Credible Plan 2012/13 CCG 
CCG Plan on a Page 2012/13 CCG 
Commissioning and Strategy 
Plan (CSP) 
2012/13 PCT or PCT Cluster (with or 
without input from CCG) 
Annual Report  2012/13 PCT or PCT Cluster 
Local Delivery Plan (LDP) 2013/14 CCG 
CCG Commissioning Plan 
(Intentions) 
2013/14 CCG 
Annual Report  2013/14 CCG 
Clear and Credible Plan 2013/14 CCG 




4.3.2.6. Validity of the locally published information 
It was important in this research project to understand how relevant the publically 
available documents were and how authoritative and reliable a source of information 
they could be. The planning and commissioning documents produced by PCOs were 
signed off and approved by the SHAs (2011/12 and 2012/13) and Area teams 
(2013/14) as well as being finally authorised by NHS England and latterly The NHS 
Commissioning Board. Delivery of the targets and priorities was monitored by the area 
teams and the NHS Commissioning Board, although the PCOs were not forced to 
reach the targets within the set timeframe (NHS Commissioning Board, 2012d). The 
advantages of using locally published information were that the development of 
organisations and views of the importance and success of local projects as seen by 
local groups of GPs and managers would be captured. In some PCOs there was 
extensive organisational change during the period from 2010 to April 2013 with several 
consortia being set up, merging and disbanding before the final configuration was 
decided upon. This information is lost in the National datasets. In the case of the use 
of local formularies and prescribing guidelines, these are by necessity produced by 
local organisations and no national dataset exists. Limitations of the local 
documentation include the possibility that PCOs may have been inclined to present the 
most positive picture to the local community and the public, so may have described a 
significantly improved service where the quantitative data may have contradicted the 
degree of improvement attained. Finally, the documents have not been produced in 
answer to a specific research question sent to them as part of this research. For 
example, there was a possibility that the organisation had identified major changes in 
diabetes care but had not mentioned this in any of the official planning documents.  
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4.4. Results of the examination of possible data sources 
The results of the exercise to find and collect data and information to populate the 
model to be used in this research are described in this section. A number of findings 
are generic and have been presented in this first part of the results. The second part 
has focused on the creation of individual explanatory indicators that reflect the 
influences on prescribing and that make up the PCO profile.  
The availability of comparative NHS data at PCO and practice level have been 
increasing steadily since the first PCO organisations were created in 1997. The 
Freedom of Information Act in 2000 allowed members of the public to request 
information from public authorities such as PCOs, health authorities, acute trusts and 
DoH. In addition, comparative data have been increasingly collected and made 
publically available in response to the UK Government Transparency Agenda policy in 
2012 (House of Commons Committee of Public Accounts, 2012) and as a result of 
initiatives to reimburse NHS organisations to collect data such as QOF introduced in 
2004/5 (Health and Social Care Information Centre, 2005). 
4.4.1. Types of data and information collected – ge neric findings 
A number of differences between the information and data were identified and a set of 
rules have been adopted to allow for uniform and logical manipulation of data. To allow 
for a meaningful comparison across the three years’, data has been collated at PCO 
level wherever possible. This can be done when data was held at practice level and 
built up to cover the organisation. However, not all information or data could be 
manipulated in this way because it only existed at organisational level. This means that 
for 2011/12 year it was sometimes reported at PCT level (152 organisations) but in 
2012/13 and 2013/14 it was available at CCG level (211 organisations). In the majority 
127 
 
of cases a CCG has been formed within the boundaries of a PCT and so the PCT 
information could be used for the relevant CCG. However, there were some instances 
where the resulting CCG was formed as a result of a merger of PCTs (7 CCGs) or as 
a result of the movement of practices within one PCT to join with practices from another 
PCT (3 CCGs). In these cases, it was not always possible to accurately allocate data 
to the new CCGs and it was apportioned from the PCTs to the new CCGs according 
to the ratio of the practices moving from each PCT to the CCG (this applies to the 
Programme Budgeting and the Better Care Better Value data). Some information has 
been retrospectively re-presented at CCG level for 2011/12 (for example prescribing 
data) and did not require any manipulation. The individual organisational changes from 
PCT to CCG are listed in detail in Appendix 2. NHS England provided a spreadsheet 
in 2014 mapping the best fit between PCTs and CCGs and this has been used to 
ensure that the calculations are as accurate as possible (Health and Social Care 
Information Service, 2014) . 
For most of the data scoring these changes do not cause a problem because the data 
is linked to specific practices and not their parent PCO. However, some data is linked 
to the PCO and is not available at practice level. Therefore, the PCT scores must be 
apportioned to the new CCGs accordingly. 
The quantitative and qualitative information that has been scored to create the 
measurements for the factors can be grouped according to the type and level of the 
data. 
4.4.2. Quantitative data only available at PCT leve l 
• 2011/12 Better Care Better Value Data 
128 
 
• 2011/12 Programme Budgeting Data 
4.4.3. Qualitative information that is recorded at PCO level 
• 2011/12 Area Prescribing Committee membership 
• 2011/12 Local Formulary involvements within the LHE 
• 2010 WCC Local Priorities 
• 2011/12 Annual Report diabetes developments 
• 2011/12 planned changes in diabetes services  
4.4.4. Data at practice level 
Wherever possible quantitative data has been collected at practice level and the 
practices linked to the PCO to calculate the PCO value. This gives us the most 
accurate picture of the results at PCO level. However, during the 3 year period there 
were changes to practices. These changes are reflected in the Organisation Profile 
(recording number of practices, % dispensing practices, % single handed practices) 
and in the GP demographics (age, gender and training of GPs. NHS England has 
provided a file linking practices with CCGs back to 2011/12 which was used for all 
calculations (Health and Social Care Information Service, 2014). 
4.4.5. Data collected at practice level and calcula ted to provide PCO level data 
GP Workforce analysis (age, gender, training) 
• Practice analysis (% dispensing practices, % single handed practices, type of 




• Prescribing Data (PACT) for drugs to treat diabetes, specific diabetes drug 
groups (LA insulin analogues and GLP-1 Agonists) and specific drugs 
(Exenatide, Liraglutde and Lixisenatide – GLP-1 Agonists). 
• QOF Data for diabetes prevalence, attainment of audit and education and 
clinical guidelines adherence. 
4.4.6. Changes in data during the period of this re search 
There were some differences in the targets or specific data that was measured over 
the three years. The new targets (in the QOF for instance) were applicable for all the 
organisations and reflected the changing landscape within the NHS in England so if 
required, the scoring rationale in each year was altered to reflect changes in national 
targets. This applied in the following comparators: 
• NICE data changes over the period (GP prescribing behaviour factor) 
• Changes in QOF targets (audit and education and clinical guideline factors) 
• Organisation culture – changes in developments of the organisations over 3 
years. 
• Organisation Profile individual comparators over the three year period. 
• Diabetes Priorities over the three year period (reflecting different NHS England 
priorities imposed on the PCOs) 
4.4.7. Diabetes prescribing data 
Prescribing data used in the analysis could not be split into treatment for type 1 or type 
2 diabetes because the treatments were the same for both groups. In this case the 
total number of diabetics is used. This is commonly not expected to corrupt results 
because of the much smaller number of type 1 diabetics and the even distribution 
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throughout the population in each PCO (Health and Social Care Information Centre, 
2014d).  
4.4.8. Practice alterations 
Practices have opened or closed during the period of study and although the practices 
within a CCG may change over the year it is possible that the number may remain the 
same. Similarly, new GPs will have joined practices and others will have retired. These 
changes were reflected in the GP demographics indicator and the Organisation Profile 
indicator. 
4.4.9. Choice of weighted data 
Some of the information sources described in Appendix 1 have used a weighted 
population when analysing the data. However, only non-weighted information has 
been used in this analysis because the purpose of this study is to identify key 
influences on prescribing so it would be inappropriate to have both an indicator for 
patient characteristics and use weighted data that has been adjusted for the population 
differences.  
4.4.10. Collection and storage of quantitative data  
In order to store the quantitative data in a systematic manner, separate Excel 
spreadsheets were created for each explanatory indicator. In all the spreadsheets 
columns containing SHAs, Area teams, practices and PCOs (PCTS and CCG) together 
with the relevant NHSID codes were recorded. To take account of the organisational 
changes in PCOs, both PCTs and the CCGs that were replaced in 2013 were identified 
and linked to Strategic Health Authorities and Area teams. Columns with the 
quantitative data for the explanatory indicator were then created for the three years of 
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this study. The precise manipulation of data required for each indicator is described in 
section 4.5. All spreadsheets are available for examination. 
4.4.11. Collection, storage and coding of qualitati ve information  
The text (qualitative data) was extracted verbatim from the public documents (and 
referenced accordingly), linked to the relevant PCO and inserted into an Excel 
Spreadsheet (separate for each explanatory indicator). In order to score the 
information, it was then described in standardised terms and natural groupings of 
similar terms were noted to allow for manual categorisation as per the concepts behind 
coding and categorisation of qualitative data outlined in Chapter 16 (Bowling A, 2009). 
4.5. Application of data sources to the modified Donabedian SPO model 
for prescribing 
The next section describes the creation of individual explanatory indicators reflecting 
the influences on prescribing in the Modified Donabedian SPO model using the 
publically available data and information described in the previous section. The list of 
individual indicators follows the order (and colour coding) set out in Structure-Process-
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4.5.1. Structure domain – Diabetes specific subgrou p 
There are six indicators in the diabetes specific subgroup: Diabetes organisation 
priorities and plans;  diabetes total spend; influence of secondary care; population 
classification; diabetes prevalence and one that reflects the influence of 
pharmaceutical companies.  
4.5.1.1. Diabetes organisational priorities 
Diabetes was already a priority area for all PCOs under the Yearly National Planning 
and Priorities Guidance (NHS Commissioning Board, 2012b); The National Outcomes 
Framework and The Quality Premium Priority Scheme (NHS Commissioning Board, 
2013c). However, some PCOs have specifically identified diabetes as a local priority 
and measuring this should reflect the extra emphasis given to diabetes services that 
comes from the organisation choosing diabetes as a local priority.  
There were a number of sources of information that could have been accessed to build 
up a picture of how significant diabetes was for each PCO during the period of 
research. Increasingly, a number of tools have been created and provided to PCOs to 
help them to use their resources more effectively and prioritise areas of clinical need 
where they were performing less well or areas where they were prescribing 
ineffectively, inappropriately or in  
PCOs have to go through a process of yearly prioritisation of need and allocation of 
funds for the coming year. These tools include the SPOT tool (Spend and Outcomes 
analysis); The Atlas of Variation and The Right Care Initiative, Programme Budgeting 
Tool and Better Care Better Value Productivity tool (see Appendix 1). Research has 
shown that PCOs have used these tools to help them (Schang et al., 2014). However, 
there are several issues with using the data from these tools as an identification of 
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whether diabetes should be a priority for a PCO. Firstly, the data used in each of the 
tools is based on previous years, for example, NHS Atlas of Variation in Healthcare for 
people with diabetes was made available in June 2012 Atlas of Variation (Right Care 
Atlas Series, 2012). The data sources were NIC 2010/11 and National Diabetes Audit 
data for 2009/10. Secondly, although some of the tools have used the relevant years’ 
data in terms of this research, the tools were not available to the PCOs during the 
period of planning and prioritisation (roughly 6 months prior to the start of each financial 
year in April). For example, the Right Care Analysis was released in October 2013 but, 
although it is based on information and data 2011/12, was not available for the PCOs 
when they were identifying clinical priorities areas for 2013/14. Finally, the underlying 
data used in these tools has been used in the creation of other factors as a measure 
of the way in which diabetes services are provided. Therefore, it would be a duplication 
to include the data again in the construction of this factor. 
This is identified their commissioning or business for the next year. They then report 
on the previous year’s achievements in their Annual Reports. Therefore, in order to 
capture all the plans and achievements made by the PCO in terms of improvements in 
diabetes care locally, both the PCO Commissioning Plans and the Annual Reports 
must be viewed for the years 2011/12 – 2013/14. Identification of major pieces of work 
on developing diabetes care pathways, service improvements, reduction of referrals to 
secondary care has therefore been collected in the local plans and annual reports of 
the PCOs. The information has been extracted and scored depending on the source 
of the information for Annual Reports, Commissioning and Business Plans and for 
2013/14 for information about the Quality Premium Priorities. The scoring for service 
developments was allocated to the year in which it had largely taken place – so if a 
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new diabetes service was set up in 2012/13 but was mentioned in a Commissioning 
Plan 2013/14 then the scoring was applied to 2012/13. Scoring for 2011/12 and 
sometimes in 2012/13 has been at PCT level and then copied to the relevant CCG 
levels so that a comparison over the 3 years is possible.  
Creation of individual indicator:  Diabetes organisational priorities 
Type of data:  Public local documents and information. Qualitative information coded 
and scored.  
Table 15: Diabetes organisational priorities scorin g 





 PCO Annual Reports – 3 years 
Score 4 major improvements or changes in local diabetes services achieved during 
the year 
Score 3 smaller specific targets achieved during the year (diabetic retinopathy 
screening, patient education) 
Score 2 planned changes – service reviews etc. within the year 
Score 1 no mention of diabetes in annual reports – or only mentioned as part of 
diabetes being detected in The NHS health Check programme or no 
Annual report for the PCO 
 Note: If the Annual Report has reported achievements to the local premium 
quality priorities then this is not scored again because this has been 
capture elsewhere. Scoring for 2011/12 and sometimes in 2012/13 has 
been at PCT level and then copied to the relevant CCG levels so that a 
comparison over the 3 years is possible.  
  
 Score for Commissioning / Business Plans 3 years 
Score 4 major specific improvements to the local diabetes services or redesign of 
care pathway planned during the year. Or Diabetes acknowledged as a 
priority area. 
Score 3 smaller specific targets planned during the year (diabetic retinopathy 
screening, patient education) 
Score 2 achievements mentioned. Plan to review diabetes care pathway 
Score 1 no mention of diabetes in Commissioning / Business Plans – or only 
mentioned as part of diabetes being detected in The NHS health Check 
programme. Or no Commissioning / Business Plans for the PCO 
 Note: The scoring for service developments is allocated to the year in 
which it has largely taken place – so if a new diabetes service is set up in 
2012/13 but is mentioned in a Commissioning Plan 2013/14 then the 
scoring will be applied to 2012/13. 
 Priorities Scoring  
 Quality Premium local priority 2013/14 
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Score 2 Diabetes a priority 
Score 1 Long Term Conditions a priority 
Score 0 Diabetes or long term conditions not a priority 
  
 Commissioning Plans 
Score 2 Diabetes a priority 
Score 1 Long Term Conditions a priority 
Score 0 Diabetes or long term conditions not a priority 
  
 Annual Report 
Score 2 Diabetes a priority 
Score 1 Long Term Conditions a priority 
Score 0 Diabetes or long term conditions not a priority 
 Scoring criteria different for all three years depending on the measures 
made over the period. 
Quintile allocation Creation of Quintiles. Data not continuous so PCOs in each quintile not 
equal. 
Diabetes Priorities 
2011/12: Q1 (38 PCOs); Q2 (44 PCOs); Q3 (24 PCOs); Q4 (61 PCOs); Q5 
(44 PCOs) 
2012/13: Q1 (38 PCOs); Q2 (52 PCOs); Q3 (80 PCOs); Q4 (34 PCOs); Q5 
(7 PCOs) 
2013/14: Q1 (30 PCOs); Q2 (66 PCOs); Q3 (40 PCOs); Q4 (55 PCOs); Q5 
(21 PCOs)  
 
4.5.1.2. Diabetes total spend 
Each PCO was required to meet a number of financial targets during the financial years 
2011/12 to 2013/14 (April to March). The financial targets for PCOs were included in 
the relevant Operating Frameworks for each year issued by The DoH and then NHS 
England.  However, it was difficult to link the relevance of the total PCO financial 
situation for a year with the total PCO budget and spend on diabetes prescribing, 
because although diabetes prescribing costs account for around 11% of the total 
prescribing budget of a PCO (Health and Social Care Information Centre, 2014d), 
prescribing is generally only reported as accounting for around 10-20% of total PCO 
budget in PCO Annual Reports. Therefore, a comparison of the spend on diabetes is 
more relevant to this research. 
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The HSCIC (and before 2012, the NHS Information Centre) have compiled data to 
compare prescribing spend for diabetes in primary care since 2005/6. Prescriptions 
issued in primary care are analysed for all medicines to treat diabetes providing the 
NIC by the Prescription Cost Analysis system. This spend figure was broken down to 
individual drug groups within the total spend and these were linked to the number of 
patients with diabetes by using QOF diabetes prevalence. However, spend on human 
long acting insulins and GP-1 agonists form a large percentage of the total spend and 
since this is the subject of our research and this data has been used to create two 
explanatory indicators it cannot be used as another indicator in the model. 
Another way to compare spend on diabetes would be to use a figure for total spend on 
diabetes including, for example, prescribing costs, primary care management, and 
secondary care referrals. Each year PCOs were required to provide a full analysis of 
the way in which they spend their budget on twenty three different healthcare 
conditions (including diabetes); a process called Programme Budgeting (Martin et al., 
2008). PCTs originally collected and analysed the information, and now CCGs are 
responsible for doing this. The Programme Budgeting data was only available at PCT 
level for 2011/12 and 2012/13, so the granularity of the information is compromised. 
However, it was possible to provide data for all PCOs for the three years. 
Creation of individual indicator: Diabetes total spend 
Quantitative data at PCO level. Yearly data available for all organisations in England. 
Programme Budgeting spend on diabetes. Department of Health. Total programme 
Budgeting spend on diabetes per 100,00 population.  
Table 16: Diabetes total spend scoring 
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Score for Diabetes 
total spend 
Description 
Data ranked 1-211 Total spend on diabetes per 100,000 population from Programme 
Budgeting data 
 Note: Weighted populations for 2012-13 were not available. Therefore the 
2012-13 weighted populations within this workbook have been calculated 
by taking the 2011/12 weighted populations as a proportion of the 
2011/12 total population, and applying this to the 2012/13 raw population 
figure. 
 Same scoring criteria for all three years. Different data for each of the 
three years. 
Quintile allocation.  Creating quintiles. Highest quintile corresponds to highest spend per 
100,000. Ranked data divided into 5 equal groups (Quintile 5 with 1 extra 
PCO) 
 
4.5.1.3. Influence of Secondary Care 
The importance of the acute hospital in affecting the prescribing behaviour of GPs is 
significant (Florentinus et al., 2009). There were several different aspects the influence 
exerted: the role of consultant and specialist team – how they prescribe new drugs has 
been shown to directly encourage similar prescribing behaviour in GPs (Larsen et al., 
2014, Mason, 2008). In the case of type 2 diabetes the two drug groups in this research 
project were usually initiated in secondary care at the beginning of the study period 
(2011/12) although that changed over the three years as GPs were trained and 
become more confident in initiating insulin therapy and GLP-1 agonists for their type 2 
diabetic patients. Schemes whereby GPs are supported to manage more complex 
patients in the community have been seen to reduce referrals to hospital and better 
glycaemic control (Choudhury et al., 2013, Kar et al., 2013). Historically, diabetes 
services have developed in many different ways across England and this has often led 
to services being predominantly provided in secondary care in some local health 
economies and far more in primary care in other places (Joint British Diabetes 
Societies for Inpatient Care (JBDS-IP), 2013). Nationally, it has long been the aim of 
the government to reduce reliance on the acute sector and provide more services in 
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primary care. This has been an ongoing yearly priority for patients with long term 
conditions over the period of this study (Department of Health, 2001a).  
The role of the acute hospital in influencing prescribing behaviour is not measured by 
any direct set of data but it is possible to build up a picture of the relationship between 
a PCO and the acute trusts within the LHE. There has been a national move to try and 
shift care from expensive secondary care towards primary care particularly for chronic 
conditions such as diabetes  and as part of this initiative, the Better Care Better Value 
Initiative (Better Care, 2007) records inappropriate referrals to secondary care for 
diabetes. Therefore, it is possible to quantify how much PCOs make use of secondary 
care when it is not deemed necessary, and conversely to identify PCOs that manage 
most of their patients (and hence the initiation and prescribing of drugs to control 
HbA1C) themselves. 
Creation of individual indicator: Influence of secondary care 
Better Care Better Value data for inappropriate outpatient diabetes referrals to 
secondary care – ranking from 1 - 211 (where a ranking of 1 denotes the lowest 
inappropriate number of referrals)  
Quantitative data. Quarterly data available for all PCOs in England from Better Care 
Better Value website. Individual comparator: Inappropriate diabetes outpatient 
referrals to secondary care. Data at PCO level (see section 4.4.2  for explanation of 





Table 17: Influence of secondary care scoring 
Score: influence of 
secondary care 
Description 
Data ranked 1-211 Ranking of data for inappropriate referrals to secondary care (ranking of 1 
for highest inappropriate referrals) 
Scoring criteria Same scoring criteria for all three years. Different data for each of the three 
years. 
Quintile allocation Creation of quintiles. Score 5 denotes the quintile for lowest inappropriate 
referrals. This data is ranked 1-211 and so can be divided into 5 quintiles 
as with the numerical continuous data 
There were two explanatory indicators that reflected the diabetes patient population 
within each PCO. 
4.5.1.4. Population classification 
It is established within healthcare research and the NHS that patient demographic 
profiles are very important when analysing patterns of healthcare provision in general 
and prescribing in particular (Brouwer et al., 2012, Wawruch et al., 2009). Risk factors 
and prevalence of diabetes vary according to patient characteristics and need. 
A dataset called The CCG Classification group comparing the patient population of 
each PCO was available and relevant to this research project. It was originally created 
by Yorkshire and Humber Health Intelligence (and latterly is the responsibility of Public 
Health England) and classified PCOs into a set of five groups with similar 
characteristics for all the organisations in England. This has been used to benchmark 
PCO level indicators and provide a comparison with PCOs that were likely to be facing 
similar challenges. The data used to build up the CCG Classification groupings 
consists of: 
1. Age structure of population 
2. % of population from Asian ethnic groups 
3. % population from Black ethnic groups 
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4. Indices of deprivation (average score) 
5. Population density 
The five groupings were given different colours with the following descriptions:  
• An older population living in rural areas and low deprivation levels. – Purple 
• A very young population with a high proportion of the population from black and 
Asian ethnic groups and high levels of deprivation. - Blue 
• A younger population with a high proportion of the population from black and 
Asian ethnic groups and moderate levels of deprivation. - Green  
• A younger population with a higher than average proportion of the population 
from black and Asian ethnic groups and moderate levels of deprivation. - Yellow  
• A population with an average age structure, average deprivation levels and a 
low population density. – Orange 
Creation of individual indicator: Population classi fication 
Measure of the predominant demographic profile of patients in the PCO with the aim 
of categorizing the level of need in terms of diabetes. 
Qualitative data coded and scored. Only one set of data for the period of this study. 
Source: Public Health England.  
Table 18: Population classification scoring 
Score for population 
classification 
Description 
Score 5 Purple group 
Score 4 Blue group 
Score 3 Green group 
Score 2 Yellow group 
Score 1 Orange group 
 Same scoring criteria for all three years. Data the same for all three years. 
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Quintile allocation Creation of quintiles. Data already divided into quintiles. Highest quintile 
denoting population group with highest propensity to develop diabetes. 
 
4.5.1.5. Diabetes prevalence 
Diabetes prevalence was measured in the yearly QOF scheme with the number of 
patients diagnosed with type 2 diabetes who are over 17 years of age. As has been 
mentioned before in the Audit and Education section, QOF has a very high uptake from 
practices in England with 7,921 practices providing information in 2013/14.  
The National Diabetes Audit (NDA) also collected information on the prevalence of 
diabetes in practices across England during the period of this study. However, the 
number of practices participating in this audit was less than in the QOF data. In 
addition, the National Diabetes Audit (NDA) runs for a 15 month period and so it is not 
aligned to the yearly analysis that is part of the research. 
QOF: Type 2 Diabetes prevalence for patients over 17 (%). The data was available 
from the HSCIC website.  
Creation of individual indicator: Prevalence of diabetes 
Quantitative data at PCO level and some at practice level. Yearly data produced by 
QOF. % of patients with type 2 diabetes in each PCO (Indicator DM019 in 2011/12; 
DM032 in 2012/13 and DM001 in 2013/14). Source: HSCIC. The data presented at 






Table 19: Diabetes prevalence scoring 
Score for Total 
diabetes prevalence 
Description 
Data ranked 1-211 % patients with diabetes (over 17) 
 Same scoring criteria for all three years. Different data for each of the 
three years. 
Quintile allocation Creation of quintiles. Highest quintile corresponds to highest spend per 
100,000. Ranked data divided into 5 equal groups (Quintile 5 with 1 extra 
PCO) 
 
4.5.1.6. Pharmaceutical company 
In the UK there is an agreed Code of Practice for the Pharmaceutical Industry that has 
been agreed with the Association of the British Pharmaceutical Industry (ABPI) July 
2012. There were no nationally publically available data comparing the interaction 
between sales and marketing personnel in a pharmaceutical companies and GPs. All 
PCO and GPs are targets to be visited by sales representatives working for 
pharmaceutical companies and recipients of marketing information produced by them. 
Therefore, it was difficult to discern any differences between PCOs based on sales 
and marketing activity. PCOs had before 2011 developed and approved policies and 
guidelines to outline appropriate joint working between them and pharmaceutical 
companies, but there was no national or locally publically available information 
detailing the amount of actual sales and marketing contact between PCOs and 
pharmaceutical companies. For this reason it has not been possible to include this 
indicator in the analysis. 
4.5.2. Structure domain - Generic subgroup 
Subheading: Group 1 collaboration indicators 
There were two separate indicators that were used to give a picture of the level of 
influence of other organisations on the diabetes prescribing of individual PCOs. 
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4.5.2.1. Area Prescribing Committees 
Organisations within the LHE have influenced each other by the shared prescribing 
decisions that are made via joint prescribing committees called area prescribing 
committees (APCs). APCs and Prescribing forums have been set up across local 
health economies in many parts of England for a varying number of years. They are 
used to help prioritise and make decisions about the choice of a particular drug within 
a therapeutic class, to develop prescribing guidelines and policies, to manage new 
drug entry into the LHE and agree prescribing decision across primary and secondary 
care organisations within the LHE (National Prescribing Centre, 2012). 
Qualitative Information about the organisations and their involvement in APCs over the 
years from 2010/11 to 2013/14 has been collected from local publically available 
information and scored following the rationale previously described – namely, that 
PCOs with a greater level of influence within the APC receive a higher score.  
Creation of individual indicator: Area Prescribing Committees 
Measure of the involvement of Acute trusts and PCOs in their local APCs.  Information 
scored from 1-5 with a score of 5 denoting where acute trusts and PCOs have the 
closest relationship and acute trusts have the greatest degree of influence of local in 
prescribing decisions. 
Table 20: APC scoring 
Score: 
involvement of 
PCO within APC 
Description 
Score 5 A 1:1 relationship between the acute trust and primary care organisation with 
one joint APC covering both organisations 
 
Score 4 Joint APC across several primary care organisations and 1 acute trust – or 1 
primary care organisation and several acute trusts 
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Score 3 There is a joint APC across several primary care organisations and acute 
trusts in the local health economy 
Score 2 There is one APC covering more than one local health economy. Or a 
relatively tight APC (1 acute trust but more than 1 primary care organisation)  
Score 1 The primary care organisation is influenced by decisions made by more than 
one APC from different LHEs or  
there is 1 APC (involving several organisations) for the LHE and another APC 
covering the LAT with several more organisations  
Or influenced and/or part of LHE across LAT borders. 
 
Note:  Reduced score by 1 if the LHE has 1 CCG or acute trust that is part of another 
APC (e.g. Swindon) 
 
Score from 1-5 Same scoring criteria for all three years. Different data for each of the three 
years 
Quintile allocation Creation of quintiles. This information is already scored from 1-5 so this 
scoring will be retained for the quintile analysis. This has not resulted in a 




4.5.2.2. Local organisations sharing formularies 
Prior to April 2013, formularies were used in some secondary care organisations, 
PCOs and across LHEs. They were sometimes joint ventures with local NHS 
organisations but also purely for use in a single organisation. There was no legal 
requirement for an organisation to produce or adhere to a formulary. In a number of 
cases, acute trusts chose to use the British National Formulary (BNF) rather than their 
own customized formulary. In 2012 as part of the Innovation, Health and Wealth 
Publication, there was a directive that NHS hospitals trusts should publish their 
formularies on line from April 2013 (Nicholson D, 2012). Since then, acute trusts have 
made available their formularies to the public. They are not produced to any particular 
blueprint and vary in content with some formularies being a list of available drugs whilst 
others contain clinical guidelines and traffic lights listing for all drugs. It should be noted 
that formularies, as with clinical guidelines are not always updated continuously and 
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do not always match up with the structural changes in organisations, however they 
have usually been adopted by the new organisations.  
Creation of individual indicator: local organisations sharing formularies  
Measure of the level of influence of PCOs on the local shared formulary.  Information 
scored from 1 - 4 with a score of 4 for the greatest degree of influence of PCOs on the 
decisions in the local formulary. 
Qualitative Information about the organisations and the local formularies they have 
produced over the years from 2010/11 to 2013/14 was collected from local publically 
available information and scored following the rationale previously described – namely, 
that PCOs with a greater level of influence on the decisions in the local formulary 
receive a higher score.  
Table 21: local joint formulary scoring 
Score: involvement of PCO in 
local formulary 
Description 
Score 4 1:1 Joint primary care organisations Acute Trust Formulary 
(single LHE) 
Score 3 joint formularies across primary care organisations and acute 
trust in LHE 
Score 2 Joint formulary across primary care organisations in LHE with 
individual acute trust formularies (when the CCGs were 
previously only one or two PCTs). Or Joint formulary across 
primary care organisations in LHE with no individual acute trust 
formularies.  
 
Score 1 Several formularies or no formularies affecting primary care 
organisation or Primary care organisation has no formulary but 
main acute trust has its own formulary or 1 formulary across 
several LHEs (more than 2 former PCTs) – many primary care 
organisation and acute trusts 
 
 Same scoring criteria for all three years. Different data for each 
of the three years. 
Quintile allocation Creation of Quintiles. Data not continuous and for this dataset 
no PCOs allocated to the 5th (top) Quintile. The Scoring into 




4.5.2.3. Organisation culture 
The different incarnations of the PCO in accordance with successive government 
initiatives to encourage primary care led commissioning have resulted in varying 
degrees of clinical engagement amongst GPs (Audit Commission, 1999, Smith et al., 
2005, Audit Commission, 2007). The one common theme from all of them is that the 
clinical engagement improves when GPs feel that they have more autonomy and 
control in responding to the needs and key issues affecting their patients (Miller et al., 
2012, Coleman et al., 2009). Smaller schemes that were limited in scope (for example 
GP fundholding) found it easier to engage all member GPs but more comprehensive 
schemes have found it difficult to engage with all GPs and where there was only a 
minority of GPs involved in decision making (as with PCGs and PCTs) there was a 
degree of disengagement and disenchantment with the system (Checkland et al., 
2008). A joint King's Fund and Nuffield Trust survey found that more than half of GPs 
have said that being a member of a CCG had altered their referral or prescribing 
patterns. The survey found that almost 60 per cent of the 207 respondents in six 
chosen CCGs had altered prescribing patterns, and that almost 75 per cent had 
changed their referral pathways and just over 50 per cent had changed their referral 
volumes (Robertson, 2014). 
The cohesiveness of the organisation can be defined in several ways but in order to 
score PCOs according to their degree of cohesiveness I had to be able to understand 
and compare how keen the GPs were to work together in each PCO, how well 
organised and able to work together as a single unit; how stable the organisation was; 
the historical experience in working together; degree of variability in practice 
performance; and degree of clinical engagement. In all of these individual comparators 
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PCOs may be more or less cohesive – in other words, some organisations had a 
history of GPs that have been involved in GP commissioning; the current PCO was 
similar in configuration to previous PCO (so there was minimal organisational 
disruption following the changes to create CCGs). Other organisations were very 
different – having lots of different configurations with multiple mergers, were last to 
become authorised and the GPs were not keen to become involved in primary care 
commissioning.  
The information about the cohesiveness or organisations and historical relationships 
that have existed locally has come from a mixture of national and local sources. 
Nationally the development of PCOs from PCTs to CCGs was a political move 
undertaken following a change in government. Due to the crucial role that PCOs play 
in commissioning care for their local population, the viability and success of the 
emerging CCGs has been of critical importance to the government and they have been 
monitoring these things by setting up an authorisation framework with a range of 
standards to be met before the CCGs can be authorised as independent 
commissioning bodies. The timescale for this has been from 2011 to 2013. The 
government have also sought to identify CCGs and groups of GPs that were keen to 
take on their new roles in managing and directing CCGs and so set up a pathfinder 
programme to allow early responsibility to be passed to those keen and ready to 
become involved. Local data and other national data sets allowed for other 
comparators to be created so that the historical relationships between local practices 
that have been involved in commissioning could be measured, as well as their ability 
to start behaving as independent organisations.  
149 
 
The detailed description of the background behind the organisational changes during 
the period from 2011/12 and 2013/14 and the subsequent creation of the individual 
indicators is discussed in greater detail in Appendix 3. 
Creation of individual indicator: Organisation culture 
Qualitative and quantitative information coded and scored at PCO level. Information 
collected throughout the three year period. DoH / NHS England comparative data. 
PCO Public local documents and board papers. 
Table 22: Organisation culture 2011/12 scoring 
Score for 
organisation 
culture in 2011/12 
Description 
 CCG mergers and organisational changes during 2011/12 
Score 4 no organisational change from April 2011 to March 2012 
Score 3 merger during 2011 prior to the DoH Risk Assessment 
Score 2 merger by end of 2011 but organisation not included in DoH Risk Assessment 
Score 1 CCG changed after March 2012 before April 2013 
  
 CCG Size Impact – DoH Risk Analysis 
Score 4 CCG boundary and population rated GREEN in DoH Dec 2011 Risk Analysis 
Score 3 CCG boundary and population rated AMBER in DoH Dec 2011 Risk Analysis 
Score 2 CCG boundary and population rated RED in DoH Dec 2011 Risk Analysis 
Score 1 CCG Impact of size not rated because CCG was formed following merger of 
consortia deemed to be unviable by the DoH 2011 Risk Analysis. 
 
  
 CCG Geography Boundary and Population – DoH CCG Risk Analysis 
Score 4 CCG boundary and population rated GREEN in DoH Dec 2011 Risk Analysis 
Score 3 CCG boundary and population rated AMBER in DoH Dec 2011 Risk Analysis 
Score 2 CCG boundary and population rated RED in DoH Dec 2011 Risk Analysis 
Score 1 CCG Impact of size not rated because CCG was formed following merger of 
consortia deemed to be unviable by the DoH 2011 Risk Analysis 
  
 CCG Geography LA Boundaries 
Score 4 CCG boundary and population rated GREEN in DoH Dec 2011 Risk Analysis 
Score 3 CCG boundary and population rated AMBER in DoH Dec 2011 Risk Analysis 
Score 2 CCG boundary and population rated RED in DoH Dec 2011 Risk Analysis  
 
Score 1 CCG Impact of size not rated because CCG was formed following merger of 
consortia deemed to be unviable by the DoH 2011 Risk Analysis 
  
 CCG Member Practice engagement 
 
Score 4 CCG boundary and population rated GREEN in DoH Dec 2011 Risk Analysis 
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Score 3 CCG boundary and population rated AMBER in DoH Dec 2011 Risk Analysis 
Score 2 CCG boundary and population rated RED in DoH Dec 2011 Risk Analysis 
Score 1 CCG Impact of size not rated because CCG was formed following merger of 
consortia deemed to be unviable by the DoH 2011 Risk Analysis. 
 
  
 CCG Commissioning Experience – PCT / PCG Correlation 
 
Score 5 CCG boundary matches 'current' PCT boundary 
Score 4 CCG boundary matches historical PCT or PCG boundary 
Score 3 CCG boundary is within, but does not match, 'current' PCT boundary 
Score 2 CCG boundary crosses 'current' PCT boundary and is coterminous with the 
combined boundaries of those PCTs 
Score 1 CCG boundary crosses 'current' PCT boundary but is not coterminous with the 
combined boundaries of those PCTs 
  
 CCG Commissioning experience – GP Consortia / PBC Group Correlation 
 
Score 4 CCG built on a previous GP Commissioning Consortium that was originally a 
PBC Group 
 
Score 3 CCG built on a previous GP Commissioning Consortium that was not originally 
a PBC Group 
 
Score 2 CCG established following merger of two or more previous emerging 
CCGs/GP Commissioning Consortia 
 
Score 1 CCG has a structure largely not based on previous GPCC/PBC Groups 
 
  
 National Pathfinder Consortia Status 
 
Score 4 CCG emerged from an existing GP Consortium that was awarded national 
Pathfinder Consortia Status 
Score 3 CCG emerged from two or more existing GP Consortia; at least one of which 
was awarded national Pathfinder Consortia Status 
 
Score 2 CCG emerged from an existing GP Consortium which was awarded national 
Pathfinder Consortia Status and then split into smaller groups 
 
Score 1 CCG emerged from GP Consortium/a that was/were not awarded national 
Pathfinder Status 
 
Quintile allocation Creation of Quintiles. Data not continuous so PCOs in each quintile not equal 
but as far as possible equal groups were created. Q1 (44 PCOs); Q2 (48 
PCOs); Q3 (45 PCOs); Q4 (35 PCOs); Q5 (39 PCOs)  






 CCG mergers and organisational changes during 2012/13 
Score 2 no organisational change during year 




 CCG Structure / Commissioning Experience – GP consortia /PBC group 
Score 4 Organisation was previously a Practice Based Commissioning Group that 
developed into a GP Consortia and finally emerged as a CCG 
Score 3 Organisation previously emerged as a GP Consortia and then proceeded as a 
CCG (not originally a Practice Based Commissioning Group) 
 
Score 2 Organisation established following merger of two or more previous emerging 
Clinical Commissioning Groups 
Score 1 Organisation has a structure largely not based on previous GP Consortia or 
emerging CCGs. May be a split of a larger GPCC/CCG. 
  
 CCG Website 
Score 4 Independent, public website with comprehensive information (Board minutes, 
CCG priorities, FOI requests etc) 
Score 3 Independent, public website with some information; or pages of PCO website 
with full information (Board minutes, CCG priorities, FOI requests etc) 
Score 2 Independent, public website, or pages of PCO website with little information 
(Board minutes, CCG priorities, FOI requests etc) 
Score 1 No public website, or very little information on website or pages of PCO 
website 
  
 CCG Commissioning Plan 2012/13 
Score 4 CCG has published a 2012/13 Commissioning Plan as well as other 
documents (Business Plan, Commissioning Intentions, Organisational 
Development Plan etc) 
Score 3 CCG has published a 2012/13 Commissioning Plan 
Score 2 CCG has published a 2012/13 Plan on a Page or similar summary plan (10 
pages or less); or CCG has a shared plan with other CCGs in the Cluster; or 
CCG has published other documents but not a Commissioning Plan 
Score 1 CCG has not published a 2012/13 Commissioning Plan or other planning 
documents 
  
 CCG Authorisation Status  
Score 9 CCG authorised in Wave 1 with full authorisation 
Score 8 CCG authorised in Wave 1 with conditions 
Score 7 CCG authorised in Wave 2 with full authorisation 
Score 6 CCG authorised in Wave 2 with few conditions (1-6) 
Score 5 CCG authorised in Wave 2 with more than 10 conditions and / or directions 
Score 4 CCG authorised in Wave 3 with full authorisation 
Score 3 CCG authorised in Wave 3 with few conditions (1-6) 
Score 2 CCG authorised in Wave 3 with more than 10 conditions and/or directions 
Score 1 CCG not authorised before end 2012/13 
 Note: Wave 1 applications for CCG authorisation. May 2012 – the NHS 
Commissioning Board Authority confirmed that there were 35 aspiring CCGs 
chosen to be assessed in the first wave of applications. Applications for 
authorisation take place in 4 waves from July 2012 to January 2013. 
Quintile allocation Creation of Quintiles. Data not continuous so PCOs in each quintile not equal. 
but as far as possible equal groups were created Q1 (41 PCOs); Q2 (36 





Table 24: Organisation culture 2013/14 scoring 
Score for 
Organisation 
Culture in 2013/14 
Description 
 CCG mergers and organisational changes during 2013/14 
 
Score 2 no organisational change during year 
Score 1 merger during 2013/14 
  
 CCG Authorisation Status (scored April 2013) 
Score 9 CCG authorised in Wave 1 with full authorisation 
Score 8 CCG authorised in Wave 1 with conditions 
Score 7 CCG authorised in Wave 2 with full authorisation 
Score 6 CCG authorised in Wave 2 with conditions and/or directions 
Score 5 CCG authorised in Wave 3 with full authorisation 
Score 4 CCG authorised in Wave 3 with conditions and directions 
Score 3 CCG authorised in Wave 4: full authorisation 
Score 2 CCG authorised in Wave 4 with 1-9 conditions 
Score 1 CCG to be authorised in Wave 4 with more than 10 conditions and/or 
directions 
  
 CCG Progress towards authorisation in 2013/14 (*) 
Score 4 Full authorisation at beginning of 2013/14 (April 2013) 
Score 3 Full authorisation granted at July or October inspection 2013 
Score 2 Full authorisation granted in February 2014 
Score 1 Full authorisation not granted by March 2013 
  
 CCG Structure / Commissioning Experience – GP consortia /PBC group 
 
Score 4 Organisation was previously a Practice Based Commissioning Group that 
developed into a GP Consortia and finally emerged as a CCG 
Score 3 Organisation previously emerged as a GP Consortia and then proceeded as 
a Clinical Commissioning Group (not originally a Practice Based 
Commissioning Group) 
Score 2 Score 2: Organisation established following merger of two or more previous 
emerging CCGs 
Score 1 Organisation has a structure largely not based on previous GP 
Commissioning Consortia or emerging Clinical Commissioning Groups. May 
be a split of a larger GPCC/CCG. 
 
  
 CCG Assurance Annual Assessment 2013/14 
 
Score 2 Assured 
Score 1 Assured with support 
 The CCGs were assessed three further times during the year (July 2013, 
October 2013 and February 2014) and some reduced the number of 
conditions and/or directions towards gaining full authorisation during this 
time. To recognise this progress a scoring to reflect progress during 2013/14 
has been created. 
Quintile allocation Creation of Quintiles. Data not continuous so PCOs in each quintile not 
equal. but as far as possible equal groups were created. Q1 (39 PCOs); Q2 




4.5.2.4. Organisation profile 
The make-up of each PCO varies in terms of number of practices, GP demographics, 
and type of practices.   
Number of GPs per population 
The number of GPs working at each PCO was collected on the National Health 
Application and Infrastructure Services (NHAIS)/Exeter General Practice Payments 
System, a computerised payment system of GPs in England. It included “details of 
each practitioner’s name, date of birth, gender, working hours/sessions, practice 
details and whether certain allowances were payable. (Health and Social Care 
Information Centre, 2014g). In February 2015 practice level data about GP numbers, 
contract type, practice type were published for 2013/14. NHS Payments to General 
Practice in England, analysed by individual provider of general practice services and 
main payment category, was published for the first time by the HSCIC Website 
accessed 3 September 2015. The Number of Practitioners (headcount) is expected to 
be lower than the Number of Practitioners (contracts) because some GPs had more 
than one contract. For example, in September 2014 there were 1,436 with two or more 
contracts; in 2013 there were 1,227; in 2012 there were 1,353; in 2011 there were 
1,482 such GPs. 
Single handed practices 
A Single-Handed Practice is defined in the NHS Workforce Census as a practice where 
“there is only 1 working GP (Provider or Salaried/Other), although a GP registrar or GP 





There were over 1000 dispensing practices in the UK in 2013/14 (NHS payments to 
GPs 2013/14). It was estimated in a report by Duerden et al. (2011) that more than 3.5 
million patients in the UK were covered by dispensing practices. In 2013, dispensing 
doctors may generally only be allowed to provide pharmaceutical services to patients 
who live in a designated controlled locality, more than 1.6km (as the crow flies) from a 
pharmacy. The only exception to this was where it was a distance selling pharmacy or 
the patient lived in a reserved location (Reviewing Patient dispensing lists June 2013 
DoH). 
Information about dispensing practices was collected by the NHS Business Services 
Authority prior to April 2013 and then more recently by the HSCIC and available in The 
Patient List size and GP count for April 2012 (providing a picture of the situation at the 
end of 2011/12); and The Practice list size and GP count in April 2013 (providing a 
picture of the situation at the end of 2012/13). This can be cross checked by looking at 
the Dispensing practices list a monthly and NHS Payments for GPs 2013/14. 
Type of practice 
Most GPs were employed by the NHS under a GMS (General Medical Services) 
Contract. This was a national financial agreement between providers (practices) and 
the NHS that set out the services the practices provided. Another type of practice was 
covered by Personal Medical Services (PMS) contract. This option was first introduced 
in 1998 to allow the practice to negotiate a local agreement for the services they will 
provide and payments they will receive, taking into account specific local healthcare 
needs. PMS practices may participate in QOF or enter into local QOF arrangements 
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These two types of contract cover the vast majority of practices in England. Two other 
types of contract existed - Alternative Provider Medical Services (APMS) and Primary 
Care Trust Medical Services (PCTMS). APMS contracts could be offered to private, 
voluntary and public sector organisations and there was greater flexibility in how 
services will be provided. PCTMS services were provided directly, as well as managed, 
by NHS England, enabling it to employ health care professionals directly, perhaps as 
salaried staff. However PCTMS contracts ceased to exist in April 2013 following the 
restructuring of the NHS in England (Health and Social Care Information Centre, 
2014h).  
In February 2015 practice level data about GP numbers, contract type, practice type 
were published for 2013/14. NHS Payments to General Practice in England, analysed 
by individual provider of general practice services and main payment category, were 
published for the first time by the HSCIC. 
No similar set of data existed for comparison in 2011/12 or 2012/13, although there 
were data containing numbers of GPs, dispensing practices and patients on April 1st 
2012 which was the equivalent of the end of year QOF data for 2011/12 and April 1st 
2013 which corresponds to the 2012/13 QOF data. Whilst practices pre 2013 can be 
linked to CCGs, there is however, no source of data that provided type of practice 
contract at practice level prior to 2013/14, so this data is unable to be used in this 
analysis. 
Creation of individual indicator: Organisation profile 
Measure of the ease of control and influence within the PCO. Number of GPs per head 
of Population (assumption - GPs have more time with patients to devote to better care. 
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% Single handed practices within the PCO (Single handed practices less able to 
provide adequate care and % of dispensing practices (dispensing practices often follow 
their own prescribing behaviour according to the benefits to themselves). 
Quantitative data at PCO level and some at practice level. Yearly data. HSCIC. The 
data was presented at practice level and the calculation at PCO level has performed 
according to the description in section 4.4.4. 





Data set ranked  1-
211  
Number of GPs per population  
Data set ranked 1-
211 
% of single handed practices (inverse scoring for this indicator) 
Data set ranked 1-
211 
% dispensing practices 
 Ranking from 1-211 for all three datasets – ranking of 1 denoting the 
highest % of each for Number of GPs per population and % dispensing 
practices but inverse scoring for single handed practices. Same scoring 
criteria for all three years. Different data for each of the three years. 
Quintile allocation Ranked data divided into 5 equal groups (Quintile 5 with 1 extra PCO) 
 
4.5.2.5. Organisation size 
There have been a number of papers looking at the relationship between the size of a 
primary care organisation and its performance but there has, however, been little 
evidence to support the hypothesis that there is an ideal size for these organisations. 
In an observational study of all 152 primary care trusts in England  (Greaves et al.), 
the size of the PCT was compared against 36 indicators of commissioning 
performance. The results were not straightforward, but larger PCTs tended to provide 
higher quality care services (in 10 out of 14 indicators). The larger PCTs were also 
serving more affluent, rural and ethnically diverse populations and once deprivation is 
taken into consideration size was no longer a significant contributor for any indicator. 
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Interestingly, larger PCTs were worse for a few indicators (lower smoking quit rates, 
poorer satisfaction with opening hours and less efficient prescribing. Other research in 
this area in 2003 confirmed that size is not a reliable predictor for performance and 
that performance is affected by a combination of their aims, tasks, functions, 
organisational features and environmental factors (Wilkin et al., 2003). It would appear 
that there is no ideal size of a primary care commissioning organisation (Smith et al., 
2004).  
There were a number of data sources available nationally that provided figures for the 
patient list size or patient population cared for by each PCO in England over the 3year 
period. However, the figures they presented were not exactly the same. A comparison 
of the two main sources of this information (QOF and NHS payments data) has been 
described in Appendix 3. For the purposes of this analysis we will use the QOF data 
source for patient list size and numbers of practices because this fits in with the other 
factors where QOF data has been used (audit and education; clinical guidelines; 
patient education; financial factors – for diabetes prevalence; and diabetes 
prevalence). 
Creation of individual indicators 
Quantitative data at practice level. Yearly data available for all organisations in 
England. QOF data produced by HSCIC. The data was presented at practice level and 






Table 26: Organisation size scoring 
Score for Organisation 
Profile in 2013/14 
Description 
Ranking from 1-211  Population size (ranking  1 for smallest population) 
  Same scoring criteria for all three years. Different data for each of the 
three years. 
Quintile allocation Ranked data divided into 5 equal groups (Quintile 5 with 1 extra PCO) 
 
4.5.2.6. GP Demographics 
There were two explanatory indicators used to reflect the GP demographics within 
each PCO that in the systematic review have been found to influence prescribing 
decisions. The GP characteristics factors were descriptive and the data was available 
as part of a general comparison of PCOs and the GPs that they have within their 
organisation. The HSCIC produced a yearly analysis of the GP workforce for each 
practice in England. This report recorded the number of GP’s in each practice, the 
gender and age breakdown, the training history, type of GP and those practices that 
were single handed.  
Creation of individual indicator: GP Demographics 
Quantitative data at practice level and the calculation at PCO level has performed 
according to the description in section 4.4.4. Yearly data available for all organisations 
in England. Source: HSCIC Workforce analysis. 
Table 27: GP age scoring 
Score for GP age Description 
Data ranked 1-211 % GPs aged over 55 (ranking 1 for lowest %) 
 Same scoring criteria for all three years. Different data for each 
of the three years. 
 




Table 28: GP gender scoring 
Score for GP gender Description 
Data ranked 1-211 % male GPs (ranking 1 for lowest %) 
 Same scoring criteria for all three years. Different data for each 
of the three years. 
Quintile allocation Ranked data divided into 5 equal groups (Quintile 5 with 1 extra 
PCO) 
 






























Domain                             Disease or generic                subdomain                           Indicator 
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4.5.3. Process domain - Diabetes specific subgroup 
There were three separate indicators in the diabetes specific sub group that could be 
used to give a picture of the level of adoption of audit and targets for keeping blood 
glucose levels within nationally agreed limits as well as prescribing and management 
for diabetic patients in general in line with national guidelines. In addition specific 
patient factors that influence the adherence to the treatment regimen required to 
control type 2 diabetes are important. 
4.5.3.1. Audit and education 
One of the major aims of the Diabetes QOF from 2011/12 to 2013/14 datasets was to 
measure and improve glycaemic control; and this was assessed by measuring levels 
of HbA1C (glycated haemoglobin). A measurement of HbA1C indicates what average 
blood sugar levels have been over a period of time. Importantly, there is a link between 
glycaemic control and the death rate of type 2 diabetic patients so the lower the 
HBA1C, the better the diabetes control and long term outcomes. There were three 
separate targets levels for HbA1C (59, 64 and 75 mmol/mol) for all three years of this 
study (NICE Guidance CC87, 2009, Checkland et al., 2013, Health and Social Care 
Information Centre, 2013c, Health and Social Care Information Centre, 2014f).  
Creation of individual indicator: Attainment of audit and education targets  
Quantitative data at practice level. Yearly data available for all organisations in 
England. Source: HSCIC.  The data was presented at practice level and the calculation 




Table 29: Audit and education scoring 




Data ranked 1-211 Diabetes Mellitus Clinical Indicator (DM26): The percentage of patients 
with diabetes in whom the last IFCC-HbA1c is 59 mmol/mol (equivalent to 
HbA1c of 7.5% in DCCT values) or less (or equivalent test/reference 
range depending on local laboratory) in the preceding 15 months.  
 
 Diabetes Mellitus Clinical Indicator (DM28): The percentage of patients 
with diabetes in whom the last IFCC-HbA1c is 75 mmol/mol (equivalent to 
HbA1c of 9% in DCCT values) or less (or equivalent test/reference range 
depending on local laboratory) in the preceding 15 months 
 Added the numerator data and the denominator data from DM026 and 
DM0928 together and then created % achievement from these figures.  
Note: the % underlying achievement for each clinical indicator would be 
used 
 2012/13 and 2013/14 
Data ranked 1-211 DM007: The percentage of patients with diabetes, on the register, in 
whom the last IFCC-HbA1c is 59 mmol/mol or less in the preceding 12 
months, NICE 2010 menu ID: NM14 
 DM009: The percentage of patients with diabetes, on the register, in 
whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 
months 
 
 Added the numerator data and the denominator data from DM07 and 
DM09 together and then created % achievement from these figures. 
Note: the % underlying achievement for each clinical indicator would be 
used 
 Same scoring criteria for all three years. Different data for each of the 
three years. 
Quintile allocation Ranked data divided into 5 equal groups (Quintile 5 with 1 extra PCO) 
 
4.5.3.2. Clinical guidelines 
Great efforts have been made to create and update comprehensive national guidelines 
for the management of diabetes. Improving the care of patients with diabetes has long 
been a priority area for the government and the first Diabetes National Service 
Framework was written in 2001(Department of Health, 2001b) outlining national 
standards in terms of prevention, clinical care standards, management of 
complications, service developments and empowerment of patients. There are also a 
number of guidelines produced by NICE outlining specific targets and developments 
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that should be undertaken in primary and secondary care to improve the standards of 
care. It has been found in a number of studies that intensive treatment with antidiabetic 
drugs can reduce micro (amputations, chronic renal disease and retinopathy) and 
macro (myocardial infarction, heart failure and stroke) vascular complications that are 
causes not only of major disability but also shortened life expectancy (Control and 
Complications Trial Research Group, 1994). Diabetes is a complex chronic condition 
and studies have also identified that cholesterol and blood pressure must also be 
controlled appropriately to reduce long term problems of stroke and heart disease (UK 
Prospective Diabetes Study Group, 1991). Therefore, attainment of the clinical targets 
by altering and adding specific medication can be seen as prescribing for patients in 
the most appropriate way according to the most up to date clinical guidelines and 
protocols.  
The Diabetes QOF collected data that reflected adherence to national guidelines with 
specific comparators. Achievement of a total number of points for the clinical targets 
would therefore give an indication of how well diabetic patients are managed in practice 
in England. It should be noted, however, that out of a possible 101 points for ongoing 
management 35 points are available for control of HbA1C targets (Checkland et al., 
2013). These comparators have been used as a measure of the success of education 
and audit initiatives, and so to include them in this analysis would allow for potential 
bias towards PCOs that only concentrate on blood glucose levels without managing 
the wider aspects of good diabetes care. Therefore, it would sensible to exclude the 
HbA1C comparators. The ongoing management targets within the diabetes QOF have 
provided a set of measurements that have measured adherence to clinical guidelines 
across PCOs in England (Health and Social Care Information Centre, 2013c, 
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Checkland et al., 2013, Health and Social Care Information Centre, 2014f). It should 
be noted that there were some changes in the individual clinical targets set for ongoing 
management of diabetes during the 3 year period. These were included in the analysis 
except for the targets not directly connected to the clinical management of diabetes 
(structured education, record of smoking status, influenza immunisation or BMI). 
Creation of individual indicator: Adherence to clinical guidelines 
QOF data for all the clinical targets (except for HbA1C management) 
Quantitative data at practice level. Yearly data available for all organisations in 
England. Source: HSCIC. The data was presented at practice level and the calculation 
of spend at PCO level has used according to the description in section 4.4.4. 
Table 30: Clinical guidelines adherence scoring  




 The percentage of patients with diabetes in whom the last blood pressure 
is 150/90 or less (Diabetes Clinical Indicator DM30) 
 The percentage of patients with diabetes in whom the last blood pressure 
is 140/80 or less (Diabetes Clinical Indicator DM31) 
 The percentage of patients with diabetes whose last measured total 
cholesterol within the preceding 15 months is 5mmol/l or less (Diabetes 
Clinical Indicator DM17) 
 The percentage of patients with diabetes who have a record of micro-
albuminuria testing in the preceding 15 months (exception reporting for 
patients with proteinuria) (Diabetes Clinical Indicator DM13) 
 The percentage of patients with diabetes with a diagnosis of proteinuria 
or micro-albuminuria who are treated with ACE inhibitors (or Angiotensin 
II receptor blockers (ARB)s) (Diabetes Clinical Indicator DM15) 
 The percentage of patients with diabetes with a record of a foot 
examination and risk classification: 1) low risk (normal sensation, 
palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high 
risk (neuropathy or absent pulses plus deformity or skin changes in 
previous ulcer) or 4) ulcerated foot within the preceding 15 months. 
(Diabetes Clinical Indicator DM29) 
Data ranked 1-211 Calculation: Added the numerator data and the denominator data from 
DM 13, 15, 17, 29, 30, 31 together and then create a % achievement 
from these figures 
  
 2012/13 and 2013/14 
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 The percentage of patients with diabetes, on the register, in whom the 
last blood pressure reading (measured in the preceding 12 months) is 
150/90 mmHg or less, NICE 2010 menu ID: NM01 (Clinical Indicator 
number DM002) 
 The percentage of patients with diabetes, on the register, in whom the 
last blood pressure reading (measured in the preceding 12 months) is 
140/80 mmHg or less, NICE 2010 menu ID: NM02 (Clinical Indicator 
number DM003) 
 
 The percentage of patients with diabetes, on the register, whose last 
measured total cholesterol (measured within the preceding 12 months) is 
5 mmol/l or less (Clinical Indicator number DM004) 
 
 The percentage of patients with diabetes, on the register, who have a 
record of an albumin:creatinine ratio test in the preceding 12 months, 
NICE 2012 menu ID: NM59 (Clinical Indicator number DM005) 
 
 The percentage of patients with diabetes, on the register, with a diagnosis 
of nephropathy (clinical proteinuria) or micro-albuminuria who are 
currently treated with an ACE-I (or ARBs) (Clinical Indicator number 
DM006) 
 
 The percentage of patients with diabetes, on the register, with a record of 
a foot examination and risk classification: 1) low risk (normal sensation, 
palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high 
risk (neuropathy or absent pulses plus deformity or skin changes in 
previous ulcer) or 4) ulcerated foot within the preceding 12 months, NICE 
2010 menu ID: NM13 (Clinical Indicator number DM012) 
 The percentage of patients with diabetes, on the register, who have a 
record of a dietary review by a suitably competent professional in the 
preceding 12 months, NICE 2011 menu ID: NM28 (Clinical Indicator 
number DM013) 
Data ranked 1-211 Added the numerator data and the denominator data from DM 02, 03, 04, 
05, 06, 12 and 13 together and then create a % achievement from these 
figures 
 Same scoring criteria for all three years. Different data for each of the 
three years. 
Quintile allocation Ranked data divided into 5 equal groups (Quintile 5 with 1 extra PCO) 
 
4.5.2.3. Specific formulary guidance for use of LA Insulin analogues and GLP-1 
agonists 
Formularies are local documents and were available from the relevant local NHS 
organisations (PCOs and acute trusts). They contained formulary directions for the use 
of LA insulin analogues and GLP-1 agonists over the period of this research study.  
Specific recommendations made by the primary and secondary care organisations in 
their formularies and prescribing guidelines with regard to diabetes drugs for the 
165 
 
treatment of type 2 diabetes (specifically for LA insulins and GLP1 agonists – the areas 
of interest in this research) have been collected over the period from 2011-2014. 
Formularies and prescribing guidelines are not necessarily updated every year and not 
all sections of a formulary are updated at the same time. Therefore, all possible 
updates over the period that refer to the diabetes drugs in question were collected. 
Once the documents were collected the directions for use of the two groups of drugs 
was summarised and placed into the most appropriate category. This exercise was 
carried out for formularies present at the end of each of the three years (2011/12; 
2012/13 and 2013/14). These formulary directions have incorporated national 
recommendations for use of these drugs. 
Creation of individual indicator: Adherence to local LA insulin analogue formulary 
guidance 
During the time of this study national guidelines encouraged the restriction of use of 
LA insulin analogues because they were more expensive than older alternatives 
(Waugh et al., 2010, NICE Evidence Summary ESNM25, 2013). Local formularies 
changed their guidance over the period of this research as is described in the table 
below: 
Trend in LA insulin analogue local formulary guidance over three years (information 
from local formularies collected as part of this research). Note: PCOs may be affected 






Table 31: LA insulin analogue formulary changes 
 














Insulins not listed in formulary or 
all LA insulins listed 
   64     18  13 
LA insulin analogues (determir 
and glargine) listed with no 
restrictions for use. Insulin 
Degludec NOT listed or classified 




   67 
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      111 
LA Insulin analogues (determir 
and glargine) listed with no 
restrictions for use. Insulin 




   0 
 
 
     3 
 
 
       2 
LA Insulin analogues (determir 
and glargine) listed but restricted 
Insulin Degludec Not listed 
 
 
  44 
 
   138 
 
     108 
LA Insulin analogues (determir 
and glargine) listed but restricted. 





   0 
 
 
     9 
 
 
       9 




  41 
 
    91 
 
     66 
Insulin Determir listed as 1st 
choice 
   4 
 
     3       2 
 
Summary of data to be used and information source:  Qualitative information from 
PCOs, Acute Trusts, Formulary Committees and APCs coded and scored. Information 
collected throughout the 3 year period.  
Table 32: LA analogue scoring 
Score for guidance for 
using LA insulin 
analogues 
Description 
Score 7 Insulin Determir listed as 1st choice 
 
Score 6 Insulin Glargine chosen as 1st choice. 
 





Score 4 LA insulin analogues listed but restricted, Insulin degludec NOT listed. 
 
Score 3 LA insulin analogues listed and insulin degludec listed but restricted. 
 
Score 2 LA insulin analogues listed with no restrictions for use. Insulin Degludec 
not listed or classified as NON formulary. 
 
Score 1 LA insulin analogues available (all insulins classified green or no 
insulins listed in formularies). 
 Note: insulins are not always listed in formularies because they are 
available for use as required. In addition prescribing traffic Light lists are 
often focused on drugs that should not be prescribed and so again, 
insulins are not often listed. When there is more than 1 formulary or set 
of guidelines affecting an organisation but one of the formulary does not 
list insulins then the final scoring will use the scoring for the formulary 
that has listed the insulins. When there is more than 1 formulary 
affecting the organisation with differing advice the score will be 0. 
 
 Same scoring criteria for all three years. Different data for each of the 
three years 
Quintile allocation Creation of Quintiles. Data not continuous so PCOs in each quintile not 
equal  but reflects the degree of restriction to the use of LA insulin 
analogues. 
Score 5 Only one LA insulin analogue (determir or glargine on the formulary) 
(score of 6 or 7 above) 
Score 4 Both  determir and glargine on formulary but restricted  (score 4 or 5 
above) 
Score 3 No restriction on determir or glargine and degludec restricted (score 3 
above) 
Score 2 No restriction on determir or glargine, but degludec not permitted (score 
2) 
Score 1 No restriction on prescribing (score of 1 above) 
 
GLP-1 Agonists local formulary guidance  
Restricting the use of GLP-1 agonists has been an important consideration for NICE 
since the cost of treatment with them is much higher than the other drug treatments in 
the groups. A number of national guidelines were issued during the time of this study 
(NICE Guidance CG66, 2008, NICE Guidance Costing Statement, 2012, NICE 
Evidence Summary ESNM26, 2013, NICE Technology Appraisal TA248, 2013, NICE 
Guidance CC87, 2009, NICE Technology Appraisal TA203, 2010) and changes in local 
guidance changed throughout the period of this study to reflect these guidelines are 
shown in the table below.  
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Table: Trend in GLP-1 agonist formulary directives over three years (information 
from local formularies collected as part of this research). 
Note: PCOs are affected by more than 1 formulary 
Table 33: GLP-1 agonist formulary changes 














Advice to use one of 2 GLP-1 







Advice to use one of 3 GLP-1 







Advice to use one of 4 GLP-1 






























Formularies are produced locally but should be in line with the national guidance 
described above. 
Creation of Individual indicator: Adherence to local GLP-1 agonist formulary 
guidance 
Scored based on the formulary decisions keeping pace with national guidelines and 
new drug introductions. Qualitative information from PCOs, Acute Trusts, Formulary 






Table 34: GLP-1 agonist scoring 
Score for guidance to use 
GLP-1 agonists 
Description 
Score 15 4 GLP-1 agonists listed and exenatide or lixisenatide 1st choice 
Score 14 4 GLP-1 agonists listed and liraglutide or lixisenatide 1st choice 
Score 13 4 GLP-1 agonists listed and Lixisenatide 1st choice 
Score 12 4 GLP-1 agonists listed and exenatide or liraglutide 1st choice 
Score 11 4 GLP-1 agonists listed and exenatide bd restricted 1st choice 
Score 10 4 GLP-1 agonists listed and exenatide 1st choice 
Score 9 4 GLP-1 agonists listed and no preference in choice 
Score 8 3 GLP-1 agonists listed and Lixisenatide 1st choice 
Score 7 3 GLP-1 agonists listed and exenatide once weekly or liraglutide 1st 
choice 
Score 6 3 GLP-1 agonists listed and liraglutide 1st choice 
Score 5 3 GLP-1 agonists listed and exenatide 1st choice 
Score 4 3 GLP-1 agonists listed and either no preference or liraglutide and 
exenatide bd 1st preference 
 
Score 3 2 GLP-1 agonists listed and exenatide bd and liraglutide 
Score 2 2 GLP-1 agonists listed and liraglutide 1st choice 
 
Score 1 2 GLP-1 agonists listed and exenatide bd 1st choice 
Score 0 GLP-1 agonists not listed, or several different decisions influencing 
PCO 
 Same scoring criteria for all three years. Different data for each of the 
three years 
Quintile allocation Creation of Quintiles. Data not continuous so PCOs in each quintile 
not equal but reflects the degree of restriction to the use of GLP-1 
agonists and adoption of new drugs during the time of the study 
Score 5 4 GLP-1 agonists with 1 chosen as first choice (score 10-15 above) 
Score 4 4 GLP-1 agonists listed no preference (score 9 above) 
Score 3 3 GLP-1 agonists listed (score 4-8 above) 
Score 2 2 GLP-1 agonists listed (score 1-3 above) 
Score 1 No formulary guidance for this class of drugs (score 0) 
 
4.5.2.4. Patient education 
NICE Guidelines recommend that patients should be offered specific education 
programmes cover all major aspects of diabetes self-management (NICE Guidance 
CG66, 2008). There was evidence from a Cochrane review that computer based 
diabetes self-management interventions could have a beneficial effect on blood 
glucose. In this way, the more knowledgeable the patient, the better their 
understanding of their disease and the likely benefits in the audited outcomes 
measures (Pal et al., 2013). 
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Such was the acknowledgement of the importance of patient education that it was one 
of the indicators that had been introduced into the 2013/14 Diabetes Indicators in the 
QOF Framework. The question in QOF is; “The percentage of patients newly 
diagnosed with diabetes, on the register, in the preceding 1 April to 31 March who have 
a record of being referred to a structured education programme within 9 months after 
entry on to the diabetes register”, NICE 2011 menu ID: NM27 (Health and Social Care 
Information Centre, 2014f). 
It was also a question posed as part of the National Diabetes Audit and has been for 
2011/12 and 2012/13. They had collected the number of patients with diabetes who 
have (a) been offered and (b) who have attended Structured Diabetes Education. The 
NDA has been collecting data on structured education in England since 2005. The 
NDA has reported whether there was a record that a person with diabetes has been 
offered or has attended structured education. Unfortunately, the percentage coverage 
of the 211 PCOs under the NDA is low and together with the fact that the data is quite 
different between the two sources has meant that this factor was not be included in 
this analysis. 
4.5.3. Process domain - Generic subgroup 
There were two indicators for measuring the process  of influencing prescribing 
behaviour within each PCO that were relevant to this research project. They covered 
the ability of the PCO to control the prescribing behaviour of GPS within the 
organisation according to national and organisation guidelines and priorities and the 




4.5.3.1. Prescribing control 
NHS England (and predecessors) set a prescribing budget for each PCOs. There are 
a number of ways in which prescribing patterns in primary care have been measured 
and the following comparators were collected and analysed nationally to provide a 
regular picture of how GPs have prescribed for selected disease and therapeutic 
areas. As an incentive to change prescribing habits a number of drugs or classes of 
drugs were identified as being targets for a reduction in prescribing (and sometimes 
an increase in prescribing if they are cheap alternatives) under the Medicines 
Management part of QIPP targets. QIPP was a national programme to improve quality 
and make efficiency savings first set up in 2011. The QIPP programme ended in March 
2013 although updates to the comparators and measurements of prescribing trends 
have continued and this prescribing comparator development work was integrated into 
the NHS England medicines optimisation work stream (Health and Social Care 
Information Centre, 2014e). 
Quarterly prescribing data for 17 individual comparators for all PCOs was analysed 
across the three years. Some comparators have changed during this time. A detailed 
description of  the individual comparators is available in Appendix 3. There was one 
missing quarter (April – June 2012) during this period. In addition, two of the individual 
comparators were concerned with the subject area of this research, namely GLP-1 
agonists and LA insulin analogues. This data has been removed from this prescribing 
comparator because it will be used to create the outcomes indicator. 
Creation of individual indicator: Degree of prescribing control 
Level of prescribing control at PCO using QIPP Prescribing comparators. 
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Quantitative data at practice level (calculated to provide PCO level information). 
Quarterly data available for all organisations in England. PACT data (QIPP 
comparators). The data was presented at practice level and the calculation at PCO 
level has performed according to the description in section 4.4.4. 





Data ranked 1-211 
for each individual 
comparator 
Add up the ranking of organisations for all appropriate drugs for all 3 years . 
The lower the final score, the higher the group. 
 Same scoring criteria for all three years. Different data for each of the three 
years. 
Quintile allocation Ranked data divided into 5 equal groups (Quintile 5 with 1 extra PCO) 
 
4.5.3.2. Prescribing behaviour of GPs 
A report discussing the need to accelerate the adoption and spread of innovation 
across the NHS was published in December 2011 (Department of Health, 2012). This 
is part of the Government’s Plan for Growth and the Life Sciences Strategy. One of the 
actions that was identified in this report was the need to improve compliance with NICE 
Technology Appraisals (TAs) and reduce the variation that was seen across NHS 
organisations in England and Wales. There is no way of accurately measuring this 
because there is no universal easy way to access patient records, however the concept 
of an Innovation Scorecard (IS) was developed to provide an indication of compliance 
and variation at PCO level. The first IS was produced in January 2013 and this used 
data from 2011. Since then there has been a report for data in 2012 (published June 
2013) and quarterly reports from Q1 2013/14 onwards that have been published since 
October 2013. The data and publication of the data was classified as experimental 
whilst feedback and development were being requested to the confirm the usefulness 
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and suitability of the data and the way it was presented. There were two types of 
analysis that are relevant to this research. Firstly, there is an in depth analysis of a 
handful of new drugs that have NICE guidelines to advise GPs in how to use them and 
that were mainly prescribed in primary care. For these drugs, an estimate of the likely 
numbers of patients who would be eligible to receive the drug (eligible population) had 
been calculated for each PCO, the expected prescribing levels based on prescribing 
of the drug in accordance with the guidelines was calculated and then the actual 
prescribing rate for each drug was measured and a ratio of observed against expected 
obtained. A number of estimates and assumptions were made in this analysis. The 
eligible patient population was estimated using The NICE Costing Tool. An example of 
such a Costing Tool is the one for GLP-1 agonists (NICE Guidance Costing Statement, 
2012). The second type of analysis was one where a range of new drugs had been 
monitored over the period to measure uptake across the PCOs. The predominant use 
of these medications is in primary care (97% or more). For this analysis prescription 
data has again be obtained from HSCIC and the data is presented in DDDs per 
100,000 resident population (Health and Social Care Information Centre, 2014b). 
Prescribing of new drugs – NICE Innovation Scorecard – across all drugs 
Note: drugs used in the analysis changed each year. In 2011/12 one of the drug 
classes analysed was GLP-1 agonists for type 2 diabetes. This has not been included 
in the creation of this indicator because it has been used as the dependent indicator. 
Creation of individual indicator: Measure of GP prescribing behaviour 
Quantitative data at PCO level. Yearly data available for all organisations in England. 
NICE Report Innovation Scorecard.  
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Table 36: GP Prescribing behaviour scoring 





Data ranked 1-211 Drugs included for analysis in 2011 (ratio of expected: observed) : 
Varenicline Osteoporosis and Statins (Health and Social Care Information 
Centre, 2013a) 
 
 Each PCO ranked from 1 (lowest prescriber of new drug) to 211 (highest 
prescriber of new drug) 
 2012/13 
Data ranked 1-211 Drugs included for analysis in 2012 (ratio of expected: observed): Exenatide 
and liraglutide in type 2 diabetes. Insulin determir and insulin glargine in type 
2 diabetes  (Health and Social Care Information Centre, 2013a) 
Drugs included for analysis of a range of primary care drugs in 2012 
(calendar year): bupropion hydrochloride; celecoxib; esomeprazole; 
etodolac; meloxicam; Orlistat; oxcarbazepine; rabeprazole sodium; 
raloxifene hydrochloride; tiagabine; zalepion and zopiclone (Health and 
Social Care Information Centre, 2014b) 
 
 Each PCO ranked from 1 (lowest prescriber of new drug) to 211 (highest 




Data ranked 1-211 Drugs included for analysis of a range of primary care drugs in 2013/14: 
dipyridamole Modified release (M/R) with aspirin; ezetimibe; febuxostat; 
fluvastatin sodium; insulin determir; insulin glargine; liraglutide; naftodrofuryl 
oxalate; pravastatin sodium; raloxifene hydrochloride; rosuvastatin calcium; 
simvastatin; strontium ranelate; varenicline tartrate; zaleplon; and zolpidem 
(Health and Social Care Information Centre, 2015b) 
 Each PCO ranked from 1 (lowest prescriber of new drug) to 211 (highest 
prescriber of new drug) 
 Note: Drugs included for analysis in 2011 and 2012: the information in this 
analysis was originally linked to PCTs but was converted to match CCG 
populations in April 2013.  
 Same scoring criteria for all three years. Different data for each of the three 
years. 








4.5.4. Outcome domain 
Figure 2: Indicators used in the Outcome Domain 
 
There were two separate outcome indicators in this research. The first was the net 
ingredient cost (NIC) per 100,00 for spend on LA insulin analogues and the second 
was the net ingredient cost (NIC) per 100,000 for spend on GLP-1 agonists. A separate 
value for each PCO in England for each of the three years from 2011/12 to 2013/14 
was calculated based on practice level prescribing spend for each of the years.  
This study was focused on type 2 diabetes although it should be noted that LA insulin 
analogues are also prescribed for patients with type 1 diabetes. The increasing uptake 
of the expensive LA insulin analogues over cheaper isophane insulin products has 
been targeted by national productivity programmes as a way of reducing prescribing 
spend in PCOs. It is therefore an example of a drug class that may be actively 
discouraged by many organisations. This has been reflected in the recommendations 
in many of the formularies whereby prescribing should only be as a second line option 







Domain                                                   Disease or generic                                 Indicator 
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was chosen by PCOs during the period of the study as one of the targets in their 
prescribing incentive schemes to reduce prescribing costs. In a similar way, GLP-1 
agonists were chosen for study because they are a relatively new therapeutic class of 
drug used as third line therapy in type 2 diabetes often as an alternative to initiating 
insulin. Their place in the treatment of type 2 diabetes according to NICE Guidance 
(NICE Guidance CC87, 2009) is after the cheaper and more established metformin 
and sulphonylureas. To encourage the use of metformin and sulphonylureas this was 
also a prescribing QIPP comparator (National Prescribing Centre, 2011, National 
Prescribing Centre, 2012). However, increasingly the newer more expensive 
antidiabetic drugs are being used. Analysis from the HSCIC Report Prescribing for 
Diabetes: England 2005-6 to 2013-14 (Health and Social Care Information Centre, 
2014d) has found that the number of items of newer antidiabetic drugs increased by 
164.3% from 2005-6 to 2013/14 with an attendant rise in net ingredient cost of 129.6% 
for the same period (£102.9 million).  
Creation of individual indicator: Prescribing of LA insulin analogues and GLP-1 
agonists 
The prescribing data for both drug classes for the period of study was available from 
the HSCIC database. The data was presented at practice level and the calculation at 
PCO level has performed according to the description in section 4.4.4. 
Table 37: LA insulin analogue prescribing score 




Data ranked 1-211 Prescribing data for LA insulin analogues  per 100,000 (ranking 1 for 
lowest rate) 





Ranked data divided 
into 5 equal groups 
(Quintile 5 with 1 extra 
PCO) 
Creation of Quintiles 
 
Table 38: GLP-1 agonist prescribing scoring 




Data ranked 1-211 Prescribing data for GLP-1 agonists per 100,000 (ranking 1 for lowest 
rate) 
 Same scoring criteria for all three years. Different data for each of the 
three years. 
 
Ranked data divided 
into 5 equal groups 
(Quintile 5 with 1 extra 
PCO) 
Creation of quintiles 
 
4.6. Discussion 
The previous chapter concluded that it was feasible to create an outline PCO Profile 
for influences on GP prescribing using a modified Donabedian SPO model as the 
conceptual  framework to structure and understand the known prescribing influences 
on GPs. This chapter examined publically available data and information to ascertain 
if it could be used to measure and reflect the varying degree of importance of each 
prescribing influence in the 211 PCOs during the three years. National datasets proved 
useful in creating a number of the indicators. However, this data was originally 
collected and intended for other purposes and although national agencies may intend 
it as a means of identifying areas for improvement it can often be regarded as a 
measure of success linked to financial payment by local organisations (Raleigh and 
Foot, 2010). This might be a problem particularly when we look at the measures of 
organisational culture and the Department of Health scores for the success and 
attainment of targets where there could be an element of political pressure for an 
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initiative to be seen to be successfully adopted. The possible solutions to this problem 
are twofold. Firstly, it is sensible to try and obtain several measures of the influence 
using different datasets from both national and local sources. Secondly, it would be 
ideal for local organisations (PCOs and acute trusts and practices for this research) to 
be contacted and the importance of each influence on prescribing to be specifically 
collected from them both from a quantitative viewpoint but also from a qualitative 
standpoint. Only then could a fully rounded view of the influences on prescribing in 
each PCO be appreciated. 
There were two gaps in the availability of data that meant that the influence could not 
successfully be measured over the three years. Therefore no indicator for the influence 
of the pharmaceutical companies, or measure of patient education were able to be 
added into the model. However, none of the previous research published in the 
literature has definitively shown that any of these three missing influences are 
consistently found to have a reproducible effect on prescribing nor have they been 
identified as particularly important in the papers included in Chapter 2. Therefore, it 
would be ideal to have the data in this analysis it is unlikely that the results would have 
been any different. Nevertheless, future studies need to include this data if it is possible 
to collect it for the great majority of PCOs.  
One final element that has not been included in this building of the PCO Profile is a 
measure of the variability between practices within a PCO. This would be another way 
of viewing the cohesiveness of an organisation and also measuring the level of 
influence that GPs within a PCO have on each other (peer pressure). This is often cited 
as significant and an important way of changing behaviour (Walker, 2004, Naylor, 
2013). Whilst a lot of the national datasets do include practice level information (QOF 
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and prescribing spend), the range of available data is more limited.  An indicator could 
therefore theoretically be constructed to reflect the degree of practice prescribing 
variability. However, practices are not all the same and just as this research has 
focused on variability in influences on prescribing in PCOs, there may be value in 
creating practice level profiles comparing influences on prescribing at practice level.  
4.7. Summary 
It has been possible to identify data to reflect the influences on prescribing for two drug 
classes used to treat type 2 diabetes. This data was used to populate PCO profiles for 
all 211 PCOs in England for the 3years of this research project. The next chapter 





CHAPTER 5: COMPARISON OF PCO PROFILES 
5.1. Introduction 
The aim of this chapter was to compare the PCO Profiles that were created by 
populating the Donabedian SPO model described in Chapter 4. To test the utility of 
Donadbedian model, this chapter examined the relationship between the two outcome 
indictors (prescribing of LA insulin analogues and GLP-1 agonists) and the structure 
and process indicators used to create the PCO profiles. PCO Profiles for all 211 PCOs 
in England were created for three successive years so that changes in the PCO profiles 
and the prescribing rates for both classes of drug could be examined over time as well 
as compared between PCOs. By repeating the exercise of creating PCO Profiles for 
three years ,changes in the influences within the structural and process domains could 
be measured. These changes over time could then be examined against the  
prescribing of the two outcome indicators to ascertain if there any patterns between 
altered influences and prescribing behaviour.  
Previous published quantitative research looking at influences on prescribing have 
focused on one off analyses of a limited number of influence (Bjerrum and Bergman, 
2000, Kasje et al., 2005, Weiss et al., 1996). This research by contrast, aimed to 
provide a more comprehensive insight into influences on prescribing over three years. 
Most other research has also chosen a sample of organisations to study but due to the 
increased availability of data and information it was also possible to build PCO profiles 
for all organisations for 3 years. This has the advantage of allowing for an examination 
of the pattern of change in PCO profiles and prescribing over time. This has not been 
done before and would allow for identification of PCOs that had similar prescribing 
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behaviour and a subsequent insight into the PCO profiles that were associated with 
this prescribing behaviour. 
One of the ways in which health data is presented to compare performance across 
different categories for an organisation is to divide the data into equal groups, for 
example when exploring the variation in diabetes care in the Atlas of Variation (Right 
Care Atlas Series, 2012) ; national audit reports on diabetes services in the NHS 
(National Audit Office Review, 2012); and comparisons of PCO organisations 
produced by Public Health England such as the Spend and Outcome Tool (SPOT) 
comparing spend and outcome for CCGs (Public Health England, 2017) and the 
comparisons of CCG care and spend on the Public Health Dashboard (Public Health 
England, 2018). The data used in this research is the same in many cases as the data 
in these national tools and publications (see Chapter 4) so it would be appropriate to 
investigate this method as a way of gaining insight into changes in data for each 
organisation over time. 
Finally, the quantitative research on influences on prescribing included in the 
systematic review in Chapter 2 overwhelmingly used multiple regression as a means 
of identifying how much of prescribing variation could be accounted for by the 
influencing factors (16 out of 23 papers). In addition, the National Diabetes Audit uses 
this method to explore the link between PCO indicators such as gender, diabetes type, 
age, deprivation etc. and achievement of care processes for diabetes (National 
Diabetes Audit, 2011/12b). This research examined the interaction of a number of 
possible factors that influenced prescribing behaviour of GPs and so the use of multiple 




These research papers used prescribing rates as the dependent variables and the 
influences on prescribing as the explanatory variables. Creating the PCO Profiles and 
measuring prescribing rates of the two drug classes allowed for a number of multiple 
regression analyses on the data. The prescribing rates became the dependent 
variables and the indicators in the structure and process domains, the explanatory 
variables.  
The multiple regression was performed separately for the two different classes of drugs 
for each year. This allowed for the results of each year to be compared. Other 
quantitative studies have identified statistically significant influences on prescribing 
that account for prescribing variability but there have been no universal findings. For 
example, one study (Morton-Jones and Pringle, 1993) investigated total prescribing 
costs and could explain 81% of variation in spend with just four explanatory variables; 
whereas another study found that 47.7% of variance in prescribing was accounted for 
by 10 explanatory variables (Hull et al., 2001). The ability to perform the multiple 
regression on the same organisations for 3years would therefore contribute to current 
understanding on the key statistically significant influences on prescribing. Looking at 
two separate dependent variables in the same disease area would also increase 
understanding of how influences might be different even within treatment for the same 
disease. 
5.2. Aims and objectives 
The final aim of this research was to compare PCO profiles for all 211 PCOs in England 
over a 3year period. Changes in the importance of individual influences within 
individual organisations over time as well as differences in profiles between 
organisations were measured. 
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There were two specific objectives: 
1. Examination of the structure, process and outcome indicators (scored into 
quintiles) across all PCOs for three years. Understanding of (a) Pattern of 
scoring for the three years, for the individual indicators and individual PCOs (b) 
Difference between PCO profiles with the same outcomes and (c) examination 
of PCO profiles in a subset of PCOs with similar outcomes. 
2. Analysis using multiple regression to ascertain if there were any statistically 
significant relationship between the indicators in the structure and process 
domains and prescribing of LA insulin analogues and GLP-1 agonists  
5.3. Method 
In order to compare the relative importance of the individual indicators for the PCOs 
(in the PCO profile) each one was scored into quintiles for all three years so that the 
relative importance of each indicator over time could be compared for each 
organisation.  In addition,  changes in indicator scoring over the three years was 
examined and a selection of individual PCOs with similar scores for the outcome 
domain of the Donabedian SPO model were examined to investigate differences and 
similarities in scores for the corresponding structure and process domains. 
Data and information for each indicator was collected, scored according to the method 
described in Chapter 4 and saved into Excel spreadsheets (separate ones for each 
indicator by year).  All manipulation of the data was performed in Excel and Access. 
To enable comparison across the years and across indicators all the indicators were 
divided into quintiles. The allocation of the data for each indicator into quintiles is 
described in detail in chapter 4, but the general rule was the greater the value (be it 
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prevalence, level of spend, cohesiveness and achievement of management goals of 
the organisation; degree of prescribing control; adoption of new drugs) then the higher 
the allocated quintile. 
5.3.1. Changes in PCO indicators in the SPO domains  over time 
In order to measure the movement between each quintile for each PCO indicator 
over the three years the pattern was assessed to be in one of four groupings:  
1. changing over the three years (not in any one direction);  
2. decreasing (moving to a lower quintile over the 3 years);  
3. increasing (moving to a higher quintile over the 3 years) and staying in the 
same quintile for the 3 years. An example of this is shown in Table 39: 















Pattern of change 
across the 3 
years  
Camden CCG 4 3 3 decreased 
Merton CCG 2 1 1 decreased 
Nottingham City CCG 1 1 1 Stayed the same 
Newcastle North and East 
CCG 
5 4 5 changed 
Greater Huddersfield 
CCG 
2 4 4 increased 
 
This action was repeated for all PCOs, all indicators and for each of the three years 
of the study period. 
5.3.2. Multiple regression analysis 
The individual indicators in the structure and process domains were also used to 
explore the relationship between them and the outcome indicators. For this part of the 
analysis the underlying data that made up the indicators was used before it was scored 
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into quintiles. The two dependent variables (in this case the two outcome indicators; 
LA insulin analogues and GLP-1 agonists) and their PCO indicators (all the indicators 
in the structure and process domains) for all 211 PCOs were compiled for the three 
successive years into separate Excel spreadsheets. They were then categorised using 
Excel functions according to the type of data (continuous / categorical for example); 
and explained according to standard mathematical descriptions (mean / median/ range 
etc.). Details of each indicators are described in Appendix 4. 
The two classes of drugs were considered separately for this analyses so the 
regression was run twice for each years’ data (once when the explanatory variable was 
the prescribing rate of LA insulin analogues and once when the explanatory variable 
was GLP-1 agonist prescribing). All the PCO indicators were the same EXCEPT for 
the specific LA insulin analogue and GLP-1 agonist formulary guidance. Only the 
relevant guidance for the particular class of drug was included in each analyses. Both 
multiple regression analyses was repeated for the three years from 2011/12 to 
2013/14. 
A general statistical software package called STATA was used to perform the multiple 
regression analysis (version 14.1) The official reference manual on performing 
multivariate statistics was used to ensure the software was used correctly (StataCorp, 
2015). In addition, online tutorials produced by STATA describing how to carry out a 
multiple regression using their software were followed. 
 5.4. Results 
5.4.1. Changes in quintile scoring for the indicato rs over the 3 years 
The movement in quintile score for the indicators over the 3 years has been 
summarised in Table 41. A number of the PCOs had stable indicators over the three 
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year period of study. This is to be expected in most of the cases; diabetes prevalence 
for example while increasing over the time period is likely to stay the same for the 
PCOs unless there has been a significant change in the patient population. The 
secondary care – area prescribing committee analysis has also mostly remained stable  
and this is to be expected because working relationships between organisations within 
the NHS tend to remain the same because of historical referral behaviour and 
groupings of primary and secondary care organisations within regions and 
geographical siting of acute trusts and neighbouring PCOs. Similarly, a large change 
in the number of male GPs in any PCO would be unexpected.  
Table 40: Changes in quintiles over the three years  for the PCO profile indicators 
Structure Domain  Number of PCOs in each category  
 
Grouping 































1 dataset 1 dataset 1 dataset 1 dataset 
 
Organisation Organisation 










1 (0.005) 4 (0.02) 3 (0.014) 203 (96%) 
211 
Organisation GP gender 34 (16%) 39 (19%) 43 (20%) 95 (45%) 211 




0 (0%) 48 (23%) 41(19%) 122 (58%) 
211 




47 (22%) 37 (18%) 23 (11%) 
211 
Collaboration Influence of 
secondary 
care 
45 (21%) 77 (37%( 73 (35%) 16 (7%) 
211 
Process Domain       
Diabetes specific Audit and 
education 




Diabetes specific Clinical 
Guidelines 
44 (21%) 54 (25%) 58 28%) 55 (26%) 
211 




15 (7%) 12 (6%) 102 (48%) 82 (39%) 
211 
Diabetes specific GLP-1 agonist 
formulary 
guidance 
40 (19%) 10 (5%) 149 (70%) 12 (6%) 
211 
Diabetes specific Prescribing 
control 38 (18%) 52 (24%) 54 (25%) 67 (33%) 
211 
Generic GP prescribing 
behaviour 
72 (34%) 50 (24%) 42 (20%) 46 (22%) 
211 





7 (3%) 31 (15%) 33 (16%) 140 (66%) 
211 
GLP-1 agonists Prescribing 
rate 
6 (3%) 45 (21%) 45 (21%) 115 (55%) 
211 
 
The results for the prescribing rates of LA insulin analogues and GLP-1 agonists are 
important because despite the overall trend for increased prescribing costs for this 
group over the three years the relative position of individual CCGs remained 
remarkably stable throughout the three years.  Regardless of the pressures on PCOs 
to reduce prescribing of LA insulin analogues two thirds (66.7%) of them remained in 
the same quintile for the three year period. Of the rest, only a small number (7) did not 
follow a trend to either increase or decrease over the three years.  The prescribing 
habits for the GLP-1 agonists showed the same trend as the prescribing behaviour of 
the LA insulin analogues but the differences were less marked with just under half 44% 
remaining in the same quintile over the 3year period. 
5.4.2. Individual PCO profiles over 3 years (change s in indicator scores)  
The below list all the PCOs and indicators with a description of the changes in quintile 
scoring that were recorded over the 3year period. For ease of understanding, only the 
decreasing (blue) or increasing (orange) indicators have been coloured. There are no 
obvious patterns between the changing of indicator scores in the structure or process 
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domains with either of the outcomes scores. Using Excel to detect duplicates, it was 
also possible to confirm that all the PCOs had a unique set of indicator changes. 
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pattern GP age pattern
influence 2 
























NHS HORSHAM AND MID SUSSEXstayed the same changed decreased increased increased stayed the same increased decreased stayed the same changed stayed the same changed stayed the same changed decreased changed decreased decreased
NHS NORTH WEST SURREY CCG decreased increased increased increased changed stayed the same changed decreased stayed the same changed stayed the same decreased changed stayed the same decreased increased decreased decreased
NHS NORTH HAMPSHIRE CCG stayed the same changed increased decreased changed stayed the same changed changed increased increased stayed the same stayed the same decreased decreased increased changed increased decreased
NHS ISLE OF WIGHT CCG decreased increased increased stayed the same changed stayed the same increased decreased stayed the same changed increased increased increased decreased increased changed stayed the same decreased
NHS NORTH & WEST READING CC stayed the same changed stayed the same increased changed stayed the same changed decreased increased increased increased increased changed changed stayed the same stayed the same decreased decreased
NHS SWINDON CCG increased changed decreased decreased increased decreased changed decreased increased increased decreased changed increased increased increased decreased stayed the same decreased
NHS SOUTH DEVON AND TORBAYstayed the same changed stayed the same increased stayed the same changed increased changed stayed the same changed increased increased decreased decreased increased increased stayed the same decreased
NHS DARLINGTON CCG decreased decreased changed decreased decreased changed increased increased stayed the same changed stayed the same increased increased decreased stayed the same changed decreased increased
NHS NORTH DURHAM CCG stayed the same changed changed increased changed decreased changed increased stayed the same changed stayed the same increased changed changed decreased decreased stayed the same increased
NHS HARTLEPOOL AND STOCKTO stayed the same increased changed increased decreased increased changed decreased stayed the same stayed the same stayed the same increased decreased decreased increased decreased decreased increased
NHS SOUTH TEES CCG stayed the same increased changed increased changed decreased changed increased stayed the same changed stayed the same increased increased decreased increased decreased stayed the same increased
NHS BOLTON CCG stayed the same decreased increased changed decreased increased stayed the same decreased stayed the same decreased stayed the same increased changed changed stayed the same stayed the same stayed the same increased
NHS CUMBRIA CCG increased changed increased increased changed stayed the same stayed the same changed decreased decreased stayed the same decreased changed stayed the same changed changed decreased increased
NHS SOUTH CHESHIRE CCG decreased changed stayed the same changed changed decreased stayed the same changed stayed the same changed stayed the same increased stayed the same changed stayed the same decreased stayed the same increased
NHS SOUTH SEFTON CCG stayed the same increased increased increased changed increased stayed the same increased stayed the same changed changed increased changed changed stayed the same decreased increased increased
NHS ST HELENS CCG stayed the same increased increased increased changed stayed the same increased increased increased changed changed increased stayed the same decreased stayed the same stayed the same stayed the same increased
NHS FYLDE & WYRE CCG stayed the same changed changed increased changed decreased changed changed decreased decreased increased decreased stayed the same changed stayed the same stayed the same increased increased
NHS BASSETLAW CCG stayed the same changed stayed the same stayed the same changed stayed the same increased stayed the same stayed the same changed decreased increased stayed the same decreased stayed the same decreased stayed the same increased
NHS DONCASTER CCG stayed the same increased changed decreased decreased increased changed decreased stayed the same increased decreased increased changed decreased decreased changed stayed the same increased
NHS HULL CCG stayed the same stayed the same increased stayed the same decreased decreased stayed the same increased decreased stayed the same increased stayed the same decreased decreased stayed the same decreased stayed the same increased
NHS LEEDS SOUTH AND EAST CCGincreased increased decreased increased increased stayed the same decreased changed increased changed increased increased stayed the same stayed the same decreased stayed the same stayed the same increased
NHS NORTH LINCOLNSHIRE CCG stayed the same increased increased decreased changed stayed the same increased decreased decreased stayed the same increased changed decreased decreased stayed the same stayed the same stayed the same increased
NHS ROTHERHAM CCG stayed the same stayed the same changed increased increased changed changed decreased stayed the same increased increased increased decreased increased increased stayed the same decreased increased
NHS EREWASH CCG stayed the same changed stayed the same increased changed increased increased decreased stayed the same decreased increased changed increased changed changed stayed the same stayed the same increased
NHS HARDWICK CCG stayed the same decreased increased increased decreased changed decreased changed stayed the same changed increased increased increased decreased increased decreased stayed the same increased
NHS MILTON KEYNES CCG stayed the same changed increased decreased changed stayed the same stayed the same decreased stayed the same changed increased changed stayed the same changed stayed the same stayed the same stayed the same increased
NHS NOTTINGHAM NORTH AND Estayed the same stayed the same decreased decreased changed stayed the same stayed the same increased stayed the same changed increased increased changed decreased increased changed stayed the same increased
NHS SOUTHERN DERBYSHIRE CCGdecreased changed increased increased changed changed increased decreased stayed the same changed increased increased changed stayed the same stayed the same decreased decreased increased
NHS WEST LEICESTERSHIRE CCG increased changed stayed the same increased changed increased changed increased stayed the same decreased increased increased decreased increased stayed the same increased stayed the same increased
NHS BIRMINGHAM SOUTH AND Cstayed the same increased changed changed decreased increased changed increased stayed the same increased decreased increased increased increased increased changed stayed the same increased
NHS NORTH STAFFORDSHIRE CCGstayed the same decreased decreased changed changed increased decreased decreased decreased changed increased increased decreased decreased changed increased increased increased
NHS REDDITCH AND BROMSGRO increased increased increased changed changed increased changed decreased stayed the same stayed the same increased increased decreased increased stayed the same changed stayed the same increased
NHS SOUTH WORCESTERSHIRE CCstayed the same increased increased increased changed decreased decreased stayed the same stayed the same changed increased stayed the same decreased increased increased increased stayed the same increased
NHS STOKE ON TRENT CCG stayed the same decreased stayed the same changed changed stayed the same stayed the same changed decreased changed increased increased decreased changed decreased decreased stayed the same increased
NHS EAST AND NORTH HERTFORDstayed the same decreased decreased increased changed decreased increased stayed the same stayed the same changed stayed the same increased changed stayed the same increased stayed the same stayed the same increased
NHS WEST NORFOLK CCG stayed the same decreased increased decreased changed stayed the same decreased increased decreased changed decreased stayed the same changed decreased increased increased stayed the same increased
NHS WEST SUFFOLK CCG stayed the same decreased increased stayed the same changed changed stayed the same changed decreased changed increased increased decreased decreased increased changed stayed the same increased
NHS ISLINGTON CCG stayed the same increased changed changed changed stayed the same changed increased increased changed stayed the same stayed the same changed increased stayed the same decreased changed increased
NHS EASTBOURNE, HAILSHAM ANstayed the same increased changed changed changed decreased decreased changed increased stayed the same stayed the same increased increased increased increased increased increased increased
NHS DARTFORD, GRAVESHAM ANstayed the same changed changed increased decreased decreased stayed the same increased stayed the same changed increased increased stayed the same decreased stayed the same changed increased increased
NHS MEDWAY CCG decreased changed changed changed increased increased stayed the same decreased stayed the same changed stayed the same increased decreased increased stayed the same increased decreased increased
NHS SURREY HEATH CCG stayed the same increased increased stayed the same decreased stayed the same increased decreased stayed the same changed stayed the same changed decreased changed decreased increased stayed the same increased
NHS THANET CCG stayed the same changed changed decreased changed stayed the same stayed the same decreased stayed the same stayed the same stayed the same increased stayed the same changed changed decreased stayed the same increased
NHS PORTSMOUTH CCG increased changed increased stayed the same changed decreased changed increased increased increased stayed the same increased increased changed increased decreased stayed the same increased
NHS SOUTH READING CCG stayed the same changed stayed the same increased changed decreased changed changed increased increased increased increased stayed the same increased increased stayed the same stayed the same increased













5.4.3. Indicators where the indicator value was in the same quintile for all three 
years (stayed the same)  
The indicators that remained in the same quintile for the 3 years have been 
summarised in Table 42 below: 
Table 42: Indicators that have remained the same fo r 3years 
Indicator 









priorities 1 6 0 5 2 14 
Diabetes total spend 
13 4 5 3 15 40 
Diabetes prevalence 
39 36 25 24 35 159 
Population 




15 4 3 3 14 39 
Organisation profile 
14 5 2 3 13 37 
Organisation size 
41 39 40 41 42 203 
GP gender 
29 13 12 14 27 95 
GP age 
12 8 5 9 25 59 
Influence of 
secondary care 0 1 13 2 0 16 
Area prescribing 
committees 6 41 37 25 13 122 
Local joint 
Formulary 2 6 13 0 0   
Audit and education 
25 7 4 5 14 55 
Clinical Guidelines 
19 7 7 8 14 55 
LA Insulin analogue 
formulary guidance 




formulary guidance 0 6 6 0 0 12 
Prescribing control 
20 7 9 7 24 67 
GP prescribing 
behaviour 17 6 3 9 11 46 
LA insulin 
analogues 
Prescribing rate 36 (86%) 25 (59.5%) 23 (55%) 22 (52%) 34 (81%) 140 
GLP-1 agonist 
Prescribing rate 33 (78.6%) 17 (40%) 15 (35.7%) 20 (47.6%) 30 (69.7%) 115 
 
5.4.4. Outcome indicators (changes over time) 
The prescribing rate for LA insulin analogues for the 3 year study period remained in 
the same quintile for all three years for 66% of PCOs. So, although the prescribing rate 
had generally increased throughout the time, the PCOs have tended to keep the same 
prescribing behaviour. This was more marked in those PCOs in either the top or bottom 
quintiles with 86% of PCOs in the bottom quintile (lowest prescribing rate) remaining 
there for all three years and 81% doing the same in the top quintile. Those PCOs that 
had changed over the three years had mostly moved in one direction (33 had increased 
prescribing rates to move to another quintile, and 31 had decreased over the same 
period). The prescribing habits for the GLP-1 agonists showed the same trend as the 
prescribing behaviour of the LA insulin analogues group but the differences were less 
marked with just under half 44% remaining in the same quintile over the 3 year period. 
The same trend whereby the top and bottom quintiles showed greater stability was 
seen with the GLP-1 agonists prescribing as it was for the LA insulin analogues 




5.4.5. Structure and process indicators (changes ov er time) 
The pattern of change over time with the PCO indicators showed a range of behaviour 
with the majority of them (audit and education, clinical guidelines, GP prescribing 
behaviour, financial - diabetes spend) being quite evenly spread across the categories 
(changed, decreased, increased or stayed the same). A few variables showed that 
most of the PCOs have stayed in the same quintile for the three years (secondary care 
– area prescribing committees, GP gender, diabetes prevalence and LA insulin 
analogues formulary guidance). One variable, secondary care – unnecessary referrals 
to secondary care showed a trend to either decrease or increase (150 PCOs) – 
demonstrating a change in the referral behaviour of PCOs over the period. Two 
variables had recorded a trend in moving from a lower to higher quintile - the 
organisation culture (70 PCOs have increased in sophistication over the three years) 
and GLP-1 agonists formulary guidance (176 have increased in the approval of use for 
GLP-1 agonists). Two variables had shown a marked move up or down to a different 
quintile in 2012/13 only to change direction the following year with Organisation – 
diabetes priorities having 104 PCOs and GP prescribing behaviour having 72 PCOs in 
this category. 
Despite the trends in results across all organisations, when each PCO scoring was 
examined individually, it could be seen that two PCOs that scored equally for 
prescribing could be quite different in their scores for individual PCO profile indicators. 
There were only a small number of PCOs that scored in the top or bottom quintile for 
both drug classes for all three years and when examining the indicator scores for these 
PCOs across the three years we find that although they may have similar prescribing 
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spend on both drugs groups for the three years the scores for their corresponding PCO 
profile indicators were quite different.  
5.4.6. Identification of PCOs with similar prescrib ing behaviour over 3 years 
In order to examine the changes in indicator scores over the 3 years in PCOs with 
similar prescribing behaviour Table 43  has been compiled. The PCOs were chosen to 
represent different prescribing behaviour over the 3 years. The first six CCGs all 
prescribed the lowest rate of  LA insulin analogues and GLP-1 for all 3 years; the next 
4 PCOs prescribed the largest amount of the two classes of drugs; the next 3 PCOs 
had all seen a reduction in prescribing rate from high to the lowest quintile and the final 
CCG had increased. The shading of each indicator reflects the quintile score so that 
the lightest colour represents the lowest quintile score. The colours chosen represent 
the sub domain groupings in the Donabedian SPO model (see the Model described in 
Chapter 3 page ), namely: 
• Structure domain, subgroup: Diabetes specific indicators: blue 
• Structure domain, subgroup: Generic indicators: green 
• Process domain, subgroup: Diabetes indicators: orange 
• Process domain, subgroup: Generic indicators: yellow 




Table 43: Identification of PCOs with similar presc ribing behaviour (outcomes) over 3years 
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5.4.7. Individual organisation – change in PCO prof iles over time 
There are only a small number of PCOs that exhibit the same prescribing behaviour 
for both classes of drug. A summary of this is shown in Table 44. 
Table 44: PCOs with the same prescribing behaviour for both LA insulin 
analogues and GLP-1 agonists in the same PCO for al l 3 years  
Prescribing rates  
Number of PCOs in the same quintile for LA 
insulin analogues and GLP-1 agonists 
prescribing rate 
Quintile 1 (lowest rate of prescribing) 11 PCOs  
Quintile 2 (second lowest rate of prescribing) 4 PCOs  
Quintile 3 (middle rate of prescribing) 0 PCOs  
Quintile 4 (second highest rate of prescribing) 6 PCOs  
Quintile 5 (highest rate of prescribing) 8 PCOs  
 
Looking at the individual PCO profile results for dependent and PCO indicators for the 
PCOs that were in the two groups above (in the same quintile for LA insulin analogues 
and GLP-1 agonists throughout the three years at the top and bottom of the prescribing 
rates) we can see that there does not appear to be any pattern to the scoring of the 
PCO  structure and process indicators despite the fact that the outcome indicators are 
in the same quintiles for all three years.  However, it does allow us to understand more 
about how prescribing for diabetes is viewed within the organisation  with some PCOs 
focusing on control of prescribing spend and others on clinical targets. This is shown 
in the Tables 45-50 below that describe the scoring of individual PCOs that have either 
the lowest rate of prescribing for both classes of drugs  for 3years (Bradford City, 
Southwark and Ipswich and East Suffolk PCOs) or the highest rate of prescribing 





Low prescribing PCOs  
Table 45: Bradford City PCO 
Scoring from the quintile analysis What this says about the organisation 
Bottom quintile for prescribing of LA insulin 
analogues and GLP-1 agonists for all 3 years 
Very low prescribing rates of LA insulin 
analogues and GLP-1 agonists  
 
Decreased unnecessary referrals to primary 
care over 3 year period) 
Decreasing importance of secondary care for 
care of diabetes patients within this PCO with 
primary care services becoming more significant 
 
Bottom quintile for audit and education and 
clinical guidelines adherence 
Low achievement of audit and clinical guideline 
targets that have not been improved on during 
the three years 
 
Moved from middle to top for organisation 
culture 
Has become a cohesive and sophisticated 
organisation over three years 
 
Bottom quintile for size Very small population covered by PCO 
Top quintile for % GPs male for all three years Very high proportion of male GPs 
Top quintile for diabetes prevalence High level of diabetes in local population 
Top or second to top for total spend High total spend on Diabetes care throughout 
the three years 
Second to top and top for diabetes priorities and 
plans 
Diabetes a chosen organisational priority with 
plans for improving care 
 
Moved from 4th to 2nd quintile then to 1st 
(bottom) quintile over 3 years for prescribing 
control  
Low level of prescribing control within the PCO. 
Decreasing importance on altering prescribing 
behaviour via medicines management initiatives 
over the three years. 
 
Moved from top (5th) to bottom (1st) quintile for 
adoption of new drugs in second and third years 
There was a shift in willingness to adopt new 
drugs amongst GPs within the PCO from the top 
quintile in the 1st year to the bottom quintile in 
the 2nd and 3rd years.  
LA insulin analogue formulary 
 
The PCO has no formulary in year 1, listed the 2 
LA insulin analogues (determir and glargine) 
with no restrictions in year 2 then added insulin 
degludec in 3rd year but with restrictions 
GLP-1 agonist formulary 
 
The PCO listed 2 GLP-1 agonists with 
exenatide twice daily as first choice for all three 
years. This was a more restrictive formulary 
than most other PCOs. 
 
Table 46: Southwark PCO 
Scoring from the quintile analysis What this says about the organisation 
Bottom quintile for prescribing of LA insulin 
analogues and GLP-1 agonists 
Very low prescribing rates of LA insulin 





Increased unnecessary referrals to secondary 
care from the bottom quintile in year 1 to the 
second highest (4th) quintile in years 2 and 3.  
Increasing importance of secondary care for 
care of diabetes patients in the PCO rather than 
primary care. 
 
Bottom two quintiles for audit and education Low achievement of audit targets throughout the 
three years 
 
Bottom quintile in first 2 years with improvement 
to middle quintile for clinical guidelines 
adherence in year 3 
Low achievement for clinical guidelines 
adherence with some improvement in year 3. 
 
 
Top quintile for organisation culture 
Consistently a cohesive and sophisticated 
organisation over three years 
 
Second to top quintile for population size A large population covered by PCO 
 
Bottom or second bottom quintile for % male 
GPs 
Low proportion of male GPs 
 
Bottom (or second bottom) quintile for diabetes 
prevalence 
Low level of diabetes in local population 
 
Middle quintile, then bottom then fourth quintile 
for total spend 
Mixed pattern of total spend on Diabetes 
throughout the period. 
 
Second to top (4th) and top (5th)  for diabetes 
priorities and plans 
Diabetes an organisational priority with plans for 
improving care 
 
Middle quintile for prescribing control Middle level of prescribing control within the 
PCO for all three years. 
 
Bottom quintile for adoption of new drugs for all 
three years 
Consistently low level of adoption of new drugs 
amongst GPs within the PCO 
 
LA insulin analogue formulary The PCO listed the 2 LA insulin analogues 
(determir and glargine) with no restrictions for 
years 1 and 2 then added insulin degludec in 3rd 
year but with restrictions.  
 
GLP-1 agonist formulary The PCO listed 2 GLP-1 agonists no preference 
in year 1 then added in a first choice of 
liraglutide for next 2 years. 
 
 
Table 47: Ipswich and East Suffolk PCO 
Scoring from the quintile analysis What this says about the organisation 
Bottom quintile for prescribing of LA insulin 
analogues and GLP-1 agonists 
Very low prescribing rates of LA insulin 
analogues and GLP-1 agonists for all three 
years.  
 
Increased unnecessary referrals to secondary 
care over three year period (2nd; 4th then 5th 
quintiles) 
Increasing importance of secondary care for 
care of diabetes patients in the PCO rather than 
primary care. 
 
Moved from 2nd Quintile to top quintile in last 
year for audit targets 




Moved from 4th quintile down to bottom quintile 
in last year for adherence for clinical guidelines 
Decreased achievement of clinical guidelines 
adherence 
 
Bottom quintile for organisation culture in 
2011/12 increasing to 3rd quintile in 2013/14 
Low but improving score for a cohesive and 
sophisticated organisation over three years 
Top quintile for population size A large population covered by PCO 
 
Second highest quintile for % male GPs High proportion of male GPs 
 
Second bottom) quintile for diabetes prevalence Low level of diabetes in local population 
 
2nd quintile for two years, then increased 
spending in 2013/14 to top quintile for total 
spend 
Increasing pattern of spend on Diabetes 
 
Mixed score (2nd quintile in 1st and 3rd year, top 
quintile for 2nd year) for diabetes priorities and 
plans 
Diabetes an organisational priority with plans for 
improving care 
 
2nd, 3rd then 4th quintile for prescribing control Increasing level of prescribing control within the 
PCO 
 
4th quintile for 2011/14 then 3rd quintile for other 
years for adoption of new drugs) 
LA insulin analogue formulary 
 
Middle level of adoption of new drugs amongst 
GPs within the PCO 
 
LA insulin analogue formulary The PCO listed the 2 LA insulin analogues 
(determir and glargine) with no restrictions for 
years 1 and 2 then all available (or none listed) 
in year 3. 
 
GLP-1 agonist formulary 
 
The directions for GLP-1 agonist use have been 
mixed over the 3 years with 2 GLP-1 agonists 
(liraglutide 1st choice) in year 1; 3 listed in year 2 
and 2 listed in year 3. 
 
Highest prescribing PCOs  
Table 48: Durham Dales, Easington and Sedgefield PC O 
Scoring from the quintile analysis What this says about the organisation 
top quintile for prescribing of LA insulin 
analogues and GLP-1 agonists 
Very high prescribing rates of LA insulin 
analogues and GLP-1 agonists for all 3 years. 
 
Increased unnecessary referrals from 1 to 5 
then 4th quintiles to secondary care over three 
year period 
Increasing importance of secondary care for 
care of diabetes patients within the PCO. 
 
Moved from 2nd Quintile to 4th quintile in last 
year for audit targets 
Increased achievement of audit targets over the 
three years. 
 
Moved from 3rd quintile up to 4th quintile in last 
year for adherence for clinical guidelines 
Increased level achievement of clinical 
guidelines adherence 
 
Bottom quintile for organisation culture in 
2011/12 increasing to 4th quintile for remaining 2 
years 
Low but improving score for a cohesive and 




4th quintile for population size A large population covered by PCO 
4th or 5th quintile for % male GPs High proportion of male GPs 
 
5th quintile for diabetes prevalence 
 
Highest level of diabetes in local population 
 
2nd quintile for two years, then increased 
spending in 2013/14 to top quintile for total 
spend 
Increasing pattern of total spend on Diabetes 
 
Middle score (3rd quintile in 1st and 2nd years, 
and 4th quintile for 3rd year) for diabetes 
priorities and plans 
Diabetes an organisational priority with plans for 
improving care 
Bottom or 2nd bottom quintile for prescribing 
control 
Low level of prescribing control within the PCO 
(less importance on altering prescribing 
behaviour via medicines management initiatives 
for the three years). 
 
 
Top quintile for all years for adoption of new 
drugs) 
 
Highest level of adoption of new drugs amongst 
GPs within the PCO 
LA insulin analogue formulary 
 
 
The PCO listed the 2 LA insulin analogues 
(determir and glargine) but with restrictions for 
years 1 and 2 then added insulin degludec in 3rd 
year but with additional restrictions.  
 
GLP-1 agonist formulary 
 
Increasing scoring over the 3 years denoting 
greater acceptance of use of GLP-1 agonists 




Table 49: North East Lincolnshire PCO 
Scoring from the quintile analysis What this says about the organisation 
Top quintile for prescribing of LA insulin 
analogues and GLP-1 agonists 
Consistently very high prescribing rates of LA 
insulin analogues and GLP-1 agonists  
Changing quintile (2nd, 4th and 3rd) for 
unnecessary referrals to primary care over three 
year period 
Mixed pattern for importance of secondary care 
for care of diabetes patients 
 
Changing quintile (4th, 2nd then 3rd) for audit 
targets 
Mixed pattern for achievement of audit targets 
Top quintile for adherence to clinical guidelines Highest achievement of clinical guidelines 
adherence for all three years. 
Top or second to top quintile for organisation 
culture 
High score for a cohesive and sophisticated 
organisation over three years 
 
Second to bottom quintile for population size Low population covered by PCO 
 
Top quintile for % male GPs High proportion of male GPs 
 
Second top quintile for diabetes prevalence High level of diabetes in local population 
 
Changing quintile (2nd, 1st and 3rd) for total 
spend on diabetes 




Top quintile in 2011/12 decreasing to 1st then 
2nd for diabetes priorities and plans 
Decreasing importance of Diabetes as an 
organisational priority with plans for improving 
care 
 
Top or second to top quintile for prescribing 
control 
High level of prescribing control within the PCO 
 
4th quintile in 1st and 3rd year and 3rd quintile for 
2nd year for adoption of new drugs) 
 
Middle or high level of adoption of new drugs 
amongst GPs within the PCO 
LA insulin analogue formulary The PCO listed the 2 LA insulin analogues with 
no restrictions for years 1 and 2 then added 
insulin degludec in 3rd year with restrictions. 
GLP-1 agonist formulary 
 
The directions for GLP-1 agonist use have been 
mixed over the 3 years with 3 GLP-1 agonists in 
year 1, 2 in year 2 and 3 in year 3 but with 1st 
choice identified) 
 
Table 50: South Kent Coast PCO 
Scoring from the quintile analysis What this says about the organisation 
Top quintile for prescribing of LA insulin 
analogues and GLP-1 agonists 
Very high prescribing rates of LA insulin 
analogues and GLP-1 agonists  
 
decreased quintiles from 5th to 1st for 
unnecessary referrals to primary care over three 
year period 
Decreasing importance of secondary care for 
care of diabetes patients over the three years. 
 
Top or second to top quintile for audit targets High achievement of audit targets for all three 
years. 
 
Moved from 4th quintile in 1st two years to middle 
quintile for last year for adherence for clinical 
guidelines 
Middle score for achievement of clinical 
guidelines adherence 
 
Bottom quintile for organisation culture Low score for a cohesive and sophisticated 
organisation over three years 
 
Second to bottom quintile for population size Small population covered by PCO 
Second to top or top quintile for % male GPs High proportion of male GPs 
 
Top or second to top quintile for diabetes 
prevalence 
High level of diabetes in local population 
 
3rd or 4th quintile for total spend on diabetes Mixed middle pattern of spend on Diabetes 
 
2nd to bottom quintile increasing to 3rd quintile in 
2nd and 3rd year for diabetes priorities and plans 
Low to middle score for Diabetes as an 
organisational priority with plans for improving 
care 
 
Top or second top quintile for prescribing control High level of prescribing control within the PCO 
 
3rd quintile for 2011/12 moving to top quintile for 
other years for adoption of new drugs 
Increasing level of adoption of new drugs 
amongst GPs within the PCO 
 
LA insulin analogue formulary 
 
The PCO listed the 2 LA insulin analogues 
(determir and glargine) but with restrictions for 
years 1 and 2 then added insulin degludec in 3rd 
year but with additional restrictions 
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GLP-1 agonist formulary Increasing scoring over the 3 years denoting 
greater acceptance of use of GLP-1 agonists (2 
listed in year 1 and 3 listed with 1st choice 
identified in years 2 and 3 
 
5.4.8. Results from the multiple regression analysi s 
The variation accounted for by the PCO indicators for LA insulin analogues shows a 
similar trend for all three years. As can be seen from the result below in Table 51 , only 
approximately 30% of variance in prescribing of LA insulin analogues was explained 
by the PCO indicators, although there was a trend for the percentage to increase over 
the three years from 22.91% in 2011/12 to 36.21% in 2013/14. 
(The adjusted R squared value reflects how well the PCO indicators account for the 
dependent variables) 
Table 51: LA Insulin analogues results of multiple regression analysis 
Year Adjusted R square 
2011/12 0.2291 
2012/13 0.2754 
2013 14 0.3621 
 
5.4.9. Covariance for LA insulin analogues 
Covariance describes the relationship between the PCO indicators and the dependent 
variables. A negative number indicated that the higher the value for the PCO indicators 
the lower the score of the dependent variable (Table 52). 





LA insulin analogues 
2012/13 
Negative coefficients 
LA insulin analogues 
2013/14 
Negative coefficients  




Yes Yes  





Yes Yes Yes 
Diabetes prevalence    
Organisation culture Yes Yes Yes 
Organisation profile Yes  Yes 
Organisation size Yes Yes Yes 
GP gender    
GP age   Yes 
Area prescribing 
committees 
  Yes 
Local joint formulary Yes   
Influence of secondary 
care 
 YES YES 
Audit and education    
Clinical Guidelines    
LA insulin analogue 
formulary guidance 
 Yes  
GLP-1 agonist 
formulary guidance 
   
Prescribing control  Yes Yes 
GP prescribing 
behaviour 
Yes   
 
The covariance results in Table 52 were interesting because the results were not the 
same for the variables for all the years apart from the effect of organisation culture and 
organisation size where the results consistently indicate that the more sophisticated 
and smaller the organisation, the lower the level of prescribing of LA insulin analogues. 
Other relationships may also be interesting although they were not inverse for all three 
years. For instance, for the last two years of the research the less the reliance on 
secondary care and the lower the level of prescribing control the greater the prescribing 
spend on LA insulin analogues.  
5.4.10. Statistically significant indicators for LA  insulin analogues 
The probability ratios obtained from the multiple regression analyses for the PCOs 




Table 53: Probability ratios for individual PCO ind icators in LA insulin analogue 











0.024 0.320 0.297 
Diabetes total spend 0.031 0.000 0.000 
Population 
classification 
0.458 0.759 0.364 
Diabetes prevalence 0.074 0.251 0.808 
Organisation culture 0.003 0.034 0.001 
Organisation profile 0.260 0.760 0.641 
Organisation size 0.039 0.047 0.178 
GP gender 0.034 0.005 0.013 
GP age 0.570 0.398 0.831 
Area prescribing 
committees 0.018 0.125 0.605 
Local joint formulary 0.884 0.535 0.517 
Influence of secondary 
care 
0.302 0.100 0.023 
Audit and education 0.225 0.075 0.591 
Clinical Guidelines 0.042 0.252 0.197 
LA insulin analogue 
formulary guidance 
0.320 0.953 0.021 
Prescribing control 0.816 0.754 0.402 
GP prescribing 
behaviour 
0.211 0.174 0.001 
 
Unsurprisingly, given the small % of variance explained by these PCO indicators only 
some of the possible PCO indicators have a statistically significant relationship with 
the outcome indicators (Table 53). Those highlighted in bold have at least one 
statistically significant result across the three years. Only organisation culture, GP 
gender and financial diabetes spend are significant for more than 1 year. 
5.4.11. GLP-1 agonist multiple regression analysis 
Like the results from the LA insulin analogue multiple regression analysis the PCO 
indicators begin to show an increasing relationship with the prescribing rate of GLP-1 
agonists (Table 54) so that the PCO indicators account for 37.6% of the variation in 
prescribing by the third year. 
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Table 54 : GLP-1 agonists results of multiple regre ssion analysis 





5.4.12. Covariance for GLP-1 agonists 
Covariance describes the relationship between the PCO indicators and the dependent 
variables. A negative number indicated that the higher the value for the PCO indicators 
the lower the score of the dependent variable. 







Negative coefficients  
GLP-1 agonists 
2013/14 











Diabetes total spend    
Population 
classification 
   
Diabetes prevalence   YES 
Organisation culture YES YES YES 
Organisation profile YES  YES 
Organisation size YES YES YES 
GP gender    
GP age    
Area prescribing 
committees 
YES YES  
Local joint formulary   YES 
Influence of secondary 
care 
YES   
Audit and education  YES YES 
Clinical Guidelines    
GLP-1 agonist 
formulary guidance 
YES   
Prescribing control  YES YES 
GP prescribing 
behaviour 




The indicators that were inversely related to the prescribing of GLP-1 agonists drugs 
(Table 55 ) were in some cases the same as those in the LA insulin analogue analysis 
as in organisation culture and size (all three years), but there was another one, 
diabetes priorities and plans, that had an inverse relationship for GLP-1 agonist drugs 
which would imply that the more focus that is spent on improving diabetes services, 
patient care and treatment the less the spend on newer more expensive drugs such 
as GLP-1 agonists. Perhaps the most interesting inverse relationship apart from these 
two, was the one for audit and education. This measure is specifically linked with the 
close management HbA1C levels and the adding in of GLP-1 agonists to patient 
regimen was recommended when HbA1C control is not as good as it should be. For 
this reason, it is surprising that the relationship was an inverse one. 
Other patterns that emerged suggested that the influence of secondary care 
(measured by three different individual PCO indicators – referrals to secondary care, 
LHE and local formulary influence) was an inverse one as well for both LA insulin 
analogues and GLP-1 agonist prescribing. This suggested that for newer drugs in type 
2 diabetes there was a greater tendency to adopt them in primary care where there 
was less influence from secondary care. Another interesting result was the inverse 
relationship between prescribing control and GLP-1 agonist prescribing. Even as the 
PCOs succeeded in exerting more control on the prescribing behaviour of the GPs in 
an effort to control overall prescribing costs, so these organisations appeared to be 
prescribing more of both LA insulin analogues or GLP-1 agonists.  
5.4.13. Statistically significant indicators for GL P-1 agonists 
The probability ratios obtained from the multiple regression analyses for the PCOs 
indicators in the GLP-1 agonist model are displayed in Table 56. 
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Table 56: Probability ratios for individual PCO ind icators in GLP-1 agonist 











0.152 0.880 0.470 
Diabetes total spend 0.072 0.012 0.000 
Population 
classification 
0.025 0.064 0.245 
Diabetes prevalence 0.324 0.494 0.916 
Organisation culture 0.373 0.445 0.409 
Organisation profile 0.390 0.851 0.668 
Organisation size 0.029 0.003 0.126 
GP gender 0.176 0.083 0.072 
GP age 0.457 0.135 0.508 
Area prescribing 
committees 0.113 0.021 0.874 
Local joint formulary 0.300 0.163 0.565 
Influence of secondary 
care 
0.049 0.151 0.235 
Audit and education 0.673 0.080 0.017 
Clinical Guidelines 0.631 0.509 0.030 
GLP-1 agonist 
formulary guidance 
0.999 0.792 0.000 
Prescribing control 0.021 0.493 0.503 
GP prescribing 
behaviour 
0.750 0.000 0.000 
 
The results for the GLP-1 agonist statistical analysis (Table 56) were interesting 
because the statistically significant variables were not the same as those identified in 
the LA insulin analogue analysis. Organisation culture was no longer significant nor 
was GP gender (although the results for 2012/13 and 2013/14 were close to 
significance). The audit and education variable was significant in 2013/14 and close to 
significance in 2012/13. In contrast, GP prescribing behaviour for new drugs and 
Programme Budgeting spend were still statistically significant for both groups for two 
out of three of the years. 
In summary, the statistically significant PCO indicators for LA insulin analogues were 
different from those found to be significant for GLP-1 agonists. 
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For the LA insulin analogues analysis, there were three PCO indicators that have a 
probability of 0.05 (or near) or lower for all of the three years: 
• Organisation Culture (3 years) 
• GP gender (3 years) 
• diabetes total spend (3 years) 
For the GLP-1 agonist analysis, no PCO indicators were statistically significant for all 
three years but the following were significant for 2 years: 
• Audit and education (2 years – 1 close to 0.05) 
• Organisation size (2 years) 
• Patient – diabetes classification group (2 years – 1 close to 0.05) 
• GP prescribing behaviour (2 years) 
• diabetes total spend (2 years and 1 close to 0.05) 
The other statistically significant PCO indicators were not necessarily the same for 
each year. One out of three of the PCO indicators covering the influence of other 
organisations were statistically significant in two out of three of the years for LA insulin 
analogues and GLP-1 agonists indicating that this was possibly an important 
explanatory variable as well as those identified above. Two other PCO indicators that 
would be expected to be linked with the prescribing of a new drug such as GLP-1 
agonists have indeed been shown to do so. These were Audit and Education and GP 
Prescribing Behaviour (both statistically significant for 2012/13 and 2013/14). This was 
not the same for the LA insulin analogues prescribing, a fact that might be explained 
by the different profiles of the two drug classes.  
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Crucially, prescribing rates did not appear to be associated with diabetes prevalence 
with no statistically significant results in any of the years for LA insulin analogues or 
GLP-1 agonists. Nor was the explanatory variable scoring the local prescribing 
guidance for LA insulin analogues or GLP-1 agonists statistically significant until 
2013/14 when the p value for LA insulin analogues is 0.021 and 0.00 for GLP-1 
agonists. Looking at the changing guidance for both these groups over the period they 
showed a very different pattern. The specific formulary guidance across the three years 
for LA insulin analogues were very similar whilst the formulary guidance for GLP-1 
agonists showed a significant change with all the 4 GLP-1 agonists being added to the 
formularies in 2013/14 influencing 93 PCOs. 
Organisation culture and organisation size consistently demonstrated a negative 
association with the increased prescribing of LA insulin analogues and GLP-1 agonists 
for all three years of the study. In addition, another negative correlation was seen with  
the patient diabetes classification group for LA insulin analogues; and the organisation 
diabetes priorities for GLP-1 agonists. 
5.5. Discussion 
The analyses of prescribing rates for LA insulin analogues and GLP-1 agonists) found 
that there was an increasing amount of money spent on these two classes of drugs 
over the period of this study. This reinforced findings of previous reports on diabetes 
prescribing (Health and Social Care Information Centre, 2014d). However, this 
research has also discovered that, when NIC per 100,000 is compared, the position of 
PCOs in relation to other organisations does not change very much. In fact, when the 
prescribing spend was allocated to one of 5 quintiles for each year based on the NIC 
per 100,000 for LA insulin analogues then 140 of the 211 PCOs remained in the same 
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quintile for all of the three years. This pattern was seen to a slightly lesser degree with 
the GLP-1 agonists with 115 out of 211 remaining in the same quintile and this 
difference between the two classes of drugs may suggest that they might be affected 
differently by the explanatory variables. This is an important result considering the 
pressure on PCOs during this time to curb spending on these drugs in accordance with 
national guidelines. It suggests that whilst adoption of the drugs has increased year on 
year over the period, that the prescribing behaviour of GPs in different PCOs when 
using these drugs has remained relatively stable.  
In contrast there was no clear -cut pattern of scoring over the 3 years for the indicators 
in the structure and process domains that made up the PCO profiles. 
This research allowed for the opportunity to assess the importance of PCOs 
themselves and to test out whether changing the organisations (from PCTs to CCGs) 
had any fundamental impact on the results. What is more interesting is that despite the 
change in PCO organisations during the 3year period of the research, the prescribing 
behaviour of the organisations has remained relatively stable. When the prescribing 
rates are put into quintiles for each of three years although the prescribing rate has on 
average increased, the PCOs have tended to remain in the same quintile. For the LA 
insulin analogues this is more marked in those PCOs in either the top or bottom 
quintiles with 86% of PCOs in the bottom quintile (lowest prescribing rate) remaining 
there for all three years and 81% doing the same in the top quintile. Prescribing for 
GLP-1 agonists showed the same trend although this stability was less marked. 
The statistical analysis using multiple regression analysis showed up several important 
facts. Firstly, that the explanatory variables (structure and process indicators) only 
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account for a relatively small percentage of variability in the prescribing rates for either 
drug group in any of the years. The biggest % was in the last year of the study but this 
only account for 36% of variation in prescribing of LA insulin analogues and 37% of 
variation in GLP-1 agonists. This fits with the results from most other quantitative 
studies measuring multiple explanatory variables that might be influencing prescribing 
behaviour. There were a few exceptions to this in the systematic review such as the 
study by Hull et al. (2001) where they found that 47.7% of variance in prescribing for 
antidepressants could be accounted for 10 explanatory variables and work in Denmark 
where 56% of variation could be accounted for the explanatory factors in one study 
comparing polypharmacy (Bjerrum, 1999) in 173 GPs and in another study where they 
found that four explanatory variables accounted for 74% of variation (Bjerrum and 
Bergman, 2000). Morton-Jones and Pringle (1993) investigated total prescribing costs 
and could explain 81% of variation in spend with just four explanatory variables that 
were all associated with GP demographics, patient characteristics and some 
organisational attributes (number of GPs per population, age, other staff, dispensing 
and single handed practices). 
However, despite the much higher percentages being attributed to the explanatory 
variables in some of the published quantitative studies they are all one-off analyses 
and have not been repeated in subsequent years. One of the other very important 
findings from this research was that the statistically significant variables were different 
in successive years so that in one-year explanatory factor such as GP gender can be 
statistically significant but not in other years. This is a crucial finding because previous 
quantitative studies identified by the systematic review looking at multiple factors have 
sometimes identified single issues that appear to explain a large percentage of 
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variability and have subsequently been focused on as being crucially important in 
changing prescribing. There is also a difference between the results for the two drug 
classes. This has not been studied previous quantitative studies and it would be useful 
to see if this is a situation found in other disease areas for different drug classes, as 
well as repeating the work in this research for different years and possibly other drugs 
used in treating diabetes.  
One criticism of this choice of statistical analysis is that it does not take into account 
the linear relationship between indicators in the SPO model whereby the structural 
domain influences the process domain and the process domain influences the 
outcomes domain. Other research (Ameh et al., 2017) has focused on the 
development of a  statistical modelling tool to do this and explore whether this linear 
relationship is crucial to understanding the relationship between the indicators. They 
found that the analysis whereby structure domain indicators could also have a direct 
influence on outcome indicators provided the best fit for the data they used. This would 
justify in some way the choice of using a simple multiple regression to look at the 
influence of all the indicators on the outcome indicators. However, they discarded 
indicators that were not found to be statistically significant. This approach was not 
adopted in my research project because I was primarily interested in identifying the 
indicators and populating the model with the corresponding data for all PCOs. The 
multiple regression analysis was performed to look for any important relationships 
between the indicators in the model, but the results of this analysis on all PCOs do not 
correspond to those for the individual PCOs. Therefore, it would not make sense to 




A number of the relationships between the indicators in the structure and process 
domains and the two outcome indicators were found to be inverse (or negative) ones. 
Again, other than organisation size the negative relationships were different for the two 
classes of drugs. For LA insulin analogues the results indicated that the more 
sophisticated and cohesive the organisation, the smaller the organisation, and the 
lower the score for diabetes as a priority within the organisation the lower the level of 
prescribing of the drugs. For GLP-1 agonists the results are very interesting with a 
negative relationship over the three years for degree of reliance on secondary care, 
audit and education, clinical guidelines and organisation size. An inverse relationship 
for audit and education and adherence to clinical guidelines (although this variable was 
not statistically significant over three years) is perverse, particularly given the fact the 
audit and education measures the level of control of blood sugar HbA1C and one of 
the indications for use of the drug is to help gain better control of HbA1C. Similarly, 
one would have expected closer management of diabetes by better adherence to 
clinical targets such as weight control would be mirrored with greater use of the drugs. 
One of the limitations of this research was that it did not explore at specific patient 
prescribing decisions and this would be necessary to ascertain the exact reasons for 
deciding to prescribe GLP-1 agonists.  
Perhaps we should expect a difference between the statistically significant indicators 
in the two drug groups and should be aware of specific issues that might affect 
prescribing behaviour. The LA insulin analogues were introduced into the market as 
alternatives to the older and cheaper NPH (neutral protamine hagedorn) insulin (NICE 
Final Appraisal Determination, 2002, NICE Technology Appraisal TA53, 2002). They 
were indicated and approved for patients who have problems with the twice daily 
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regimen (hypoglycaemia, failure to reach HbA1C target, cannot use the NPH device 
or need someone else to administer it) and who would benefit from a once daily long 
acting insulin analogue. They were specifically identified as a class of drugs that should 
be discouraged as a first line option during this research period because of their greater 
cost and limited clinical benefit over the cheaper NPH insulin. However, it was found 
by looking at the local formulary information that two of the LA insulin analogues 
(determir and glargine) were available in the local formularies as an option for use over 
the three years either with no restrictions on their use or where insulins were all 
classified as green or not listed in over a third of all local documents. So it would appear 
that the push to limit their use was often only a national QIPP and medicines 
management target rather than one linked to local disease management and practice. 
The guidance for use of GLP-1 agonists changed over the time 2011/12 to 2013/14. 
They were originally restricted as third line therapy for patients with type 2 diabetes 
inadequately controlled (in terms of HbA1C) on metformin and sulphonylureas (NICE 
Technology Appraisal TA203, 2010, NICE Guidance CC87, 2009, NICE Guidance 
Costing Statement, 2012). Patients had to have a BMI of over 35 (or if under 35 have 
reasons for not using insulin or have complications of obesity). However, their ability 
to help weight loss, the introduction of two once daily preparations and then a once 
weekly injection, and their role in reducing HbA1C (a target from QOF) has led to 
subsequent guidelines widening their use (NICE Evidence Summary ESNM26, 2013, 
NICE Guidance Costing Statement, 2012, NICE Technology Appraisal TA203, 2010). 
In this case and in contrast to the situation with the LA insulin analogues, the local 
formularies have changed significantly over the period with four GLP agonists included 
in the formularies in 2013/14 in 22% of documents compared to 0% in 2011/12 and 
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2012/13. Another change that might go some way to explaining the increased use of 
GLP-1 agonists over the time was the increased awareness of the significant number 
of obese patients with type 2 diabetes and how this group of drugs could play a role in 
helping them to lose weight. However, if treatment was being used in a targeted way 
towards obese patients we would have expected to see a correlation between diabetes 
prevalence and GLP-1 agonist use. Ninety five per cent of type 2 diabetes patients are 
assessed as obese (Public Health England, 2014). This link between diabetes 
prevalence and GLP-1 agonist prescribing was not something found in this research. 
5.6. Conclusion 
The analysis of the data that populated the Donabedian SPO model to create PCO 
profiles showed that PCOs with similar prescribing behaviour could have quite different 
individual scores for indicators in the structure and process domains.  
The Profiles provided a useful means to examine the effect on prescribing of changing 
a specific influence in individual PCOs over time. The profiles give an overview of how 
prescribing habits of an organisation are balanced against other clinical targets for the 
disease area. 
A multiple regression to explore the relationship between outcomes (prescribing rates) 
and influences is the traditional way of examining the effect of several explanatory 
variables on a dependent variable. This analysis provided interesting conclusions 
about the possible importance of influences on prescribing behaviour. The statistically 
significant influences varied according to year and were different according to the drug 
class studied. This explains the differening results obtained from previously published 
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research included in the systematic review. It also justifies creating separate PCO 
profiles for different drug classes and repeating this exercise over several years. 
The results of multiple regression analysis are based on the aggregated statistics 
across all 211 PCOs and implied that associations between the dependent and PCO 
indicators in the total population of PCOs reflected the situation in individual PCOs. 
However, this is not the case when the individual PCO profiles are examined. Similar 
prescribing behaviour can be linked to quite different individual PCO Profiles . This 
phenomenon is not unknown and has been described as the ecological fallacy 
(Greenland, 2001). It does not mean that multiple regression analysis is not useful, but 
it does mean that both population level analyses and individual (in this case individual 
PCOs) should be performed (PEARCE, 2000). 
5.7. Summary 
The Donabedian SPO model for prescribing was a useful framework to create PCO 
Profiles that provided insight into the influences on prescribing in individual PCOs. The 
profiles could act as a tool to enable organisations to evaluate the effect of changing 




CHAPTER 6: GENERAL DISCUSSION AND CONCLUSIONS 
6.1. Discussion 
This thesis has examined organisational influences on prescribing within the primary 
care sector. A number of separate influences have been suggested in the literature, 
and results from the systematic review in chapter 2  concluded that the influences upon 
prescribing activity in primary care are multifactorial with no clear hierarchy of 
influences. They interact with each other and some are more important than others in 
particular local situations. International studies can provide some useful information, 
but the local influences and national framework within which care is provided (including 
national guidelines, health policies and targets) as well as the organisational 
structures, management and culture were all found to be important when attempting 
to understand influences on prescribing. The qualitative studies identified a wide range 
of influencing factors such as specialist training and education of GPs; influence of 
consultants and other hospital specialist staff; the way local service provision is 
provided and organisations interact; the importance of the type of organisation that the 
GP is part of and influence of other GPs within the organisation.  
The systematic review identified a number of limitations in the current knowledge of 
influences on prescribing. Only 5 out of 48 papers included in the review had utilised  
conceptual models and four of these were based on sociological (qualitative research 
papers) and 1 on economic models (quantitative research). The quantitative research 
in this area were also confined to one off analyses of a limited set of influences. Results 
identifying the statistically significant influences on prescribing vary across the 
published research with no agreed list of influences. Finally, the majority of research 
has concentrated on influences when prescribing antibiotics whereas in type 2 
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diabetes, as in other chronic diseases, disease management is more complex and 
depends on how care is delivered locally for patients, with local interactions between 
primary and secondary care being particularly important. The quantitative research did 
not measure this as an influence on prescribing. There are also often several options 
for drug treatment in chronic disease management and there is even less research 
specifically comparing influences in different classes of drugs treating the same 
disease.  
One of the aims of this research was to investigate the use of a conceptual model as 
a means of understanding and ordering the known prescribing influences in primary 
care. Since the papers included in the systematic review did not routinely use this 
method to evaluate the prescribing influences, I turned towards the field of health 
services research to see if there were conceptual models that could be adapted to be 
used in this research project. A literature review of papers was carried out to find 
healthcare research papers that have utilised conceptual models to measure and 
monitor health services, quality intiatives in healthcare, performance targets in 
healthcare. This resulted in the identification of the Donabedian SPO conceptual model 
as a viable option to base the building of PCO profiles upon. The Donabedian SPO 
model is particularly popular when investigating the relationship between indicators 
that make up the three domains of structure, process and outcomes at an 
organisational level. Using the generic descriptions of indicators that have been 
included in the Donabedian SPO model, I went through an exercise of allocating the 
prescribing influences identified from the systematic review into the structure and 
process domains. Since the aim of this  research project was to create PCO profiles 
measure prescribing influences it was logical to choose outcome indicators reflecting 
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prescribing activity. This enabled the indicators in the domains to be specifically 
adapted to this project in a manner described in numerous papers (Mainz, 2003, 
Donabedian A, 2003, Nocella et al., 2016, Ameh et al., 2017, Gardner and Mazza, 
2012, Reeve et al., 2015, Kunkel et al., 2007, Neville et al., 1996, Nuckols et al., 2013). 
The prescribing influences identified in chapter 2 were all included in this conceptual 
model.  
Having chosen the Donabedian SPO model as the conceptual framework to structure 
the prescribing influences the next stage of this research was to look for publically 
available data and information to populate the model. Nationally produced data and 
local NHS organisation information were used in the creation of datasets that reflected 
the individual indicators in the PCO profile. The nationally produced data has the 
advantage of being collected for all PCOs and having been audited and tested for 
consistency in many situations, for the example the QOF data; the National Diabetes 
Audit data; the NICE prescribing data for new drugs; demographic data; practice 
workforce data and the practice level prescribing data. Local qualitative information 
produced by PCOs, acute trusts and local NHS organisations (such as area prescribing 
committees) was also sought. Local information allowed for a greater understanding 
of the way in which individual local health economies interacted and organisations 
developed and behaved. For example, how PCOs had managed the organisational 
changes required by government reforms and how local formularies responded to the 
changing NICE guidelines for LA insulin analogues and GLP-1 agonists. This 
qualitative information was collected, coded and scored to allow for its inclusion ino the 




Chapter 5 described the comparison of the PCO profiles for the 3 years of the study. 
Two main methods were employed to compare the profiles. The data for all the 
indicators was divided into quintiles and the movement over the 3years was analysed 
for each PCO.  This method of analysis showed that PCOs with the similar prescribing 
of LA insulin analogues and GLP-1 agonists could have quite different PCO profiles. It 
also showed that prescribing for the two drug classes remained similar for the three 
years in the majority of PCOs. This is despite the period of study encompassing a time 
of significant organisation change for some PCOs in England.  
The second method of analysis was to perform three multiple regression analyses for 
both of  the outcome indicators to determine how much of the variability in prescribing 
of LA insulin analogues and GLP-1 agonists could be attributed to the influencing 
indicators. In all 3 years only approximately 30% of variability in prescribing could be 
accounted for by the influencing indicators. The multiple regression analysis also 
looked for any statistically significant relationships between the indicators in the 
structure and process domains and the two outcomes indicators (prescribing 
behaviour).  This analysis found that the statistically significant indicators varied in the 
different years and according to the drug class studied. 
6.2. Limitations 
There were two potential major limitations to this research project. The first was that it 
was not possible to find data or information for all the possible influences on prescribing 
identified in the literature review for all 211 PCOs. The most important one not to be 
included was probably the measure of pharmaceutical company influence. This may 
be significant in this project because companies benefit significantly if they can get 
their brand of specific diabetes drug used within a LHE. However, this influence was 
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partly covered by the changes in formulary recommendations over the three years for 
both of the drug classes studied (section 4.5.2.3. Specific formulary guidance for use 
of LA Insulin analogues and GLP-1 agonists). Distinct differences in brand 
endorsement are seen across different geographical areas over this time. Although It 
would have been good to understand the relative pressure exerted by different 
companies upon individual PCOs, we can perhaps discern the success of the different 
companies by the adoption of individual brands in the different local formularies. Linked 
to this was a lack of acute trust prescribing information. Again, the formulary changes 
applied to acute trusts within the LHE, but having actual prescribing data from the acute 
trusts would have enhanced understanding of how adoption of a drug in an acute trust 
filtered down to the PCOs within the LHE. The second potential limitation was that the 
project focused on PCOs and therefore the degree of variation of individual influences 
at practice level were not measured. If this had been examined, then we could have 
seen significant differences in PCOs that at organisational level appeared similar. 
Future research could potentially include a measure of the degree of variability in 
practice prescribing behaviour across a PCO. Such a measure could be included in 
the structure domain as a measure of organisational variability/cohesiveness. 
However, this approach is not without problems because practice level variability in 
prescribing would need to be understood in relation to variation to other practice level 
data. Some practices within a PCO might have completely different profiles in terms of 
patient demographics; size; management and arguably it would be better to create 
practice level profiles based on the Donabedian SPO model to enhance the results of 
the PCO profiles. This level of data collection and analysis would be beyond the scope 
of this doctoral research project.  
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6.3. Future research 
This research has created the starting point for understanding prescribing in primary 
care organizations by using a Donadbedian SPO conceptual model. Future research 
to continue this work should: 
• Expand the use of the Donadbedian SPO model to include other drugs used to 
treat diabetes and update the current PCO Profiles for these 2 classes of drugs.  
This would build on the results obtained here and allow for a identification of the 
key influences on diabetes prescribing in each individual PCO. It would then be 
possible for PCOs to focus resources more effectively towards those influences 
that are significant in their organisations. The PCO profiles need to be updated 
because since 2013/14 there have been more organisational changes (including 
mergers between CCGs and joint sharing of budgets across different organisations 
(Manchester LHE); additional financial pressures on PCOs which have led to 
changes in service provision and developments. 
• Create PCO profles for drugs used to treat other conditions managed in primary 
care. A number of the influences on prescribing were not disease specific so the 
creation of PCO profiles for other disease areas would not be an onerous task. The 
creation of such PCO Profiles would allow for examination of repeating patterns of 
behaviour within PCOs. Knowing the interaction and level of importance between 
influences would allow for targeted actions to alter prescribing behaviour. For 
instance, in some PCOs the restrictive formulary guidance had no effect on 
prescribing behaviour so it is of secondary importance as an influence. 
• Work with individual PCOs to further refine the PCO profile. Direct work with PCO 
and acute trust staff within a local health economy would allow for qualitative 
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research to refine the profiles. Additional understanding  of practice variation within 
the organisation; identification of key local opinion leaders; local major issues 
affecting prescribing behaviour; and important local interactions between 
organisations and groups could be  captured within the model. This exercise would 
also validate the results of the quantitative analysis because, as previously 
discussed, the data used to populate the PCO profiles has not primarily been 
collected for this purpose. There is potential danger in relying solely on this 
secondary data when seeking to understand local situations. This was exemplified 
by the recent assertion that weekend mortality rates in hospitals in England are 
higher than during the week (Freemantle et al., 2012). This was based on 
quantitative data collected for national analysis but more detailed research in the 
area has found that a proper investigation of the local situation is required to truly 
understand what the data means and is telling up about the pattern in mortality 
rates (Wise, 2016). 
6.4. Conclusion 
The present study is the first to apply the Donabedian SPO model to influences on 
prescribing. This conceptual model provided a good fit for all the known influences on 
prescribing identified in the systematic review. Use of this conceptual model to 
measure changes in healthcare are evident in other branches of health services 
research where the model provides a useful framework for comparing effectiveness 
and quality of healthcare interventions. This research has demonstrated that adopting 
a similar approach to understand prescribing variation in PCOs is a valid one and pulls 
together previously unconnected influences to provide a good summary of how 
prescribing is influenced in a PCO. 
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There was adequate publically available data and information to populate this model 
for all PCOs in England. The resulting PCO profiles provided insight into the relative 
importance of the individual influences on prescribing in each PCO. Focusing on 
individual classes of drugs and adapting the Donabedian SPO model accordingly 
afforded a picture of varied uptake patterns in PCOs across the country. By creating 
the PCO profiles for several consecutive years it was possible to see the effect of 
different influences of prescribing behaviour over time in different organisations.  
Continuing to create PCO profiles each year for a range of classes of drugs for other 
disease areas would build up an in depth knowledge of how individual PCOs react to 
national and local pressures when prescribing. This in turn could lead to more 




Nationally available diabetes datasets covering the  period 2011/12 to 2013/14 
Table 57: Sources and descriptions of datasets rele vant to this  research 










QOF data. The 
Quality Management 
and Analysis System 
(QMAS) was used 
for the extraction of 
QOF data in 2011/12 
and 2012/13. Now it 
is Calculating Quality 
Reporting Service 
(CQRS), together 
with the General 
Practice Extraction 
Service (GPES). 
Reported by HSCIC. 
Over 90% of 
practices 
participated in 






























England, Right Care, 
HSCIC, NHS 
England, Diabetes 
UK) as important 
measure of clinical 
care, outcomes and 
disease prevalence. 
QOF Diabetes 
prevalence is used 
as the most accurate 
number available of 
identified patients. 
QOF data is used 
extensively in 
various data packs 
produced by a 
number of 
organisations, as 




1. Healthier Lives 
Tool (Public Health 
England)            
2. DOVE outcomes 
(Public Health 
England)               
3. CCG Diabetes 
Profiles (Right Care)         
4. Atlas of Variation 
(Right Care)              
5. HSCIC Diabetes 
Compendium data 
set (HSCIC)                        
6. Spend and 
Outcome Tool 
Very relevant. 









Audit (NDA) primary 
care. Commissioned 




rates falling to 
around 70% by 
2012/13 with36 
PCOs reporting 




worse and much 
less than QOF 
data. 15 month 
 Accepted by 
National Bodies 
(Public Health 











as part of the 
National Clinical 
Audit Programme 
and delivered by 
HSCIC in partnership 
with Diabetes UK 
and The National 
Cardiovascular 
Intelligence Network 
(part of Public Health 
England 
practices being 
involved in the 
audit and 19 
returning less 
than 25%. No 
2013/14 data 
 








data analysis for 
previous years. 
UK) as important 
measure of clinical 
care, outcomes and 
complications. NDA 
data is available on 
the HSCIC website. 
It is also available as 
part of other 
datasets:            
1. Healthier Lives 
Analysis  
2. CCG Outcomes 
Tool –  
3. Diabetes 
Community profile  
4. Diabetes CCG 
profile  





other data is 
available (in 





2012/13) .  
Prescribing Data 
(ePACT data) 
produced by HSCIC 
100% coverage 
of all practices in 
England. The 
PCO where the 
prescriber is 
located is used 
















England, Right Care, 
HSCIC, NHS 
England, Diabetes 





used extensively in 
other data sets:                     
1. QIPP Prescribing 
comparators              
2. Innovation 




Reports                  
4. NICE Innovation 
Scorecard                         
5. DOVE tool                    
6. CCG 
Commissioning 
Insight Value Pack                     
7. CCG Diabetes 
Profiles          
8. Atlas Variation                 












NICE uptake of a 
specified range 
of new drugs in 
primary care. It is 
intended to 
identify where 
variation in the 
Variation in the 
use of 
medicines may 
be due to many 
reasons such as 
Differences in 
the patient 
Data is viewed as 
experimental by 




observed based on 
Relevant as a 
general view 

















different in the 
three years to 
reflect the 
adoption rates of 
new drugs 




















The Scorecard is 
intended as a means 
of stimulating the 
monitoring of uptake 
of drugs in 
accordance with 




Appraisals in the 




diabetes for all 
three years.  

















HES and SUS 
referral data 
(analysed by Dr 
Forster). 
PCO level data 




may reflect the 























Budgeting Spend / 
Analysis. Produced 
by NHS England 
The programme 
Budgeting data is 











every year from 
CCGs / PCTs. 
Area Teams 
responsible for 
ensuring data is 
complete. 
PCO level data 




















England, Right Care, 
HSCIC, NHS 
England, Diabetes 
UK) as important 
measure of 
spending analysis. 
Used in various data 
sets: Right Care: 
(CCG 
Commissioning 
Insight Packs);  





Profile 2012;  
Diabetes CCG 
Profiles 2013.  
DOVE tool 
Relevant. Will 
add to other 











The QIPP target 
drug areas are 
The purpose of the 





of for all the 
target drug 





and PCOs may 




practice in all or 
any of these 
areas. 
Prescribing data 








and support local 
discussion and 
decisions regarding 






useful view of 
how effective 


















unit, practice and 
provider unit. 
Admissions data 
does not take 
into account the 
differing patient 
population for 
each acute trust.  
HES data linked 
to acute trust 
and PCO is 
currently not 
available due to 
issues with data 
security. The 
quality of HES 
data has been 
rated as variable 




are an issue in 
some 
organisations, 
so the data is 
not always 




HES data used to 
create Better Care 
Better Value 
indicators (although 
used in conjunction 
with other data). 
Data quality issues 
have been identified. 
Also used in Public 
Health analyses, 

























Groups provide a 
grouping of 





uses the a range 
of data to assign 
CCGs to the best 
Data used to 
build up the 
CCG 
Classification 
groupings:          
1. Age structure 
of population 





several risk factors 
may obscure 






Groups. Also in           
1. CCG Diabetes 
profiles 
Very Relevant. 
Many of the 
limitations of 
the other data 
described 
here are 





This data and 
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match based on 





3. % population 
from Black 
ethnic groups 






2. Joint Strategic 
Needs Assessments 
classification 
will allow the 
patient 
demographic 
to be included 
in the 
analysis. 
Similar CCGs The similar 
CCGs 
classification has 
been used to 
group GGCs 





based on the 
following:                        
1. deprivation   
2. Average of 
the health 
domain from the 
multiple 
deprivation 
index  3. Total 
population 
registered with 
the CCG  4. Age 
profile 
populations  5. 
Population 
density and 6. 
Ethnic origin of 
population. 
This ranking system 
is used in the Right 
Care Commissioning 
for Value packs. It is 























causes of death 
(there is a 
significant under 
recording of 
diabetes as an 
underlying cause 
of death because 
the deaths are 
often coded 






diabetes:            
1. Number by 
age group 
annually;               
2. indirectly 
standardised 
ratio (SMR) all 
ages or different 
age ranges,         
3. directly 
standardised 





Portal 2011/12 the 
latest data available 
Not relevant. 




Years Lost. HSCIC 
Indicator Portal. 
Years of life lost 





is to compare the 
Years of life lost 
due to mortality 
from diabetes: 1. 
directly 
standardised 
rate, 1-74 years, 
3-year average, 
HSCIC Indicator 
Portal 2011/12 the 
latest data available 
Not relevant. 










death within a 
particular 
population and it 
can therefore be 
used by health 
planners to 
define priorities 
for the prevention 
of such deaths  
MFP           2. 
Crude rate 1-74 










Potential years of life 






















The most recent 
data available is 
for 2011/12; the 
figures include 
type 1 and type 
2 diabetes and 
the data is 
available at local 
authority level 
rather than PCO 
level. 
 










As has been described in the table 58 below a number of the datasets described above 
have been combined with others to create a specific dataset for analysis. However, 
there are several issues with using the data from these tools. The data used in each 
of the tools is based on previous years, for example, NHS Atlas of Variation in 
Healthcare for people with diabetes was made available in June 2012 Atlas of Variation 
(Right Care Atlas Series, 2012). The data sources were Net Ingredient Cost 2010/11 
and National Diabetes Audit data for 2009/10. Some of the tools have used the relevant 
years’ data in terms of this research, but the tools were not available to the PCOs 
during the period of planning and prioritisation (roughly 6 months prior to the start of 
each financial year in April). For example, the Right Care Analysis was released in 
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October 2013 but, although it is based on information and data 2011/12, was not 
available for the PCOs when they were identifying clinical priorities areas for 2013/14. 
Finally, the underlying data used in these tools has already been used in the creation 
of influences on prescribing. 
Table 58: Combined data available in tools  
Dataset name Dataset description Content 
Healthier Lives Produced by Public 




The interactive ‘heat map’ includes 
information on prevalence of the 
conditions and their complications, 
levels of care provided and the 
quality of care achieved in each 
area by local authority (LA), clinical 
commissioning group (CCG) and 
general practice, compared to the 
England average. 
1. National Diabetes Audit 
data (primary care) 
2. National Diabetes Audit 
(secondary care)                         
3. QOF data                     
4. HES referral data 
5. Deprivation 
CCG Commissioning for Value 
Insight Pack. Produced by Right 





Right Care. October 2013.  
Identification of disease areas that 
could be improved according to 
quality; financial measures and 
patient outcome measures 
1. Programme Budgeting 
Spend analysis. 2011/12 
Health Outcomes and 
healthcare variation. 
Potential lives saved per 
year 2011/12.  Diabetes 
QOF outcomes 2011/12. 
Prescribing data. 
Identification of similar 
CCGs (in terms of 
population) 
CCG Commissioning for Value 
Pathways on a Page. Produced by 





Identification of clinical areas that 
CCGs could make improvements 
in based on data analysis and 
comparison of similar CCGs. This 
is the second set of information 
and analysis in the Commissioning 
for Value support pack for CCGs 
and provides a more detailed look 
at the clinical areas where the 
CCGs could probably make the 
largest improvements in terms of 
spend and quality / outcomes. The 
packs identify CCGs with a similar 
population that are better or worse 
at meeting specific disease targets 
for diabetes.  
 
 
Analysis based on             
similar CCGs (population 
analysis); Diabetes QOF 
2012/13;       Diabetes 
NDA 2012/13;      
Programme Budgeting 
spend 2012/13 
The Diabetes Outcomes Versus 
Expenditure (DOVE) Outcomes 
tool. Tool for CCGs (PCTs) and 
practices. Produced by National 
Cardiovascular Intelligence 
The DOVE tool allows spending on 
diabetes care to be compared with 
clinical outcomes by Clinical 
Commissioning Group (CCG). A 
CCG can be compared with other 
1. QOF 2012/13 data             
2. Deprivation                  









CCGs with similar populations and 
all other CCGs. The tool also 
identifies the potential changes to 
costs that would result from 
changing outcomes or expenditure 
to benchmarked levels. 
Spend and Outcome Tool (SPOT). 
Produced by Right Care, Public 




The tool has been designed to 
compare spend and outcome for 
CCGs in England. It is an aid to 
identify programmes that may be 
outliers and need further 
investigation. 
Outcomes from QOF 
2011/12, 2009/10 
diabetes complications. 
Spend analysis uses 
Programme Budgeting 
data 2011/12 
Atlas of variation in treatment of 
diabetes June 2012. Developed by 
Right Care. Available at: 
http://www.rightcare.nhs.uk/index.
php/atlas/diabetes/ 
The aim of the Diabetes Atlas is to 
identify and quantify the extent of 
‘unwarranted’ variation that may 
be due to unjustified geographical 
differences in medical practice 
and/or patients not gaining access 
to the appropriate level of 
intervention for their need. It 
includes 22 maps of indicators 
relating to the key care processes 
and outcomes, utilisation of 
secondary care, diabetic 
complications and prescribing. 
 
National Diabetes Audit. 
DOVE tool, PCT spend 
and outcome factsheets 
(SPOT) Prescribing 
analysis. Use of inpatient 
services 




Diabetes Compendium of 
Population Health Indicators - 
Years of life lost due to mortality 
from diabetes: directly 
standardised rate, 1-74 years, 3-
year average, MFP 
 
Diabetes specific data  
 
Organisations responsible for production / output o f data  
The Health and Social Care Information Centre (HSCIC) was established on 1st April 
2013. It was formed from the amalgamation of several organisations: The NHS 
Information Centre, Connecting for Health and informatics functions previously sited in 
Strategic Health Authorities and Primary Care Trusts. NHS Choices (previously 
managed by Capital) was transferred to HSCIC in August 2013 and some functions 
from NHS Direct were transferred in April 2014. The Centre provided national 
information and information technology systems to health and social care 
organisations so they could provide better services and improve health standards. It 
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analysed, published and disseminated health and social care data (Health and Social 
Care Information Centre, 2014a). 
NHS England was established on 1st April 2013 and took on many of the functions of 
the former primary care trusts (PCTs) with regard to the commissioning of primary care 
health services, as well as some nationally-based functions previously undertaken by 
the Department of Health. NHS England commissioned specialised services and had 
27 area teams to help with supporting clinical commissioning groups in their 
commissioning role. NHS England also published a range of statistics on health and 
care subjects although much of these were also published by HSCIC. The organisation 
was responsible for setting out plans and priorities for NHS organisations in England 
as well as improving patients experience and quality within the NHS.  
The NHS Improving Quality (NHS IQ) was established on 1 April 2013 and is hosted 
by NHS England. It is responsible for improving health outcomes for people by focusing 
on the five domains outlined in the NHS Outcomes Framework. The organisation works 
to facilitate partnerships across NHS organisations and works to help them improve 
capacity and capability so that health outcomes can be improved for the population. 
This organisation has taken over responsibility for the Better Care Better Value 
Initiative. This Initiative was set up to identify potential areas where NHS organisations 
could make savings through changing practice. Primary Commissioning Organisations 
and Acute Trusts were included in this initiative and it was focused around changing 
referral patterns – reducing emergency admissions; bed days, follow up appointments; 
secondary care outpatient appointments and readmissions (all with the aim of reducing 
the more expensive secondary care based care in favour of primary care); reducing 
costs in prescribing; and improving efficiency by reducing the workforce sickness. 
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Opportunities were identified by estimating the savings an organisation could make by 
changing their behaviour to match the best performing organisations. One of the 
disease areas where data is collected and reported is diabetes outpatient referrals to 
secondary care. 
The role of Public Health England (PHE) was to protect and improve the nation’s health 
and tackles health inequalities. It was established on 1 April 2013. The National 
Cardiovascular Intelligence network (NCVIN) was part of Public Health England. 
Historically diabetes data was produced under the auspices of The National Diabetes 
Information Service. This has been merged to form the National Cardiovascular 
Intelligence Network. part of this network). The NCVIN brought together 
epidemiologist, clinicians, analysts and patient representatives. Public Health England 
coordinated a number of other disease specific networks. One of the key roles of the 
NCVIN was to analyse health data from surveys, audits and statistics and display the 
results of the analyses in easily understandable products such as interactive profiles, 
maps and charts. 
There was a wide array of nationally available quantitative data that has been collected 
and made available publically.  
The majority of the datasets described above were relatively simple with the exceptions 
of the Quality Outcomes Framework data, The National Diabetes Audit data and the 
NICE Innovation Scorecard.  
Quality Outcomes Framework (QOF) Diabetes dataset  
Description: Annual Incentive Scheme for GP practices and CCGs to meet a range of 
clinical targets (including diabetes). Coverage:  
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• 2011/12 QOF - 8,123 general practices in England 
• 2012/13 QOF - 8,020 general practices in England 
• 2013/14 QOF - 7,921 general practices in England 
Type of Information: Diabetes has been included as one of the clinical targets since 
inception of the scheme. Individual comparators making up the diabetes section have 
changed over time with 2013/14 scheme having 16 individual targets compared to 14 
in 2011/12. They have been changed over the years to reflect changing clinical practice 
and priorities. The diabetes register (indicator DM32) was redefined for 2012/13 and 
expanded to include all types of diabetes (with the exception of gestational diabetes). 
The QOF diabetes register does not distinguish between types of diabetes and patients 
are captured to a single register (Health and Social Care Information Centre, 2014f). 
In terms of this research project, this is not an issue because type 2 diabetes accounts 
for over 90% of all diabetes in adults. Prevalence of type 1 diabetes is also evenly 
spread across PCOs and so is unlikely to influence the results (National Diabetes 
Audit, 2011/12b) . Moreover, HSCIC, NICE, Public Health England all use the total 
diabetes prevalence in patients over 17 as their reference number. 
One of the decisions that needed to be taken when considering the data to be used in 
this doctoral research was the exact measurement that should be used for the 
individual measure of attainment of QOF measurements. There were two options; 
firstly, to use the underlying % of patients attaining a specific target (net of exceptions). 
Patient exceptions being defined as people to whom the indicator applies but who are 
not included in the indicator denominator because they are part of the agreed 
exception criteria (see below). Secondly, there was the option to use the percentage 
of patients receiving the intervention. This gives a more accurate indication of the rate 
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of the provision of interventions as the denominator for this measure covers all patients 
to whom the indicator applies, regardless of exception status (i.e. indicator exceptions 
and indicator denominator). However, it is common practice to use the underlying % 
of patients attaining a specific target (Health and Social Care Information Centre, 
2014f) and so this figure has been used in this research project. 
The following criteria have been agreed for exception reporting of QOF data:  
• patients who have been recorded as refusing to attend review who have been 
invited on at least three occasions during the preceding twelve months  
• patients for whom it is not appropriate to review the chronic disease parameters 
due to particular circumstances e.g. terminal illness, extreme frailty  
• patients newly diagnosed within the practice or who have recently registered 
with the practice, who should have measurements made within three months 
and delivery of clinical standards within nine months e.g. blood pressure or 
cholesterol measurements within target levels  
• patients who are on maximum tolerated doses of medication whose levels 
remain sub-optimal  
• patients for whom prescribing a medication is not clinically appropriate e.g. 
those who have an allergy, another contraindication or have experienced an 
adverse reaction  
• where a patient has not tolerated medication  
• where a patient does not agree to investigation or treatment (informed dissent), 
and this has been recorded in their medical records  
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• where the patient has a supervening condition which makes treatment of their 
condition inappropriate e.g. cholesterol reduction where the patient has liver 
disease  
• where an investigative service or secondary care service is unavailable 
(Checkland et al., 2013). 
National Diabetes Audit (NDA) primary care dataset  
Description: The National Diabetes Audit (NDA) answers four key questions based on 
the diabetes National Service Framework (NSF): 
1. Is everyone with diabetes diagnosed and recorded on a practice diabetes 
register? 
2. What percentage of people registered with diabetes received the nine NICE key 
processes of diabetes care? 
3. What percentage of people registered with diabetes achieved NICE defined 
treatment targets for glucose control, blood pressure and blood cholesterol? 
4. For people with registered diabetes what are the rates of acute and long term 
complications (disease outcomes)? 
Audit participation in primary and secondary care. Data tables with information about 
care processes (percentage recorded), HbA1c results, patient age distribution, 
average age and BMI, diabetes type distribution and ketoacidosis episodes. Further 
in-depth analysis at a national and local level on: registration and prevalence; 
complications; care processes and treatment targets. Comparative spreadsheets and 
separate organisation profiles are available on the Health and Social Care Information 
Centre website under the heading “National Diabetes Audit”.  
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NDA data is collected over a fifteen month period, between 1st January and 31st March 
of the next year, whereas QOF data is collected over a 12 month period, between 1st 
April and the 31st March. Therefore, the figures are not directly comparable. 
Participation in the NDA is voluntary; however, it does cover 71.1% of the people 
diagnosed with diabetes in England (when compared with QOF).  
The National Diabetes Audit covers all PCOs in England and Wales but one of the 
major caveats in using this information is that participation in the audit is voluntary. The 
participation rate decreased in the 2012/13 audit to 70.6% of GP practices from 87.9% 
for the 2011/12 audit and 82.8% in the 2010/11 audit. The % of practices involved 
varies sharply across PCOs in England with 36 PCOs reporting less than 50% of 
practices being involved in the audit and 19 returning less than 25%. (National 
Diabetes Audit, 2011/12a) 
The complications data whilst being extremely useful reported complications recorded 
in years before the timeframe of this research with the most recent data being 2011/12 
(National Diabetes Audit, 2012/13).  
Finally, the NDA was collected retrospectively and the collection period for the 2013/14 
year (1st January 2013 to 31st March 2014) is from March 2015 to June 2015. 
Therefore, there was no NDA data available for 2013/14 when the data collection was 
undertaken.  
NICE Innovation Scorecard  
There were two types of analysis that are relevant to this research. Firstly, there was 
an in depth analysis of a handful of new drugs that have NICE guidelines to advise 
GPs in how to use them and that were mainly prescribed in primary care. For these 
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drugs, an estimate of the likely numbers of patients who would be eligible to receive 
the drug (eligible population) has been calculated for each CCG, the expected 
prescribing levels based on prescribing of the drug in accordance with the guidelines 
is calculated and then the actual prescribing rate for each drug was measured and a 
ratio of observed against expected was obtained.  
A number of estimates and assumptions were made in this analysis. The eligible 
patient population was estimated using The NICE Costing Tool. This was designed to 
help local NHS organisations to estimate the local cost impact of implementing 
guidance at the time of publication. However, it was used in this analysis to establish 
an estimate for eligible populations. The figures used were based on various literature 
sources (peer based reviews, expert opinions and other data sources). Where 
available, Defined Daily Doses (DDDs) as defined by the World Health Organisation 
(WHO) were also used (rather than the more commonly used net ingredient cost (NIC). 
The Observed use of the medicines under consideration was obtained by using 
prescription data in primary care provided by the HSCIC. Finally, a comparison of 
estimates of predicted use and observed use could be made. It was concluded by 
NICE that variation in the use of medicines may be due to a number of factors such as 
a local variation in population; presentation to the NHS organisations and keenness to 
adopt a specific treatment both at patient and across LHE. The data was accessible 
on the Health and Social Care Information Centre (HSCIC) website under the heading: 
NICE technology Appraisals. 
Drugs have been chosen where it was possible to estimate the number of patients who 
would be expected to receive the drug against the actual prescribing rate. This was 
difficult to achieve for several reasons – many drugs have several indications; there 
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are usually alternatives to them and NICE guidance usually recommends a number of 
treatment options that are not always drugs (Health and Social Care Information 
Centre, 2015b). 
The second type of analysis is one where a range of new drugs was monitored over 
the period to measure uptake across the CCGs. The predominant use of these 
medications was in primary care (97% or more). For this analysis prescription data had 
again be obtained from HSCIC and the data was presented in Defined Daily Doses 
(DDDs) per 100,000 resident population. It should be noted that in this analysis a 
volume per head of population is obtained but this did not linked to any calculation of 
the numbers of patients per organisation and takes no account of differences in gender 
or age distribution (Health and Social Care Information Centre, 2014b). 
The Innovation Scorecard was not intended to be used for performance management. 
It was intended to identify where variation in the adoption of TAs may have existed 
between healthcare organisations and for these organisations to understand, be 
challenged and explain any variation that had occurred. This was based on the 
assumption that reduced variation will result in improved quality of care. 
The observed use of a medicine or technology may have differed for a range of reasons 
and should not be assumed to definitely indicate either ‘under’ or ‘over prescribing or 
implementation. A technology may not be the only treatment for a particular condition 
recommended in NICE guidance, or otherwise available in the NHS. Medicines are 
generally recommended as options for treatments. Other options may include non-
appraised medicines or other appraised medicines. Therefore, variation in the use of 
individual medicines would be expected. Assessment of compliance cannot be made 
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using currently available data. Variation in the use of medicines or medical 
technologies between NHS organisations may be due to a number of valid factors 
described in the Innovation Scorecard including: 
1. Natural variation in populations, both in demographic profile and disease 
prevalence. 
2. Variation in presentation to the NHS by the relevant populations. 
3. Variation in choice of preferred treatment option at the local level. 
4. Variation in the use of alternative products or procedures. 
5. Differences in the extent to which local utilisation information is available. 
6. Differences in services provided between organisations, for example 
differences in 
7. The extent to which a service is provided in primary or secondary care. 
Difference in levels of informed patient dissent to intervention (Health and 
Social Care Information Centre, 2013a, Health and Social Care Information 




Organisational changes from PCT to CCG 
Source of Information: NHS England Website. Available at: 
http//www.england.nhs.uk/ccgs/. Accessed 01 May 2012 – 15 May 2015. 
Table 59: PCTs that have merged with other PCTs to form a single CCG 
Name of PCT Description of organisational 
change 
New CCG 
Bournemouth and Poole 
PCT 
Merger with neighbouring PCT Dorset CCG 
Dorset PCT Merger with neighbouring PCT Dorset CCG 
Cambridge PCT Merger with neighbouring PCT Cambridge and Peterborough 
CCG 
Peterborough PCT Merger with neighbouring PCT Cambridge and Peterborough 
CCG 
Hartlepool PCT Merger with neighbouring PCT Hartlepool and Stockton on 
Tees CCG 
Stockton on Tees PCT Merger with neighbouring PCT Hartlepool and Stockton on 
Tees CCG 
Redcar and Cleveland 
PCT 
Merger with neighbouring PCT South Tees CCG 
Middlesbrough PCT Merger with neighbouring PCT South Tees CCG 
 
Table 60: PCTs that have split up to create CCGs wi th new boundaries 
Name of PCT Description of organisational 
change 
New CCG 
Heart of Birmingham 
Teaching PCT 
Practices from part of one 
PCT merged with practices 
from another PCT  
Birmingham South and 
Central CCG 
South Birmingham PCT Practices from part of one 
PCT merged with practices 
from another PCT 
Birmingham South and 
Central CCG 
Heart of Birmingham 
Teaching PCT 
Practices from part of one 
PCT merged with practices 
from another PCT 
Sandwell and West 
Birmingham CCG 
Sandwell PCT PCT merged with practices 
from another PCT 
Sandwell and West 
Birmingham CCG 
Birmingham East and North 
PCT 
PCT merged with practices 
from another PCT 
Birmingham CrossCity CCG 
South Birmingham PCT Practices from part of one 
PCT merged with practices 
from another PCT 
Birmingham CrossCity CCG 
Derby City PCT PCT merged with practices 
from another PCT 
Southern Derbyshire CCG 
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Derbyshire County PCT Practices from part of one 
PCT merged with practices 
from another PCT 
Southern Derbyshire CCG 
Devon PCT Practices from part of one 
PCT merged with practices 
from another PCT 
North East West (NEW) 
Devon CCG 
Plymouth Teaching PCT PCT merged with practices 
from another PCT 
North East West (NEW) 
Devon CCG 
Devon PCT Practices from part of one 
PCT merged with practices 
from another PCT 
South Devon and Torbay 
CCG 
Torbay Care Trust PCT merged with practices 
from another PCT 
South Devon and Torbay 
CCG 
 
Table 61: PCTs that split up to form smaller CCGs 
Name of PCT that split to form smaller CCGs Name of CCG 
Berkshire East PCT Bracknell and Ascot CCG 
 Slough CCG 
 Windsor, Ascot and Maidenhead CCG 
Berkshire West PCT Newbury and District CCG 
 North and West Reading CCG 
 South Reading CCG 
 Wokingham CCG 
Bradford and Airedale Teaching PCT Airedale, Wharfedale and Craven CCG 
 Bradford City CCG 
 Bradford Districts CCG 
Buckinghamshire PCT Aylesbury Vale CCG 
 Chiltern CCG 
Central and Eastern Cheshire PCT Eastern Cheshire CCG 
 South Cheshire CCG 
 Vale Royal CCG 
Central Lancashire PCT Chorley and South Ribble CCG 
 Greater Preston CCG 
 West Lancashire CCG 
County Durham PCT Durham Dales, Easington and Sedgefield 
CCG 
 North Durham CCG 
Derbyshire County PCT Southern Derbyshire CCG (with practices 
from Derby City CCG) 
 Erewash CCG 
 Hardwick CCG 
 North Derbyshire CCG 
East Sussex Downs and Weald PCT Eastbourne, Hailsham and Seaford CCG 
 High Weald, Lewes and Havens CCG 
Eastern Coastal Kent PCT Ashford CCG 
 Canterbury and Coastal CCG 
 South Kent Coast CCG 
 Swale CCG 
 Thanet CCG 
Halton and St Helens PCT Halton CCG 
 St Helens CCG 
Hampshire PCT Fareham and Gosport CCG 
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 North East Hampshire and Farnham CCG 
 North Hampshire CCG 
 South Eastern Hampshire CCG 
 West Hampshire CCG 
Hertfordshire PCT East and North Hertfordshire CCG 
 Herts Valley CCG 
Kirklees PCT Greater Huddersfield CCG 
 North Kirklees CCG 
Leeds PCT Leeds North CCG 
 Leeds South and East CCG 
 Leeds West CCG 
Leicestershire County and Rutland PCT East Leicestershire and Rutland CCG 
 West Leicestershire CCG 
Lincolnshire Teaching PCT Lincolnshire East CCG  
 Lincolnshire West CCG 
 South Lincolnshire CCG 
 South West Lincolnshire CCG 
Manchester PCT Central Manchester CCG 
 North Manchester CCG 
 South Manchester CCG 
Newcastle PCT Newcastle North and East CCG 
 Newcastle West CCG 
Norfolk PCT North Norfolk CCG 
 Norwich CCG 
 South Norfolk CCG 
 West Norfolk CCG 
North Lancashire PCT Fylde and Wyre CCG 
 Lancashire North CCG 
North Yorkshire and York PCT Hambleton Richmondshire and Whitby CCG 
 Harrogate and Rural District CCG 
 Scarborough and Ryedale CCG 
 Vale of York CCG 
Nottinghamshire County PCT Mansfield and Ashfield CCG 
 Newark and Sherwood CCG 
 Nottingham North and East CCG 
 Nottingham West CCG 
 Rushcliffe CCG 
Sefton PCT South Sefton CCG 
 Southport and Formby CCG 
South Staffordshire PCT Cannock Chase CCG 
 East Staffordshire CCG 
 South East Staffs and Seisdon Peninsula 
CCG 
 Stafford and Surrounds CCG 
South West Essex PCT Basildon and Brentwood CCG 
 Thurrock CCG 
Suffolk PCT Ipswich CCG 
 West Suffolk CCG 
Surrey PCT East Surrey CCG 
 Guildford and Waverley CCG 
 North West Surrey CCG 
 Surrey Downs CCG 
 Surrey Heath CCG 
Sutton and Merton PCT Merton CCG 
 Sutton CCG 
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Warwickshire PCT South Warwickshire CCG 
 Warwickshire North CCG 
West Kent PCT Dartford, Gravesham and Swanley CCG 
 West Kent CCG 
West Sussex PCT Coastal West Sussex CCG 
 Crawley CCG 
 Horsham and Mid Sussex CCG 
Worcestershire PCT Redditch and Bromsgrove CCG 
 South Worcestershire CCG 






Detailed background information about individual in dicators 
Organisation culture variable - Detailed informatio n  
Clinical engagement and enthusiasm to set up a new PCO  
During the period of this study, primary care trusts were grouped together to form 
primary care clusters and CCGs were formed. This evolution has not been the same 
for all organisations and there has been a significant difference between the speed 
and enthusiasm that local GPs and practices have come together to set up the new 
local CCGs and have been able to agree plans and priorities going forward. The 
scoring for this measure has been created to assess the organisation in terms of 
clinical and organisational cohesiveness during the year that is being measured. This 
has meant that the scoring criteria is different for each year according to the challenges 
and targets that have been set for the year. There has also been a more extensive 
scoring for past commissioning experience in 2011/12 because it was the first year 
that organisations were working together as CCGs, however by 2013/14 the CCGs 
themselves had their own experience of working together so the number of scores 
based on historical organisations has been reduced. 
Another important note is that the number of emerging CCGs in 2011/12 is not the 
same as the final number of CCGs in 2012/13 and 2013/14 because some of the 
original CCGs ended up merging with neighbouring organisations. This has been 
captured in the scoring by adding in additional score for changing organisational 




CCG Risk Assessment in 2011 and subsequent authoris ation wave 
The authorisation of the CCGs was carried out by the NHS Commissioning Board in 
line with their guidance, all CCGs were required to complete a risk assessment by 
December 2011 to help them establish whether they would meet the criteria for 
authorisation (NHS Commissioning Board, 2011). Four key areas of CCG activity were 
assessed – proposed configuration; sign up from practices, geographical coverage 
and organisational viability. The risk assessment was led by the SHA clusters and 
supported by the Commissioning Development team in the Department of Health. The 
results of the risk assessment can be used to reflect how viable the organisations were 
according to the criteria set out in Appendix 5. However, the process of the SHA run 
risk assessment whereby some GP consortia were advised to merge prior to the 
process being carried out, meant that the final results of the analysis showed a very 
high number of viable CCGs scoring green on the rating although some had only 
recently been formed by making those organically created consortia merge with other 
groups. Therefore, in the analysis for 2011/12, organisations were scored on the basis 
of organisational changes in 2011/12 as well as for their past history of previously 
worked together as commissioning groups so that a more rounded understanding of 
the degree of clinical engagement and organisational cohesiveness could be found. 
The CCG Assurance Framework was updated as the process has developed with the 
final framework relevant to this this research being approved in November 2013 (NHS 
England, 2013a). 
Those organisations that were authorised in the first wave had been deemed to be 
ready to be established as separate commissioning units and able to begin to function 
as PCOs for their local population (NHS Commissioning Board, 2012a). The 
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authorisation process was built around six domains, agreed with emerging CCGs and 
patient and professional organisations. Assessing CCGs through these six domains 
provides assurance that CCGs could safely discharge their statutory responsibilities 
for commissioning healthcare services. They were also intended to encourage CCGs 
to be organisations that were clinically led and driven by clinical added value. The 
domains were: 
1. A strong clinical and multi-professional focus which brings real added value 
2. Meaningful engagement with patients, carers and their communities 
3. Clear and credible plans which continue to deliver the QIPP challenge within 
financial resources, in line with national requirements (including outcomes) and 
local joint health and wellbeing strategies 
4. Proper constitutional and governance arrangements, with the capacity and 
capability to deliver all their duties and responsibilities, including financial 
control, as well as effectively commission all the services for which they are 
responsible 
5. Collaborative arrangements for commissioning with other clinical 
commissioning groups, local authorities and the NHS Commissioning Board as 
well as the appropriate external commissioning support 
6. Great leaders who individually and collectively can make a real difference. 
Within each domain, the guide outlined criteria, the threshold for authorisation for those 
criteria, the evidence required and the sources for that evidence. The thresholds were 
set to ensure CCGs can be innovative in delivering improved outcomes, while also 
remaining safe as statutory bodies responsible for commissioning health services. 
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From 2011 onwards CCGs were assessed and authorised as organisations in 
accordance with the domains described above (NHS England, 2013b). In March 2013 
The NHS Commissioning Board authorised and established the fourth and final group 
of CCGs, which comprised 48 in total so that the new clinical commissioning system 
was set up across England and 211 CCGs were ready to take up their responsibilities 
from 1 April 2013 (NHS Commissioning Board, 2013a) . 
However, authorised CCGs were not all equal with some needing to improve in certain 
areas. By March 2013, there were a total of 106 CCGs that were fully authorised. The 
remaining were authorised with conditions and were offered support and development 
in order to discharge those conditions and become fully authorised. A smaller number 
of these (15) also needed more substantial official support – legal directions to help 
them to move towards authorisation (NHS Commissioning Board, 2013b) (NHS 
England, 2014a) (NHS England, 2014b). 
CCG pathfinder status  
Following on from the 2010 White Paper, Strategic Health Authorities decided to 
facilitate and encourage the development of clinical commissioning groups by 
supporting pathfinder groups and emerging CCGs. Pathfinder groups began to be 
formed in 2010 and they were created to allow practices to learn and share good 
practice with others during the transition period (until April 2013 when all PCTs were 
abolished and CCGs have all been authorised). This a comparator where the 
organisations have been ranked as to how keen the practices within the CCG have 
been to undertake commissioning. If all practices within a CCG have been involved 
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then it is likely to be easier to move forward with all practices in making commissioning 
decisions and changing behaviour. 
CCG mergers and organisational changes during 2011/ 12 
During 2011/12 a number of GP consortia were deemed unviable by the Department 
of Health Risk Assessment (carried out from October 2011 – December 2011) and 
subsequently merged with neighbouring consortia. The number of emerging GP 
consortia at the beginning of April 2011 was 269 but by the Department of Health Risk 
Assessments had reduced to 227 (March 2012) and by April 2013 was further 
decreased to 2012. This was confirmed by work from the Association of Public Health 
Observatories (APHO) in March 2012, as well as collection of information from local 
PCTs, PCT clusters and emerging consortia.  
Capturing these mergers could be done in 2 ways. Firstly, there were a number of 
mergers following the Department of Health (DoH) Risk Assessments. A number of 
consortia were assessed as unviable and merged as a result to form new CCGs by 
March 2012. Other consortia were advised to merge prior to the Risk Assessment.  
CCG 2012/13 Commissioning Plan: This comparator reflected the ability of the 
organisation to start to work together, ahead of the 2013 April deadline to formulate 
plans and priorities for the local population.  
CCG Website 2012/13: This comparator was another reflection of the ability of the 
CCG to begin working as a new organisation ahead of the official deadline of April 
2013. 
CCG Assurance Annual Assessment 2013/14: At the end of 2013/14, CCGs were 
assessed to ensure that they were operating effectively and able to commission safe 
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and high quality services within their resources. There were 6 assurance domains and 
the process was designed to allow for continuous development over the year. National 
Data (Delivery Dashboard, 360 survey, JSNA, national data) and locally produced 
information (CCG plans, previous assurance reports, soft intelligence) had been used 
as evidence for appropriate commissioning (NHS England, 2013a). 
Historical Relationships amongst practices within a n organisation 
The research in chapter 2 has highlighted the importance of organisational stability 
and previous relationships of practices working together so previous involvement with 
other practice based commissioning schemes, GP fundholding, locality 
commissioning, total purchasing pilots, practice based commissioning has been 
assessed to rank organisations according to their historical experience of working as 
one unit. The assumption being that it would be easier for organisations that have a 
history of working together to make decisions. Historical relationships between CCGs 
and PCT, PBC Group Consortia, GP fundholding, total purchasing pilots and locality 
commissioning have all been ranked using local and national qualitative information 
and the 2011 DoH CCG Risk Assessment. 
The historical relationships were arguably more important in 2011/12 than in 2013/14 
when the CCGs will have built up their own experience of working together, so the 
individual comparators for 2011/12 are separately scored for the different stages of 
primary care commissioning whereas for 2012/13 and 2013/14 the previous 
relationships with the most recent practice based commissioning group consortia has 




DEPARTMENT OF HEALTH RISK ANALYSIS OF EMERGING CCGs  in 2011 
Member Practice Engagement 
GREEN: The emerging CCG has a defined geographical area, a significant majority 
of registered patients live in this area, and the GP practices that make up the CCG 
are not drawn from a dispersed area. 
AMBER: The emerging CCG has a defined geographical area, a significant majority 
of registered patients live in this area, but the GP practices that make up the CCG 
come from a dispersed area. This was the pre-merger rating. Post merger the ccg is 
expected to be green rated 
RED: The emerging CCG does not have a defined geographical area, or a significant 
majority of registered patients do not live in the proposed area, and/or the GP 
practices that make up the CCG are drawn from a widely dispersed area. 
Geography: boundary and population 
GREEN: The emerging CCG has a defined geographical area, a significant majority 
of registered patients live in this area, and the GP practices that make up the CCG 
are not drawn from a dispersed area. 
AMBER: The emerging CCG has a defined geographical area, a significant majority 
of registered patients live in this area, but the GP practices that make up the CCG 
come from a dispersed area. 
RED: The emerging CCG does not have a defined geographical area, or a significant 
majority of registered patients do not live in the proposed area, and/or the GP 
practices that make up the CCG are drawn from a widely dispersed area. 
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Geography: LA boundaries 
GREEN: CCG geographic area is coterminous with a unitary or upper tier local 
authority boundary (or the boundaries of two combined local authorities); or falls 
wholly within a unitary or upper tier local authority boundary; or The emerging CCG 
can demonstrate an overriding patient/population centred reason for straddling 
unitary or upper tier local authority boundaries and has the demonstrable support of 
the local authorities for being able to discharge effective joint commissioning (for 
example, reflecting major patient flows along care pathways into acute healthcare). 
AMBER: The emerging CCG can demonstrate an overriding population centred 
reason for straddling unitary or upper tier local authority boundaries but cannot yet 
demonstrate support of the local authorities. 
RED: The emerging CCG cannot demonstrate an overriding reason for straddling 
unitary or upper tier local authority boundaries. 
Impact of size 
GREEN: The emerging CCG is very small and confident that arrangements through 
which it could secure the capacity and capability to carry out all its commissioning 
responsibilities [within its running costs] are on track; or is very large but 
arrangements for local practice engagement are on track. 
AMBER: The emerging CCG is very small and is developing options for 
arrangements through which it could secure the capacity and capability to carry out 
all its commissioning responsibilities [within its running costs]; or is very large and is 
developing options to secure local practice engagement. 
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RED: The emerging CCG is very small and cannot identify a future arrangement 
through which it could secure the capacity and capability to carry out all its 
commissioning responsibilities [within its running costs]; or is very large and has no 
realistic plans to secure local practice engagement. 
Organisation size – detailed information 
During the period of this research project, the HSCIC produced a Quarterly Patient List 
Size and GP count for each practice in England. This report published the patient list 
size for each practice in England, split between prescribing and dispensing patients. It 
also published the number of GP’s in each practice. Another report, “Patient List” 
produced by HSCIC collated the dispensing practices for each organisation on a 
monthly basis 
The number of patients registered at a GP practice data has also been extracted as a 
quarterly snapshot in time from the GP Payments system maintained by the HSCIC. 
This has been released at GP Practice, Clinical Commissioning Group, NHS England 
Area Team and NHS England Region levels data in 5-year age bands, split by gender 
and aggregated.  
A sum of the practice list sizes for each practices was also available from the QOF 
analysis. This has been estimated to represent over 99% of all registered patients in 
England (Health and Social Care Information Centre, 2015a). 
Mid year estimates for 2011 PCO population are available (ONS estimates) which are 
different and other data sources because they estimate the resident population 
associated with each PCO. More patients may appear on the patient list because they 
have not been removed either when a patient has died or moved away or because 
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patients are registered at more than 1 practice or because This GP “list inflation” may 
be caused, for example, by patients who have not been removed from patient lists 
following death, emigration or moving home, patients being dual registered at practices 
following a change of address or due to registered patients not completing the 2011 
census (Health and Social Care Information Centre, 2014h). 
The most accurate comparison is the 2013/14 data because the CCGs have become 
official organisation on 1 April 2013. Prior to this the CCGs were not official 
organisations and so the CCG list size in 2011/12 has been calculated from the QOF 
Practice level population sizes and the practices that are linked to each CCG.  
Comparing 2013/14 numbers of practices and contract type from QOF and the NHS 
Payments to general practices for 2013/14 (Table) we were able to compare numbers. 
The NHS Payments data was published for the first time in February 215 and covered 
the 2013/14 year so there was no comparable dataset for 2011/12 or 2012/13. 
However, it was an opportunity to check to accuracy of the QOF figures for practices 
and list size and check other datasets (dispensing practices) to allow us to estimate 
the accuracy of the other datasets. 
Table 62: Comparison of practice numbers from 2013/ 14 QOF data with NHS 
payments data 





recorded in the 
QOF database 
and the NHS 
Payments 
system. 
1 PCO has 4 less practices in the QOF data source 
compared with NHS Payments data source 
1 PCO has 3 less practices in the QOF data source 
compared with NHS Payments data source 
9 PCOs have 2 less practices in the QOF data source 
compared with NHS payments data source 
39 PCOs have 1 less practice in the QOF data source 
compared with NHS Payments data source 
The number of practices linked to each PCO is the 
same in 146 out of 211 PCOs for both data sources. 
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12 PCOs have 1 more practice in the QOF data source 
compared with NHS payments data source 
2 PCOs have 2 more practices in the QOF data source 
compared with NHS payments data source 
1 PCO has 1 more practices in the QOF data source 




List size less in QOF data source for 33 PCOs 
compared with NHS payments data source 
List size more in QOF data source for 178 PCOs 
compared with NHS payments data source 
 
When the two patient list sizes from the QOF data and the NHS payments data are 
compared the list size for the majority of PCOs (143 - 67.7%) showed a difference of 
less than 1% between the two sources. A further 45 PCOs showed a difference of 
between 1 and 2%. Only 2 PCOs show a difference of more than 5% with the biggest 
difference was 5.34% for North East Essex PCO with the QOF data reporting 330,971 
patients on the practice lists compared with 313299 in the NHS Payments practice 
lists.  
For the purposes of this analysis we will use the QOF data source for patient list size 
and numbers of practices because this fits in with the other factors where QOF data 
has been used (audit and education; clinical guidelines; patient education; financial 
factors – for diabetes prevalence; and diabetes prevalence). 
No similar set of data exists for comparison in 2011/12 or 2012/13, although there are 
data containing numbers of GPs, dispensing practices and patients on April 1st 2012 
which is the equivalent of the end of year QOF data for 2011/12 and April 1st 2013 
which corresponds to the 2012/13 QOF data. It should be noted that practices were 
not officially part of CCGs until April 2013 and hence the data was shows a link 
between practice and PCT rather than practice to CCG for the April 2012 data. Practice 
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codes are present however, so the practices have been linked to the CCGs to create 
a comparative file. 
Organisation Profile - detailed information 
Table 63: Sources of data for organisation profile and comparison of datasets 
available 
2011/12 Data 
 QOF Patient list size 
and GP count 
General practice 







YES Practices linked 
to PCOs  
Practice linked 
to PCOs 
No only PCO 
level 
Patient list size YES YES NO Only PCO level 
Dispensing 
practices 
 YES NO NO 
Single handed 
practices 
 NO NO No only PCO 
level 
Contract type  NO NO NO 












 NO NO Only PCO level 
Time of data 
collection 






HSCIC HSCIC  GP gender, age 
and numbers 
from Exeter 






 QOF Patient list size 
and GP count 
General practice 







YES YES YES No only PCO 
level 
Patient list size Yes YES  Only PCO level 
Dispensing 
practices 





 NO  No only PCO 
level 
Contract type  NO  NO 








 NO  Only PCO level 
Time of data 
collection 









 QOF Patient list size 











YES  YES YES 
Patient list size YES   YES 
Dispensing 
practices 
NO   YES 
Contract type    YES 
GP numbers     
GP 
demographics 
    
Patient 
demographics 
   NO 
Time of data 
collection 
End March 2014  September 30 
2013 
1 April 2013 – 












Service (GPES).  
Information in 
QOF 2013/14 
derived from the 

















patients, and the 
services they 
provide. 















Diabetes Organisational Priorities - detailed infor mation 
2011/12 Priorities: Diabetes as a priority under the WCC Initiative - Identification of 
diabetes as a local priority in 2010 under the WCC Initiative provided an audited 
prioritisation process undertaken before the period of this research, so can act as a 
baseline assessment. However, the PCOs have changed since this time, and choices 
made for PCTs may not be wholly relevant for the smaller CCGs because they might 
have populations with needs dissimilar to that of the original PCT and may have 
different referral patterns and costs for their diabetes care. This choice was therefore 
important but not as relevant as within the 2011/14 time period. 
2012/13 Priorities: Annual Report for PCTs in 2012/13 contained less information than 
usual in many cases because they consisted of the winding up of the organisations 
and were in essence official end of year annual accounts rather than reports of 
achievements during the year.  The NHS Commissioning Board decreed that “Whilst 
CCGs will not produce annual accounts for 2012/13, they will need to demonstrate that 
they have considered the systems and processes that they will need to ensure that 
they can produce their annual report and accounts for 2013/14 (NHS Commissioning 
Board, 2012c).  
2013/14 Priorities: Quality Premium Priorities 2013/14 - Another significant initiative to 
encourage PCOs to identify priority disease areas for their local population by offering 
them a financial incentive was introduced by the NHS Commissioning Board in 
2013/14. The PCOs were offered financial rewards if they meet 4 national targets that 
were based on the Outcome Frameworks and three locally identified targets. The three 
local measures are supposed to “be based on local priorities that have been identified 
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in joint health and wellbeing strategies. These will be agreed by individual CCGs with 
their Health and Wellbeing Boards and with the area teams of the NHS Commissioning 
Board. This information has been recorded in a variety of places – commissioning 
plans, annual reports, and in board papers. In a small number of PCOs it was not 
present in any publically available information and was requested under the Freedom 
of Information Act 2000. The choice of diabetes as a local priority under the Quality 
Premium Priority Process is less important than that of a local clinical priority area 
because the scope of the Quality Premium Priorities is smaller. The scheme is 
designed to judge improvements in performance for a chosen indicator over a single 
year and looking at the indicators chosen, they are mostly around improving the 
achievement of the QOF outcomes measure of getting HbA1C figures to meet with 
national standards. This is mainly an achievement connected with improving 
prescribing and management of individual patients by their GPs rather than something 
involving wholesale changes in diabetes care(NHS England, 2013c)   . 
Limitations with the data 
It has been made clear in National Prioritisation documents produced by The 
Department of Health and NHS Commissioning Board, that previous clinical priorities 
and work should continue despite yearly changes in National Directives (NHS 
Commissioning Board, 2012b) . It is also the case that major changes are unlikely to 
be achieved in one year alone. For this reason, the choice of priority from the World 
Class Commissioning Initiative made in 2010 has been used in the 2011/12 scoring. 
This initiative (Department of Health, 2007) required several independent sources 
within the LHE to ensure that priorities were chosen in an appropriate manner that 
reflected accurately the needs of the population and the state of the services providing 
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care. It is also true that health priorities do not change suddenly and improvements in 
care take many years to achieve.  
Identification of diabetes as a local priority under the Joint Strategic Needs Assessment 
(JSNA) analysis produced by PCOs and local authorities (and latterly Health and 
Wellbeing Boards), have been undertaken during the time of the research and more 
importantly encompasses the time when the CCG have been formed. However, this is 
not as important as the PCO choosing diabetes as a local priority because the 
organisation may have many local issues to address within its local population and 
diabetes may not be the most important issue. For this reason, the JSNA reports have 
not been included in this analysis. 
Prescribing control – detailed information 
Table 64: Ranking for the QIPP prescribing comparat ors  
Specific indicator QIPP aim Description Indicator use 
Laxatives 
ADQ/STAR PU 




(ADQs) for laxatives 





ACE inhibitors % 
items 
More prescribing the 
better 
No prescription items 
for ACE inhibitors as 
% of total number of 
items for all drugs 





Lipid modifying drugs 
low cost 
More prescribing the 
better 
No prescriptions for 
generic statin as % 
total number 








August 2013 Q1 
2013/14) 
Ezetimibe % items Less prescribing the 
better 








combinations as % of 
total number 






Omega 3 ADQ/STAR 
PU 
Less prescribing the 
better 
Number ADQs for 
omega 3 fatty acid 
compounds per 
omega 3 fatty acid 
compounds ADQ 
based STAR PU 
Introduced August 
2013 (Q1 2013/14) 
Hypnotics 
ADQ/STAR PU (ADQ 
based) 
Less prescribing the 
better 
Number ADQs for 
benzodiazepines and 
Z drugs per 
hypnotics ADQ 
based STAR PU 
Introduced March 
2011. Amended 





Less prescribing the 
better 












More prescribing the 
better 
Number of 
prescription items for 
1st choice generic 
SSRIs as % of total 
number of 





Antibacterials items / 
STAR PU 
Less prescribing the 
better 
Number prescription 
items for antibacterial 
drugs per oral 
antibacterials ITEM 




quinolones % items 





quinolones as % total 
number of 





Trimethoprim 3 days 
ADQ/item 
More prescribing the 
better 
Number ADQs per 






Less prescribing the 
better 
Number ADQs for 






Less prescribing the 
better 
Number ADQs for all 
NSAIDs per oral 







naproxen % items 
More prescribing the 
better 
Number prescription 
items for ibuprofen 
and naproxen as % 
total number 




Wound care NIC/item Less prescribing the 
better 
Cost (NIC) per item 




(Health and Social Care Information Centre, 2013b, National Institute Care and Clinical 
Excellence, 2013) 
Definitions  
Average daily quantities (ADQs) are defined as a measure of prescribing volume 
based on prescribing behaviour in England. It represents the assumed average 
maintenance dose per day for a drug used for its main indication in adults. The ADQ 
is not a recommended dose but an analytical unit to compare prescribing activity.  
ASTRO-PU weightings: ASTRO-PU stands for Age, Sex and Temporary Resident 
Originated Prescribing Units. This weighting is designed to weight individual practice 
or organisation populations for age and sex to allow for better comparison of 
prescribing patterns. These figures are based on the cost or volume of prescribing 
across all therapeutic areas, and these weightings should be used only when 
considering all prescribing. The number of temporary residents attending practices is 
no longer captured or included in funding allocations. 
STAR-PU weightings: There are differences in the age and sex profiles of patients who 
are prescribed drugs in specific therapeutic groups. For example: drugs for dementia 
are generally prescribed for older people. STAR-PUs (Specific Therapeutic Group 
Age-sex weightings Related Prescribing Units) allow more accurate and meaningful 
comparisons within a specific therapeutic group by taking into account the types of 
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people who will be receiving that treatment. These have been developed using the 
same methodology as used for ASTRO-PUs but are based on costs within therapeutic 
groups rather than all prescribing. The STAR-PU weightings for anti-bacterials are item 
based, as this is more appropriate for such prescribing. These weightings should be 
used only for the specific therapeutic area. Note: ADQ based weightings have been 
introduced for hypnotics and antidepressants. (HSCIC Website accessed April 12 
2015). 
The data was available from the HSCIC website. The data was presented at practice 
level and the calculation of practice achievement of prescribing targets at PCO level 
has used a linking data file produced by NHE England that has allocated practices to 






Description of Data used to create PCO profiles 
Description of outcome indicators  








Median 1st quartile 
3rd quartile 
 







215,720.88 55,732.00 188,211.30 174,755,72 251,224.42 







216,812.92 56,522.48 183,279.18 171,097.50 254,018.67 







221,261.96 59,252.15 178585.21 172,464.71 262,172.19 
 
The prescribing spend on LA insulin analogues (Table 65) showed a general increase 
year on year over the three years with the mean net ingredient cost per 100,000 
increasing from 215,868.41 in 2011/12 to 262,172,19 in 2013/14. However, the median 
values did not show the same trend and this together with an examination of the spread 
of the data suggested that this increase in the mean value may have been due to a 
relatively small number of organisations spending significantly more over the three 
years.  









Median 1st quartile 3rd quartile 


















102,836.30 40,461.02 157,321.10 76,792.38 126920.50 








117,966.63 46,453.29 136,660.38 88,192.48 142,557.21 
 
The mean prescribing spend on GLP-1 agonists shown in Table 17 showed an 
increase over the three years (46%) and this increased spending was also evident 
when looking at the median spend. This increase was seen across the majority of 
organisations with the range and 1st and 3rd quartiles all showing increased values for 
the period studied.  
Structure and process Indicators  
The continuous data and the categorical ordinal data that made up the structure and 
process indicators for each year were the same for both the LA insulin analogues and 
GLP-1 agonists analysis. They are described in the Tables below. However, there were 
2 variables that were specific to one of the drug classes, namely the specific formulary 
directives for LA insulin analogues and GLP-1 agonists and these have been described 







Table 67: Continuous indicator data applicable for Both LA Insulin Analogues 

































































































































































0-39.81 10.53 7.28 6.06 5.2 14.29 
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9.62-42.73 23.28 6.58 22.61 18.01 26.20 



































































































































































































































Table 68 : Categorical ordinal data - applicable fo r both LA insulin analogues 
and GLP-1 agonists 
Explanatory 
variable 























2.82 1.03 3.00 2.00 3.50 
Secondary 






1-5 2.82 1.03 3.00 2.00 3.50 
Secondary 






1-5 2.82 1.20 3.00 2.00 4.00 
Secondary 






1-4 2.64 0.92 3.50 2.00 3.00 
Secondary 






1-4 2.17 1.01 1.5 1.00 3.00 
Secondary 








































































1-5 3.70 0.98 3.50 3.00 4.00 
 
Table 69: Trend in LA insulin analogue formulary di rectives over three years 
(information from local formularies collected as pa rt of this research) 
Note: PCOs may be affected by more than 1 formulary 
 














Insulins not listed in formulary or 
all LA insulins listed 
   64     18  13 
LA insulin analogues (determir 
and glargine) listed with no 
restrictions for use. Insulin 
Degludec NOT listed or classified 




   67 
 
 
   162 
 
 
      111 
LA Insulin analogues (determir 
and glargine) listed with no 
restrictions for use. Insulin 




   0 
 
 
     3 
 
 
       2 
LA Insulin analogues (determir 
and glargine) listed but restricted 
Insulin Degludec Not listed 
 
 
  44 
 
   138 
 
     108 
LA Insulin analogues (determir 
and glargine) listed but restricted. 
 
 
   0 
 
 
     9 
 
 
       9 
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Insulin degludec listed but more 
restricted. 
  




  41 
 
    91 
 
     66 
Insulin Determir listed as 1st 
choice 
   4 
 
     3       2 
 
Table 70: Trend in GLP-1 agonist formulary directiv es over three years 
(information from local formularies collected as pa rt of this research) 
Note: PCOs are affected by more than 1 formulary 














Advice to use one of 2 GLP-1 







Advice to use one of 3 GLP-1 







Advice to use one of 4 GLP-1 
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